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Hao Zhang 
 
THE IMPACT OF MTOR, TFEB AND BID ON NON-ALCOHOLIC FATTY LIVER 
DISEASE AND METABOLIC SYNDROME 
 
Non-alcoholic fatty liver disease and metabolic syndrome induced by high 
nutrient status have increasingly become a global health concern as it cause 
multiple complications. The mTOR complex is central in regulating anabolic 
reactions within cells under growth factors or under high nutrients stimulation. 
Constitutive and persistent activation of mTOR can impair cellular functions. In 
the first part of this study, we demonstrate a damping oscillation of mTOR activity 
during a long-term treatment of high fat diet. TFEB translocation and lysosomal 
enzyme activity also oscillate, but in an opposite direction. TFEB controls the 
lysosomal activity, autophagic degradation and lipid metabolism. Overexpression 
of wild type and mutant TFEB could inhibit NAFLD development in mice. In 
addition, TFEB location in nucleus inversely correlates with NAFLD severity in 
patients. mTOR activation under hypernutrition status suppresses TFEB 
translocation, inhibits lysosomal functions and autophagic degradation of lipid 
droplets. Inhibition of mTOR activity by rapamycin reverse the above 
phenotypes. Because mTOR activation also requires normal lysosomal function, 
the inhibition of TFEB by mTOR leads to decreased lysosomal function and 
mTOR downregulation. This negative feedback may explain the oscillation 
pattern of mTOR activation in long term high fat diet regimen and is a novel 
mechanism for inhibition of mTOR. In the second part of study, we report that Bid 
vii 
 
protein, previously known for its pro-apoptosis function in promoting 
mitochondrial permeability, plays an unexpected role in regulating fatty acid beta 
oxidation. Deletion of Bid in mice reprograms the body’s response to hyper-
nutrition caused by high fat diet, leading to the resistance to the development of 
obesity, liver steatosis and metabolic syndrome. These mice present a higher 
oxygen consumption, a lower respiratory quotient, and an increased beta-
oxidation rate. Mechanistically, the high fat diet regimen triggers translocation of 
the full length Bid molecule to mitochondrial membrane. Genetic deletion of Bid 
also affects the stability of its binding protein, MTCH2 in the mitochondrial 
membrane. In summary, we describe in this study a mTOR-TFEB-lysosome 
feedback loop, which can regulate NAFLD development, and a novel Bid-
mediated regulatory mechanism in beta-oxidation, which limits energy 
expenditure and promotes obesity development.  
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Part I. The Function of mTOR and TFEB in NAFLD and Obesity 
 
1.1   Introduction 
 
1.1.1 mTOR, the Pathway and The Regulation. 
 
1.1.1.1 Introduction 
 
The mammalian target of rapamycin (mTOR) has a central role in cell 
metabolism, proliferation and survival. As an energy sensor, it can sense 
intracellular and extracellular signals. Discoveries that have been made over the 
last decade have shown that the mTOR pathway is activated during various 
pathophysiological processes (e.g. tumor formation and angiogenesis, insulin 
resistance, adipogenesis and T-lymphocyte activation etc.) and is deregulated in 
human diseases such as cancer and type 2 diabetes [1]. Most importantly, 
mTOR is a central intracellular molecule in controlling the transition between 
catabolic and anabolic states, allowing mammals to survive and to grow in 
different environments.  
 
mTOR interacts with many proteins to form two basic multiprotein complexes: 
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). In addition to 
their different protein compositions, the mTOR complexes have important 
differences in their sensitivities to rapamycin, in the upstream signals they 
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integrate, in the substrates they regulate, and in the biological processes they 
control [2]. mTORC2 is not as well studied for its regulation and for its function in 
energy regulation [3]. We will discuss primarily mTORC1 in this thesis. 
 
1.1.1.2 mTOR Complex and Upstream Regulators 
 
mTORC1 is sensitive to rapamycin and integrates inputs from at least five major 
signals—growth factors, genotoxic stress, energy status, oxygen, and amino 
acids—to regulate many processes involved in the promotion of cell growth and 
proliferation. The complex of mTORC1 consists of a regulatory component 
known as regulatory-associated protein of mTOR (RAPTOR), The regulatory 
component of mTORC2 is called rapamycin-insensitive companion of mTOR 
(RICTOR) [4, 5]. These companions function as scaffolds for assembling the 
complexes and for binding substrates and regulators. mTORC1 and mTORC2 
share a common component, mammalian lethal with SEC13 protein 8 (mLST8; 
also known as GβL), and the recently identified DEP domain-containing mTOR-
interacting protein (DEPTOR), which play a positive function and negative 
function, respectively [6, 7]. However, mTORC1 also includes a negative 
regulator, Pro-rich Akt substrate (PRAS40) [8]. The domain organization of 
mTOR resembles that of other PI3K-related protein kinases (PIKK) family 
members. Biochemical and structural evidence has also suggests that mTORC1 
may exist as dimers [9, 10]. 
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mTORC1 has a number of very diversified upstream regulators. The mTORC1 
pathway integrates inputs from at least five major intracellular and extracellular 
signals--growth factors, stress, energy status, oxygen, and amino acids. The 
heterodimer complex consisting of tuberous sclerosis 1 (TSC1; also known as 
hamartin) and TSC2 (also known as tuberin) is the key upstream regulator of 
mTORC1 and functions as a GTPase-activating protein (GAP) for the Ras 
homolog enriched in brain (Rheb) GTPase. Rhab activates mTORC1 but TSC1/2 
inhibits Rhab as its GAP. The GTP-bound form of Rheb directly interacts with 
mTORC1 and strongly stimulates its kinase activity. As a Rheb GAP, TSC1/2 
negatively regulates mTORC1 by converting Rheb into its inactive GDP-bound 
state [11, 12]. TSC1/2 transmits many of the upstream signals to mTORC1, 
including growth factors, such as insulin and insulin-like growth factor 1 (IGF1), 
which can further stimulate PI3K and Ras pathways. The effector kinases of 
these pathways—protein kinase B (Akt/PKB), extracellular-signal-regulated 
kinase 1/2 (ERK1/2), and ribosomal S6 kinase (RSK1) can directly phosphorylate 
the TSC1/TSC2 complex to inactivate it and thus activate mTORC1 [12-14].  
 
TSC2 can also be directly phosphorylated by Akt, which destabilizes and disrupts 
its interaction with TSC1. This process is involved in stimulating cell growth. Akt 
also signals to mTORC1 in a TSC1/2-independent fashion by phosphorylating 
and causing the dissociation from raptor of PRAS40, an mTORC1 inhibitor [15, 
16]. Pro-inflammatory cytokines, like tumor necrosis factor-α (TNFα) can also 
activate mTORC1 [17]. IKKbeta, a major downstream kinase in the TNFalpha 
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signaling pathway, physically interacts with and phosphorylates TSC1 at Ser487 
and Ser511, resulting in suppression of TSC1. The IKKbeta-mediated TSC1 
suppression activates the mTOR pathway, enhances angiogenesis, and results 
in tumor development. Lastly, the canonical Wnt pathway, a major regulator of 
cell growth, proliferation, polarity, differentiation, and development, also activates 
mTORC1 through TSC1/2. Wnt activates mTOR via inhibiting GSK3 without 
involving beta-catenin-dependent transcription. GSK3 inhibits the mTOR pathway 
by phosphorylating TSC2 [18]. 
 
Stress signal can also activate/suppress mTORC1 through TSC1/2. Among the 
stress inducers, low energy and oxygen levels and DNA damage being the best 
characterized. Adenosine monophosphate-activated protein kinase (AMPK), in 
response to hypoxia or a low energy state, phosphorylates TSC2. Like Akt, 
AMPK also communicates directly with mTORC1; it phosphorylates RAPTOR, 
leading to 14-3-3 protein to bind and inhibit mTORC1 [19]. DNA damage, as an 
internal stress signal, signals to mTORC1 through multiple mechanisms, all of 
which require p53-dependent transcription. DNA damage induces the expression 
of Tsc2 and PTEN, causing downregulation of the entire PI3K-mTORC1 axis [20] 
and activating AMPK through a mechanism that depends on the induction of 
Sestrin1/2 [21].  
 
Different amino acids, particularly leucine and arginine, activate mTORC1 and 
must be present for any upstream signals, including growth factors, to activate 
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mTORC1 [22]. Although it has been known for some times that amino acids act 
independently of TSC1/2, the molecular mechanism through which mTORC1 
senses intracellular amino acids remains unknown until in 2008 when the 
Sabatini and Guan’s group has found that the Rag proteins--a family of four 
related small guanosine triphosphatases (GTPases)--interacted with mTORC1 in 
an amino acid-sensitive manner and were necessary for the activation of the 
mTORC1 pathway by amino acids. A RagA or RagB binding to GTP can reduce 
mTORC1 pathway resistant to amino acid deprivation where expression of a 
GDP bound RagA or RagB mutant can prevent stimulation of mTORC1 by amino 
acids. The Rag proteins do not directly stimulate the kinase activity of mTORC1, 
but, like amino acids, promote the intracellular localization of mTOR to lysosome 
membranes, which harbor its activator Rheb [23].  Mammals have four Rag 
proteins, RagA to RagD, which form obligate heterodimers consisting of RagA or 
RagB with RagC or RagD. The two members of the heterodimer have opposite 
nucleotide states, so that when RagA/B is bound to GTP, RagC/D is bound to 
GDP and vice versa. Amino acids can promote the loading of RagA/B with GTP, 
which enables the lysosome-associated heterodimer to interact with the 
RAPTOR component of mTORC1 [23], thus recruiting mTORC1 to the lysosomal 
membranes, where the Rag proteins reside. How do amino acids activate Rag 
proteins? A set of proteins encoded by complex encoded by the MAPKSP1, 
ROBLD3, and c11orf59 genes, which was collectively termed as Ragulator, 
interact with the Rag GTPases upon the effect of amino acid, recruit them to 
lysosomes, and are essential for mTORC1 activation. This interaction results in 
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the translocation of mTORC1 from a poorly characterized cytoplasmic location to 
the lysosomal surface [10, 24]. More recent findings have shown that different 
amino acids use different mechanisms to activate mTORC1 [25], mTORC1 is 
differentially regulated by glutamine and leucine. RagA and RagB are essential 
for mTORC1 activation by Leucine, but not by Glutamine. 
 
The localization of the Ragulator and Rag GTPases to the lysosomal surface, but 
not on other endomembranes where Rheb also resides, suggests the sensing of 
amino acids happens by lysosome. In the year 2011, an inside-out model of 
amino acid sensing was established [26]. The vacuolar H(+)-adenosine 
triphosphatase ATPase (v-ATPase) located in the lysosome membrane is 
necessary for amino acids to activate mTORC1. The v-ATPase engages in 
extensive amino acid-sensitive interactions with the Ragulator. In a cell-free 
system, ATP hydrolysis by the v-ATPase is necessary for amino acids to regulate 
the v-ATPase-Ragulator interaction and to promote mTORC1 translocation. 
These findings suggest that amino acid signaling begins within the lysosomal 
lumen and initiate the downstream events. The v-ATPase directly interacts with 
the Ragulator, providing a physical link between the v-ATPase and the Rag 
GTPase on the surface of lysosomes. The ATPase activity of the v-ATPase and 
the associated rotation of its V0 section appear to be essential to deliver the 
amino acids signal from the lysosomal lumen to the Ragulator and Rag GTPases 
[26].  
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mTOR activation by amino acid is also regulated by a feed-back loop in 
lysosomal function. Researchers have found that mTORC1 regulates the 
expression of, among other lysosomal genes, the V-ATPases. mTORC1 
regulates V-ATPase expression both in cells and in mice. V-ATPase regulation 
by mTORC1 involves a transcription factor translocated in renal cancer, TFEB. 
TFEB is required for the expression of a large subset of mTORC1 responsive 
genes. mTORC1 coordinately regulates TFEB phosphorylation and nuclear 
localization in a manner dependent on both TFEB and V-ATPases. [27]. Finally, 
phosphatidic acid (PA) has also been identified as an activator of mTORC1 [28].  
 
1.1.1.3 Cellular Process Downstream of mTOR Signaling 
 
With the unique composition of the mTORC1, the protein complex controls 
cellular protein synthesis by regulating its substrates. The two major mTORC1 
substrates are P70S6 kinase 1 (p70S6K1) and eIF4E-binding protein 1 (4E-BP1). 
They are associated with mRNAs and regulate mRNA translation initiation and 
progression, thus controlling the rate of protein synthesis [29]. 4E-BP1 are 
translational repressors which upon phosphorylation by mTORC1, dissociate 
from eIF4E. This leads to the binding of eIF4G to eIF4E at the 5′-end of mRNAs 
and promotes cap-dependent translation initiation.[30]. When phosphorylated by 
mTORC1, P70S6K1 first phosphorylates S6, which than further promotes mRNA 
translation by phosphorylating or binding multiple proteins, including eukaryotic 
elongation factor 2 kinase (eEF2K) [31], and S6K1 Aly/REF-like target [30], which 
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collectively affect translation initiation and elongation. Recent studies found that 
mRNAs under control of mTOR encode proteins belonging to the translation 
machinery, such as ribosomal proteins or elongation factors [10, 32].  
 
mTORC1 mainly regulates protein synthesis by directly phosphorylates the 
translational regulators eukaryotic translation initiation factor 4E (eIF4E) binding 
protein 1 (4E-BP1) and p70S6 kinase 1 (p70S6K1). Regulation of the mRNA 
cap-binding protein eIF4E is mediated directly by mTORC1, which 
phosphorylates the eIF4E inhibitors — the 4E-BPs [33]. In quiescent cells, 
hypophosphorylated 4E-BP1 binds tightly to eIF4E. As 4E-BP1 competes with 
eIF4G for an overlapping binding site on eIF4E, 4E-BP1 prevents eIF4G from 
interacting with eIF4E. On mTORC1 activation, hyperphosphorylated 4E-BP1 
dissociates from eIF4E, allowing for the recruitment of eIF4G and eIF4A to the 5' 
end of an mRNA. Finally, eIF3, the small ribosomal subunit and the ternary 
complex (comprising eIF2, Met-tRNA and GTP) are recruited to the cap, resulting 
in the assembly of the 48S translation pre-initiation complex, ribosome scanning 
and translation initiation [34, 35]. 
 
The activation of S6K1 leads, through a variety of effectors, to an increase in 
mRNA biogenesis, as well as translational initiation and elongation. S6K1 was 
originally thought to control the translation of an abundant subclass of mRNAs 
characterized by an oligopyrimidine tract at the 5′ end (5′ TOP mRNAs), which 
encode most of the protein components of the translational machinery. Two 
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essential phosphorylation sites have been identified, including Thr229, which is 
located in the catalytic activation loop, and Thr389, which is located at a 
hydrophobic motif that is carboxy-terminal to the kinase domain [36]. S6K 
activation is initiated by mTORC1-mediated phosphorylation of Thr389, resulting 
in the formation of a docking site for phosphoinositide-dependent kinase 1 
(PDK1), which then phosphorylates Thr229 to activate S6K [36]. S6Ks are also 
thought to coordinate the regulation of ribosome biogenesis, which in turn drives 
efficient translation [35, 37]. 
 
mTORC1 also upregulates the protein synthesis machinery in other ways. For 
example, it regulates Pol I transcription by modulating the activity of motif-
containing protein-24(TIF-IA), a regulatory factor that senses nutrient and growth-
factor availability [38]. mTORC1 also participates in regulating TSC2- VEGF 
pathway. TSC2 loss results in the accumulation of HIF-1alpha and increased 
expression of HIF-responsive genes including VEGF [39]. Other study has 
confirmed mTORC1 as the upstream regulator of HIF-1. Amplified signaling 
through mTOR can enhance HIF-1-dependent gene expression in certain cell 
types and cancer model [40]. 
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1.1.2 mTOR in Lipid synthesis,  Liver Function and Metabolism 
Syndrome/NAFLD  
 
1.1.2.1 mTOR and Lipid Homeostasis 
 
mTOR protein kinase has emerged as a crucial link between growth signals and 
the regulation of lipid metabolism. The regulation of de novo sterol and fatty acid 
synthesis by signaling pathways, especially insulin signaling could be one of the 
activator of mTOR. Unlike most terminally differentiated cells, hepatocytes and 
adipocytes can synthesize lipids de novo through pathways in which cytosolic 
acetyl-CoA, derived from glucose or amino acid catabolism, is used to form the 
hydrophobic carbon backbone of lipids [41, 42]. Both the sterol and fatty acid 
synthesis branches comprise of many steps requiring many specific enzymes. 
Importantly, the SREBPs are transcription factors that stimulate the expression of 
genes encoding nearly all of these lipogenic enzymes [42]. SREBP1a and 1c are 
products of alternative splicing of the SREBF1 gene and have been primarily 
implicated in the control of genes involved in fatty acid synthesis, although 
SREBP1a is thought to activate most SRE-containing genes [42]. SREBP2 is 
encoded by SREBF2 and is believed to have a more important role in the 
transcription of steroidogenic genes, including those involved in cholesterol 
synthesis in the liver [43]. Studies have identified the SREBPs as major 
transcriptional effectors of mTORC1 signaling.  mTORC1 signalling promotes 
SREBP activation and lipogenesis in response to both physiological and genetic 
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stimuli. Insulin or feeding has been shown to increase the expression of the 
major liver isoform of SREBP1c and its targets, and to promote de novo lipid 
synthesis in a manner that is sensitive to rapamycin [44]. mTORC1 may also 
regulate the SREBP transcriptional network via the negative regulation of lipin1 
[45]. Lipin1 is an mTORC1 substrate with multiple phosphorylation sites, 
including both rapamycin-sensitive sites and sites phosphorylated by mTORC1 
that are relatively insensitive to rapamycin. Phosphorylation of lipin1 by mTORC1 
regulates its subcellular localization, with phosphorylated lipin1 residing in the 
cytoplasm and dephosphorylated lipin1 accumulating in the nucleus. Inhibition of 
mTORC1 in the liver significantly impairs SREBP function and makes mice 
resistant, in a lipin 1-dependent fashion, to the hepatic steatosis and 
hypercholesterolemia induced by a high-fat and -cholesterol diet. [45].   
 
Different studies also suggest that mTORC1 may control lipid homeostasis by 
regulating the expression and the activation state of PPAR-γ.  Many independent 
groups [46] have reported that mTOR inhibition with rapamycin reduces mRNA 
and protein levels of PPAR-γ and C/EBP-α and the expression of numerous 
lipogenic genes in vitro. PPAR-gamma activity is dependent on amino acid 
sufficiency, revealing a molecular link between nutrient status, adipogenesis and 
possibly, mTOR status. The mTOR pathway and the phosphatidylinositol 3-
kinase/Akt pathway act in parallel to regulate PPAR-gamma activation during 
adipogenesis by mediating nutrient availability and insulin signals [47]. 
Additionally, constitutive activation of mTORC1 through TSC2 deletion increases 
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PPAR-γ and C/EBP-α expression and promotes adipogenesis [48]. Some 
evidences indicate that 4E-BP1 and 2, which are negative regulators of 
translation that are inhibited by mTORC1, are important for the regulation of 
PPAR-γ and C/EBPs by mTORC1 [49, 50]. Although the activation of S6K1, and 
probably other mTORC1 substrates, is induced by the deletion of 4E-BP1/2, 
these results suggest that mTORC1 controls adipogenesis/lipogenesis by 
inducing the translation of mRNA coding for key components of the adipogenic 
program.  
 
Direct knock-out of mTOR downstream genes also has effects on glucose/lipid 
metabolism. Mice deficient for S6K1, an effector of the mTOR that acts to 
integrate nutrient and insulin signals, were shown to be hypoinsulinaemic, 
glucose intolerant and have reduced beta-cell mass. However, S6K1-deficient 
mice maintain normal glucose levels during fasting, suggesting hypersensitivity to 
insulin. S6K1-deficient mice are protected against obesity owing to enhanced 
beta-oxidation. However on a high fat diet, levels of glucose and free fatty acids 
still rise in S6K1-deficient mice, resulting in insulin receptor desensitization. 
S6K1-deficient mice remain sensitive to insulin owing to the apparent loss of a 
negative feedback loop from S6K1 to IRS1 [51]. 
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1.1.2.2 Role of mTOR in Liver Metabolic Functions. 
 
The liver is the most important metabolic organ which carries most of the 
metabolic functions. mTOR is a well-known regulator of metabolism and is highly 
expressed in hepatocyte, indicating its important role in metabolism regulation in 
the liver.  
 
First, mTORC1 signaling in the liver affects systemic glucose and insulin 
homeostasis. In the liver of liver-specific TSC1 knockout mice, chronic activation 
of mTORC1 signaling has very strong inhibition effect on IRS-1, resulting in 
decreased Akt signaling. This impairs hepatic glycolytic flux and hence glucose 
clearance from the blood, leading to glucose intolerance [52, 53]. Contrary to the 
TSC knockout mouse, liver-specific raptor knockout mice have increased 
systemic glucose tolerance that can be explained by enhanced Akt signaling and 
insulin-induced glucose uptake in the liver [45, 54]. Hence, hepatic mTORC1 
signaling results in systemic regulation of glucose and insulin signaling, most 
probably due to changes in AKT pathway. In a normal liver, insulin suppresses 
gluconeogenesis and promotes lipogenesis. In type 2 diabetes, the liver exhibits 
selective insulin resistance by failing to inhibit hepatic glucose production while 
maintaining triglyceride synthesis. Evidence suggests that the insulin pathway 
bifurcates downstream of Akt to regulate these two processes. Second, Obesity-
induced insulin resistance depends, in part, on chronic activation of mammalian 
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target of rapamycin complex 1 (mTORC1), as another evidence of mTOR in liver 
glucose homeostasis [2, 55].  
 
Interestingly, TSC knockout mice that have constitutive mTORC1 activation in 
the liver have dramatic effect on its normal function. These mice developed 
normally but displayed mild hepatomegaly and insulin resistance without obesity. 
Unexpectedly, the TSC-null livers showed minimal signs of steatosis even under 
high-fat diet condition. This 'resistant' phenotype was reversed by rapamycin. 
These observations suggest that mTORC1 activation only by genetic modulation 
is not sufficient for steatosis and may need outside stimulations such as high fat 
diet feeding [55]. 
 
A recent study by Cornu et al. [56] demonstrated another interesting connection 
between hepatic mTORC1 signaling and whole body physiology in liver specific 
TSC1 KO mice. They displayed reduced locomotor activity, body temperature, 
and hepatic triglyceride content in a rapamycin-sensitive manner. Ectopic 
activation of mTORC1 also caused depletion of hepatic and plasma glutamine, 
leading to peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α)-
dependent fibroblast growth factor 21 (FGF21) expressions in the liver. Injection 
of glutamine or knockdown of PGC-1α or FGF21 in the liver suppressed the 
behavioral and metabolic defects due to mTORC1 activation. Thus, mTORC1 in 
the liver controls whole-body physiology possibly through PGC-1α and FGF21. 
By an unknown mechanism, this metabolic stress stimulates PGC-1α-dependent 
15 
 
FGF-21 production in the liver. FGF-21 in turn acts on the central nervous 
system to decrease locomotor activity and body temperature.  
 
mTORC1 also promotes glutamine anaplerosis (i.e. formation of an intermediate 
metabolic alpha-ketoglutarate  from glutamate) by activating glutamate 
dehydrogenase (GDH). This regulation requires transcriptional repression of 
SIRT4. Mechanistically, mTORC1 represses SIRT4 by promoting the 
proteasome-mediated destabilization of cAMP-responsive element binding 2 
(CREB2).  Glucose-limited TSC-deficient cells are addicted to glutamine as an 
alternative carbon source, further accentuating the role of mTORC1 in regulating 
glutamine metabolism [57, 58]. Other study found the central regulator of energy 
intake molecule ghrelin also has its function carried by mTOR [59]. By interacting 
with peroxisome proliferator-activated receptor-γ (PPARγ), mTOR mediates the 
ghrelin-induced up-regulation of lipogenesis in hepatocytes. The stimulatory 
effect of ghrelin on hepatic lipogenesis was significantly attenuated by PPARγ 
antagonism in cultured hepatocytes and in PPARγ gene-deficient mice.  
 
Another interesting study has linked mTOR with ketogensis in the liver. Sabatini’s 
group found that liver-specific loss of TSC1 leads to a fasting-resistant increase 
in liver size and to a pronounced defect in ketone body production and ketogenic 
gene expression on fasting. The loss of raptor has the opposite effects. In 
addition, the inhibition of mTORC1 is required for the fasting-induced activation 
of PPARα, the master transcriptional activator of ketogenic genes, and that 
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suppression of NCoR1 (nuclear receptor co-repressor 1), a co-repressor of 
PPARα, reactivates ketogenesis in cells and livers with hyperactive mTORC1 
signaling. Moreover, the suppressive effects of mTORC1 activation and ageing 
on PPARα activity and ketone production are not additive, and that mTORC1 
inhibition is sufficient to prevent the ageing-induced defect in ketogenesis. Thus, 
those findings reveal that mTORC1 is a key regulator of PPARα function and 
hepatic ketogenesis [52]. 
 
Similar to hepatic mTORC1, mTORC2 signaling in the liver also affects systemic 
glucose and insulin homeostasis. Liver-specific rictor knockout (LiRiKO) mice 
have increased circulating insulin levels and impaired glucose tolerance and 
insulin sensitivity. Fed LiRiKO mice displayed loss of Akt Ser473 phosphorylation 
and reduced glucokinase and SREBP1c activity in the liver, leading to 
constitutive gluconeogenesis, and impaired glycolysis and lipogenesis, 
suggesting that the mTORC2-deficient liver is unable to sense satiety. Hepatic 
mTORC2 affects systemic glucose and insulin homeostasis mainly by affecting 
hepatic glucose uptake via Akt signaling [60, 61].  Rapamycin-induced insulin 
resistance is mediated by mTORC2 loss and uncoupled from longevity, the first 
study indicating rapamycin in liver can affect longevity by suppreing the mTOR 
[62].  
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1.1.3. TFEB-lysosome Regulation Pathway  
 
1.1.3.1 Introduction 
 
TFEB (transcription factor EB) is a transcription factor within the family of 
basic/helix–loop–helix/leucine zipper (bHLH-LZ) transcription factors. This family 
also includes Microphthalmia-associated transcription factor (MITF), TFE3, and 
TFEC [63-65]. All members of the MITF/TFE family share a similar structure that 
includes three critically important regions. The basic motif binds to specific areas 
of DNA while the helix–loop–helix and the leucine-zipper motifs are critical for 
protein interactions. Homodimerization and heterodimerization within members of 
the MITF/TFE family is critical for binding to DNA and transcriptional activation of 
target genes [66]. In addition, it is well established that the MiTF/TFE family 
specifically binds to E-box (CANNTG) and/or M-box (AGTCATGTGCT) response 
elements present in the promoter region of their downstream target genes [67]. 
 
TFE3 and TFEB show a very ubiquitous pattern of expression and have been 
detected in multiple cell types [68]. TFEB and TFEC contain multiple alternative 
first exons with restricted and differential tissue distributions, whereas the TFE3 
gene seems to be regulated by a single promoter[69].  
   
18 
 
1.1.3.2 Regulation of TFEB  
 
The major function of TFEB is to regulate lysosome biogenesis and function. 
Lysosome has been proved to be central in nutrient sensation and autophagy 
degradation. Therefore, a key point in understanding TFEB regulation is the 
change of cellular nutrient status. In fully fed cells, TFEB remains in the cytosol 
and cannot access the promoter region of its target genes. In contrast, upon 
short times of starvation, TFEB rapidly translocates to the nucleus and induces 
expression of autophagy and lysosomal genes [70, 71]. Therefore, TFEB can 
sense and respond to fluctuations of nutrient levels in the cell. [71, 72]. In fully 
fed cells, mTORC1 phosphorylates TFEB at several serine/threonine residues, 
including serine 211 (S211) [73]. Phosphorylated S211 functions as a binding 
site for the cytosolic chaperone 14-3-3, which keeps TFEB sequestered in the 
cytosol probably through masking the TFEB nuclear import signal. [73]. 
Settembre et al. [72] used an mTORC1 in-vitro kinase assay and a phosphor-
specific antibody to demonstrate that besides S211, S142, previously found to be 
phosphorylated by ERK2, is also phosphorylated by mTOR and that this 
phosphorylation site has a crucial role in controlling TFEB subcellular localization 
and activity. 
 
Interestingly, the Rag GTPase complex, which senses lysosomal amino acids 
and activates mTORC1, is both necessary and sufficient to regulate starvation- 
and stress-induced nuclear translocation of TFEB. This Rag-mediated 
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redistribution of TFEB to the lysosomal surface facilitates the phosphorylation of 
TFEB by mTORC1 and constitutes an efficient mechanism to link nutrient 
availability to TFEB inactivation. Inhibition of the interaction between TFEB and 
Rags results in accumulation of TFEB in the nucleus and constitutive activation 
of autophagy under nutrient-rich conditions, thus indicating that recruitment of 
TFEB to lysosomes is critical for proper control of this transcription factor [72].  
When nutrient levels are low, mTORC1 is inactivated, the TFEB/14-3-3 complex 
dissociates, and TFEB is free to translocate to the nucleus and activate 
processes (such as autophagy and lipid degradation) that will assist in cellular 
survival during starvation conditions [29]. Since lysosomes play a critical role in 
the activation of mTORC1, TFEB and mTORC1 would work together as major 
regulators of cellular homeostasis by coordinating nutrient sensing with 
transcriptional regulation of lysosomal biogenesis, autophagy, and lipid 
catabolism.  
 
In addition to mTORC1, other cellular kinases may contribute in regulation of 
TFEB activation. For example, phosphorylation of Ser142 by ERK2 helps 
promote cytosolic retention of TFEB [70], whereas TFEB becomes more resistant 
to degradation upon phosphorylation by PKCβ [74]. Furthermore, cells in which 
mTORC1 is hyperactivated, such as TSC2-null murine embryonic fibroblasts, 
TFEB is phosphorylated in several serine residues located between amino acids 
462–469, and this modification promotes its nuclear translocation [27]. Self-
regulatory mechanism also attributed to TFEB. Under starvation conditions, 
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TFEB translocates to the nucleus and binds to several CLEAR motifs present on 
its own promoter, thus enhancing its own expression [75]. The CLEAR network 
regulation of TFEB is discussed in the next section. It is thought that this auto-
regulatory feedback loop is particularly relevant to achieve a sustained response 
under prolonged starvation conditions. 
 
Activation of TFEB also happens when the lysosome function is affected. 
Incubation with chloroquine, a lysosomotropic agent that prevents lysosomal 
acidification, induces rapid redistribution of TFEB to the nucleus [72, 73]. TFEB 
also shows a predominantly nuclear distribution in several different cellular 
models of Lysosomal Storage Disorders (LSDs) [76]. LSDs are metabolic 
disorders characterized by the progressive accumulation of undigested material 
in lysosomes that subsequently disrupts cellular physiology. These observations 
suggest that TFEB is involved in a broader pathway of cellular response to 
lysosomal stress.  
 
1.2.3.3 Downstream Effects upon TFEB Activation 
 
The downstream effects of transcription factor TFEB are mainly targeting at 
autophagy and lysosome related genes, and lipid metabolism. 
 
Autophagy is a critical cellular process that allows cells to degrade their own 
components and recycle important molecules in situations of nutrient deprivation. 
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Many autophagy-related genes (ATG) encode protein complexes that act 
sequentially to regulate engulfment of portions of the cytosol into 
autophagosomes and subsequent delivery to lysosomes for degradation. It is 
important for cells to possess the capability of increasing transcription of 
autophagy genes when nutrients are deficient as autophagy is a key process in 
acquiring energy in starvation. TFEB functions as a key transcriptional regulator 
of autophagy [70]. It directly binds to the TFEB-target sites present in the 
promoter regions of numerous autophagy genes and promotes their expression. 
These include UVRAG, WIPI, MAP1LC3B, SQSTM1, VPS11, VPS18, and 
ATG9B. In addition, its overexpression in various cell lines increases the number 
of autophagosomes, whereas depletion of endogenous TFEB by RNAi reduces 
autophagosome numbers [70]. TFEB is not the only transcription factor have 
effect on autophagy gene regulation. FoxO3, HIF-1, and p53 have also been 
shown to activate the expression of autophagy genes in response to various 
stresses [77, 78], However, while FoxO3, HIF-1, and p53 promote expression of 
genes implicated in the initial steps of autophagosome formation, TFEB appears 
to have a much broader role since it upregulates a more comprehensive network 
of autophagy genes. This network not only includes key regulators of 
autophagosome biogenesis but also proteins required for fusion between 
autophagosomes and efficient degradation of the autophagic content. In other 
words, TFEB is a major master autophagy regulator that control both the 
activation and degradation. In addition, by simultaneously regulating autophagy 
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induction and lysosomal formation, TFEB plays a unique role in the coordination 
of the two main degradative pathways in the cell.  
 
As such TFEB can regulate lipid catabolism [75], via the autophagic-lysosomal 
pathway. It was shown that TFEB is induced by starvation through an 
autoregulatory feedback loop and exerts a global transcriptional control on lipid 
catabolism via Ppargc1α and Ppar1α. Thus, during starvation, a transcriptional 
mechanism links the autophagic pathway to cellular energy metabolism. TFEB’s 
role in lipid metabolism is multi-faceted. Over-expression of TFEB in mouse liver 
leads to increased expression of genes implicated in different types of lipid 
breakdown, including fatty acid oxidation, lipophagy, and ketogenesis. TFEB 
over-expression is sufficient to reverse obesity and metabolic syndrome in mice. 
However, this rescue is not observed in autophagy-deficient animals (Atg7 −/−), 
thus suggesting that functional autophagy is essential for the role of TFEB in lipid 
metabolism. Finally, liver-specific TFEB knockout results in defective degradation 
of lipids during starvation, further showed the important role played by TFEB in 
responding to the varying energetic demands of the cell. 
 
TFEB is critical in the regulation of a gene network named CLEAR (Coordinated 
Lysosomal Expression and Regulation) [79].  The CLEAR gene network and its 
master gene transcription factor TFEB can regulate lysosomal biogenesis and 
function. A combination of genomic approaches, including ChIP-seq (sequencing 
of chromatin immunoprecipitate) analysis, profiling of TFEB-mediated 
23 
 
transcriptional induction, genome-wide mapping of TFEB target sites and 
recursive expression meta-analysis of TFEB targets, has identified 471 TFEB 
direct targets that represent essential components of the CLEAR network. This 
analysis revealed a comprehensive system regulating the expression, import and 
activity of lysosomal enzymes that control the degradation of proteins, 
glycosaminoglycans, sphingolipids and glycogen. The CLEAR network also 
involved in the regulation of additional lysosome-associated processes, including 
autophagy, exo- and endocytosis, phagocytosis and immune response. 
Furthermore, non-lysosomal enzymes involved in the degradation of essential 
proteins such as hemoglobin and chitin are also part of the CLEAR network. 
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1.1.4. Autophagy, Its Regulation Pathways, and Functions in Liver  
 
1.1.4.1 Introduction 
 
Autophagy is an evolutionarily conserved cellular process essential for 
development, differentiation, homeostasis and survival. Although the concept of 
autophagy was established quite early [80], it is only recently that this 
phenomenon becomes an intensely studied subject for its implications in 
fundamental cell biology and its roles in the pathogenesis of such disease status 
as tissue injury, microbial infection, cancer, neurodegeneration, and aging [81].  
 
Autophagy (from the Greek, “auto” oneself, “phagy” to eat) refers to cellular 
degradation that involves the delivery of cytoplasmic cargo (macromolecules or 
organelles) to the lysosome.  There are three types of autophagy, 
macroautophagy, microautophagy and chaperone-mediated autophagy[82].  
Macroautophagy is a process in which cytosolic materials are sequestered by 
autophagosomes, which transport them to the lysosome for degradation.  
Macroautophagy can be activated by many signals and is perhaps the most 
active form of autophagy in terms of the turnover of the cytosolic materials.  The 
process of microautophagy includes direct engulfment of cytoplasmic cargo at a 
boundary membrane of the lysosome, which mediate both invagination and 
vesicle scission into the lumen of lysosomes [83].  Microautophagy is mainly 
defined in the yeast, but also seen in the mammalian cells [84].  Microautophagy 
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of soluble substrates can be induced by nitrogen starvation or by rapamycin.  
Microautophagy process is regarded as a protection mechanism in both 
mammalian and non-mammalian cells [85].  Similar to macroautophagy, 
mmicroautophagy is can be either non-selective or selective. Selective 
microautophagy includes micropexophagy, piecemeal microautophagy of the 
nucleus, and micromitophagy.[86-88]  Chaperone mediated autophagy (CMA) 
involves direct shuttling of specific proteins across the lysosomal membrane for 
degradation in the lumen [89]. All the proteins internalized in lysosomes through 
CMA contain in their amino acid sequence a pentapeptide motif that is necessary 
and sufficient for their targeting to lysosomes.  These sequences can be 
recognized by chaperone proteins. CMA thus does not involve the formation of 
non-lysosomal vesicles.  
 
This section will focus on the signaling and role of macroautophagy in liver 
pathobiology and disease.  Macroautophagy, referred to as autophagy here, has 
been widely studied in the context of liver pathophysiology.  In fact, degradation 
of mitochondria and other intracellular structures was observed in 1960s by 
Christian de Duve and the colleagues in rat livers perfused with glucagon [90]. 
Autophagy in hepatocytes can be quite active at the basal stage as well as under 
stressed conditions, thus contributing to normal hepatocyte functions and 
pathogenic changes in the liver. 
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1.1.4.2 The Molecular Mechanism of Autophagosome Biogenesis 
 
The cargo-carrying vesicular structure formed during autophagy is known as the 
autophagosome.  The origin of the autophagosomal membrane has been 
controversial.  Various models have been proposed [91]. These include that the 
membrane is synthesized de novo and that it is derived from pre-existing cellular 
membranes such as the endoplasmic reticulum (ER) [92, 93], the Golgi complex 
[94], the mitochondria [95] and the plasma membrane [96]. Recent studies 
suggest that the ER is the most plausible candidate for the initial membrane 
source and/or the platform for autophagosome formation following amino acid 
starvation [97]. Electron tomography studies found the connection of initial 
autophagosomal membranes to the ER membranes [98, 99].  An ER membrane 
structural known as the omegosome identified by the molecule DFCP1 seems to 
be a site where transition into autophagosomal membrane occurs [100].  In 
addition, ER-derived COPII-coated vesicles, which bud from a specialized 
domain of the ER called the ER exit site (ERES), are found to contribute to 
autophagosome formation [101]. COP II vesicles are generally transporter 
vesicles, migrating from ER to the Golgi. Consistently, Liang et al used a 
systematic membrane fractionation approach and identified the ER-Golgi 
intermediate compartment (ERGIC) as the most efficient membrane substrate for 
LC3 lipidation by recruiting the key early autophagic factor ATG14 [94]. It has to 
be noted that membranes other than that of ER could contribute to 
autophagosome formation and/or maturation at the early or later phase of the 
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process.  This may be particularly meaningful in selective autophagy in which 
specific subcellular organelles are selectively targeted.  
 
In the past decade, researchers have elucidated key molecular pathways that 
regulate the autophagy. These cascades consist mainly of Atg (Autophagy) 
proteins [102].  In mammalian cells, the initiation of autophagosomes requires 
ULK1 complex [103] and the autophagy-specific Beclin 1 complex, whereas 
autophagosomal membrane expansion requires two ubiquitin-like conjugation 
systems, Atg12 conjugation to Atg5 and LC3 conjugation to 
phosphatidylethanolamine (PE).  The ULK complex is composed of ULK1 or 
ULK2 (the mammalian ortholog of yeast Atg1), FIP200, mAtg13 and Atg101 [104].  
The autophagy-specific Beclin 1 complex is composed of Beclin 1 (the 
mammalian ortholog of yeast Atg6), Atg14, and class III phosphatidylinositol-3-
kinase (PI3KC3) subunits Vps34, and Vps15. In response to decreased or 
increased nutrient and energy supplies, AMP activated protein kinase (AMPK) 
promotes autophagy, while the mTOR suppresses autophagy, respectively. 
AMPK can directly activate ULK1 by phosphorylation of the residues Ser317 and 
Ser777 while mTOR can inhibit ULK1 by phosphorylation of the residue Ser757, 
which disrupts the interaction between ULK1 and AMPK [105]. This coordinated 
phosphorylation is important in autophagy induction. Following amino-acid 
starvation or mTOR inhibition, the activated ULK1 phosphorylates Beclin-1 on 
Ser14, which is required for full autophagic induction by enhancing the activity of 
the ATG14-containing VPS34 complexes [106].  These events occur at the 
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candidate autophagosomal membranes following the recruitment of the 
molecular complexes, resulting in an increase of phosphatidylinositol 3-
phosphate (PI3P) on these membranes.   
 
Yeast Atg18/Svp1 and its related protein Atg21 both have the Phe-Arg-Arg-Gly 
(FRRG) motif, through which they can bind PI3P and phosphatidylinositol 3,5-
bisphosphate (PI(3,5)P2) [107, 108].  Atg18 localizes to the autophagosome 
initiation site in the yeast cells or the endosomes, and regulates the autophagy 
and vacuolar morphology through binding with PI3P and PI(3,5)P2, 
respectively[109]. Atg2, an Atg18-interacting protein of 200 kDa, is also 
important for the localization of Atg18 to the autophagy site in the yeast [110].  
There are four mammalian Atg18 homologs, WIPI1, WIPI2, WIPI3 and WIPI4.  
However, it seems that only WIPI2 is recruited to the autophagosomal 
membranes via binding to PI3P [111](Sharon Tooze).  WIPI2b can then recruit 
Atg16 complex onto the membranes via its interactions with Atg16 [112]. 
 
The latter is in a complex with the conjugated Atg12-Atg5.  Conjugation of Atg12, 
a ubiquitin-like molecule, to Atg5 requires Atg7, a molecular similar to the 
ubiquitin-activating enzyme (E1), and Atg12, an E2-like molecule.  The Atg12-
Atg5 complex then binds to Atg16 to form a multimer-complex in which two units 
of Atg12-Atg5-Atg16 are presents [113].  Another ubiquitin-like pathway involves 
the conjugation of LC3 and several other yeast Atg8 homologs, also ubiquitin-like 
molecules, to phosphatidylethanolamine (PE) on autophagosomal membranes, 
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through the effect of Atg7, and another E2-like molecule, Atg3 [113]. Notably, the 
Atg5-Atg12-Atg16 complex is required for the efficient conjugation of LC3 to PE, 
thus acting like an E3 ligase functionally [114]. This requirement may also ensure 
that LC3 conjugate to the candidate autophagosomal membrane where Atg5-
Atg12-Atg16 is located due to the interaction with AIPI2b [115].  The conjugation 
of LC3 is required for the autophagosomal membrane to expand and to complete 
the formation of the vesicular structure.  The Atg5-Atg12-Atg16 complex 
disengages the membranes after LC3 is conjugated.  These molecules are thus 
associated only with the early autophagosomal membrane and are considered as 
its markers.  LC3 and other Atg8 homologs remains on the autophagosomes and 
are considered as the general marker of autophagosomes from the early to the 
later stage [116].   
 
While there is only one Atg8 in the yeast, there are at least six Atg8 homologs in 
mammalian cells, which include three LC3 subfamily members (LC3A, LC3B, 
and LC3C), and three GABARAP subfamily members (GABARAP, GABARAP-
L1/Atg8L, and GABRAP-L2/GATE16).  Before activation by Atg7, Atg8 molecules 
have to be first processed by a cysteine protease, Atg4, at a conserved glycine 
site.  This exposed glycine is required for these molecules to be conjugated to 
PE [116, 117].  There are four mammalian homologues of Atg4 including Atg4A, 
4B, 4C, and 4D.  Their cleavage activity is different with Atg4A mainly targeting to 
the GABARAP subfamily proteins while Atg4B can effectively cleave all but more 
so toward the LC3 subfamily members [118].   
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Atg9 is another important molecule for autophagosome expansion. Since it 
cycles between the initiation site and different cytoplasmic membranes [119], it 
has reasonably been assumed to be associated with membrane that contributes 
to autophagosomes. Recent studies in yeast suggested that tubulovesicular 
structures containing Atg9 are delivered to the initial membrane [120]. 
Mammalian Atg9 (mAtg9) was more recently implicated in autophagy. Under 
normal growth conditions, this transmembrane protein, which is synthesized in 
the ER, localizes to the Golgi complex, the trans-Golgi network, and the late 
endosomes. Following amino-acid starvation, this protein translocates to LC3-
labeled autophagosomes in an ULK1- and PI3K-dependent manner [121]. 
Cycling of mAtg9 is negatively regulated by p38α MAPK, which competes with 
mAtg9 for binding to p38IP [122].    
 
After autophagosome are formed, they migrate to where lysosomes are located 
and engaged in the fusion with the later form the autophagolysosome, in which 
the content of the autophagosome is degraded.  The cytoskeleton seems to be 
involved in the movement of autophagosomes, which tend to be distributed 
closer to cell surface, toward the perinuclear region, where the lysosomes are 
enriched.  Agents such as nocadazole, which are microtubule poisons, can block 
fusion of the autophagosome with the lysosome, perhaps by preventing the 
movement of autophagosomes.  Numerous molecules can participate in the 
fusion process, including the Rab family GTPase Rab7, Sec18, the SNARE 
proteins Vam3, and the class C Vps/HOPS complex proteins. Recent findings 
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have identified syntaxin 17 (Stx17) as the autophagosomal SNARE required for 
fusion with the endosome/lysosome [123]. Stx17 localizes to the outer membrane 
of completed autophagosomes, interacts with SNAP-29 and the 
endosomal/lysosomal SNARE family molecule, VAMP8. Stx17 has a unique C-
terminal hairpin structure mediated by two tandem transmembrane domains 
containing glycine zipper-like motifs, which is essential for its association with the 
autophagosomal membrane.  
  
Once fused, the inner membrane of the autophagosome and the cytoplasm-
derived materials contained in the autophagosome are degraded by 
lysosomal/vacuolar hydrolases i.e. Cathepsin B, Cathepsin D. Monomeric units 
of the digested macromolecules, such as amino acids, are exported to the 
cytosol for reuse.  
 
1.1.4.3 Regulation of Autophagy by Metabolic and Stress Pathways   
 
The process of autophagy is well regulated. Multiple stimuli can promote or 
inhibit autophagy via different mechanisms.  Nutrient deprivation is one of the 
best known autophagy stimulators.  Other autophagy inducers include ER stress, 
oxidative stress, DNA damage [124].  The presence of extracellular nutrients (i.e, 
amino acids, fatty acid, and glucose) and growth factors (e.g., insulin and insulin-
like growth factor) can inhibit autophagy.  The Class I phosphatidylinositol 3-
kinase (PI3K) and the mammalian target of rapamycin (mTOR) are major 
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inhibitors of autophagy along the signaling pathways mediated by nutrients and 
growth factors [125].  AMPK, being a inhibitor of mTOR, can also promote 
autophagy.  It seems that AMPK is particularly responsive to glucose level, and is 
thus responsible for autophagy triggered by glucose-deprivation [126].  As 
discussed above, AMPK and mTOR can directly modulate ULK1 and Beclin 1 
complex to regulate autophagy induction.  
 
ER stress is another well-known autophagy inducer. The ER is the key 
compartment in the cell to facilitate folding of newly synthesized proteins and 
initiate the pathway of vesicular movement of membrane and proteins to various 
organelles and the cell surface. A number of factors can serve as ER stress 
stimuli, including expression of aggregate-prone proteins, glucose deprivation 
(resulting in reduced glycosylation and decreased energy for chaperone activity), 
hypoxia and oxidative stress (causing decreased disulfide bond formation), Ca2+ 
efflux from the ER and inhibition of proteasomes, all leading to the accumulation 
of unfolded proteins in the ER [127].  When the folding capacity of ER is 
exceeded, the unfolded protein response (UPR) signaling is triggered.  
Mammalian UPR involves three distinct downstream pathways mediated by IRE1 
(similar to yeast Ire1), ATF6 (activating transcription factor 6), and PERK (RNA-
dependent protein kinase-like ER kinase), respectively.  UPR causes a general 
reduction of protein synthesis but activation of the transcription of a selective 
group of proteins to increase ER folding capacity and degradation of unfolded or 
mis-folded proteins.  The latter is mainly mediated by the proteasome, known as 
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the ER-associated degradation (ERAD), but also by autophagy, known as ER-
associated autophagy (ERAA), particularly in the condition when the proteasome 
is suppressed [128-130].  It seems that mTOR is eventually suppressed, thus 
causing autophagy activation [131]. 
 
1.1.4.4 Autophagy in Liver Diseases-General Introduction 
 
Among the body organs, liver seems to possess the highest protein turn-over 
rate, which mainly depends on autophagy.  During starvation, mouse liver’s 
protein degradation rate increases from 1.5% of total liver protein per hour to 4.5% 
per hour.  If mice are starved for 48h, 40% of total protein in liver will be 
degraded [132, 133]. The high autophagy degradation rate is ensured by the 
abundant presence of lysosomes in the liver.  
 
As discussed above, Atg7 and Atg5 are very important autophagy core proteins 
due to their roles in the conjugation reactions. Mice lacking Atg7 or Atg5 have 
severe hepatomegaly, and livers can weigh as much as 30% of the body weight 
[134, 135].  Hepatocytes contain mitochondria and peroxisomes with marked 
structural alterations, as well as abundant amounts of polyubiquitinated proteins.  
One of the significantly accumulated proteins is SQSTM1/p62. This protein is 
able to polymerize via an N-terminal PB1 domain and can interact with 
ubiquitinated proteins via the C-terminal UBA domain. SQSTM1/p62 can bind 
directly to LC3 and GABARAP family proteins via a specific sequence motif [136].  
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The protein is itself degraded by autophagy and may serve to link ubiquitinated 
proteins to the autophagic machinery to enable their degradation in the lysosome. 
The accumulation of the misfolded polyubiquitinated proteins in the Atg7-deficient 
mice could be eliminated by a co-deletion of SQSTM1/p62, supporting its role in 
the liver pathogenesis caused by Atg7-deletion [137].  Furthermore, accumulated 
p62 could interact with Keap1, releasing Nrf2 to dramatically increase Nrf2-
dependent biological activity [138].  Although it is not quite understood, the liver 
injury caused by Atg5 or Atg7 deletion could be also reversed with the deletion of 
Nrf2 [138], suggesting that Nrf2 can mediate the liver injury phenotype in the 
absence of autophagy function.  
 
Traditionally autophagy is viewed as a non-selective process under nutrient 
deprivation condition. The non-selective bulk degradation of cytoplasm and 
organelles by autophagy can provide the basic building materials to support 
anabolic metabolism during starvation. However, selective removal of specific 
organelles by autophagy has now been well recognized [139]. All major 
organelles could be specifically targeted by autophagy, including mitochondria 
(mitophagy), ribosomes (ribophagy), endoplasmic reticulum (ER-phagy), 
peroxisomes (pexophagy), and lipid droplets (lipophagy).  The selective functions 
of autophagy indicate that it is important for maintaining cellular homeostasis by 
removing superfluous or injured organelles.   
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Selective autophagy can be important in liver disease.  Autophagy induced by 
ethanol seems to be selective for damaged mitochondria and accumulated lipid 
droplets, but not long-lived proteins [140]. Hepatitis C Virus (HCV) induces 
intracellular events that trigger mitochondrial dysfunction and can induce 
mitophagy, this process is evidenced by the colocalization of LC3 puncta with 
Parkin-associated mitochondria and lysosomes [141]. Similarly, HBV can also 
induce mitophagy and attenuates apoptosis [141].  Other researchers found 
mitophagy sometimes is harmful to liver instead of protection. Cadmium-induced 
hepatotoxicity is one of the examples: Cadmium induces mitochondrial loss via 
the over-activation of mitophagy following dynamin-dependent mitochondrial 
fragmentation, which seems to be the main mechanism of its liver toxicity [142]. 
 
One major function of liver is drug metabolism. A well-studied example is the 
induction of the cytochrome P-450 system by phenobarbital (PB)[143]. Notably, 
this is usually accompanied by extensive proliferation of smooth ER, where the 
catabolic reactions occur. Interestingly, smooth ER membranes could be 
selectively sequestrated by autophagic vacuoles. This is perhaps the first 
demonstrated example of selective autophagy. The removal of extra ER 
membranes through autophagy, known as ER-phagy, was later on confirmed by 
detailed morphological studies as well as biochemical studies. In the latter, 2 
typical ER membrane proteins, PB-inducible cytochrome P-450 and NADPH-
cytochrome P-450 reductase, were found to be selectively degraded by 
autophagy in rat liver following phenobarbital withdrawal [144]. Thus, autophagy 
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is important for the recovery of normal ER structure and function after drug 
treatment in order to avoid potential cellular dysfunction. 
 
1.1.4.5 Autophagy and Alcoholic/non-alcoholic Fatty Liver Disease  
 
Alcoholic fatty liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) 
share similar pathological changes that involve steatosis, inflammation, fibrosis 
and cirrhosis.  Autophagy has been found to be affected by the fatty liver disease 
and has been found to play important roles in the development of the disease.  
Autophagy function can vary in alcoholic livers depending on the stage.  Acute 
alcohol treatment activated hepatic autophagy in vivo and in cultured primary 
hepatocytes, which required ethanol metabolism, generation of reactive oxygen 
species, and inhibition of mammalian target of rapamycin signaling [140, 145]. 
Suppression of autophagy with pharmacologic agents or small interfering RNAs 
significantly increased hepatocyte apoptosis and liver injury; autophagy therefore 
protected hepatocytes from the toxic effects of ethanol.  
 
Chronic alcoholic treatment using the Lieber-DeCarli model also showed an 
elevation of autophagy when ethanol was given at a lower level (accounting for 
29% of the caloric need), but signs of suppression when ethanol was given at a 
higher level (accounting for 36% of the caloric need) [146].  However, in both 
cases, suppression of autophagy exacerbated liver injury while enhancement of 
autophagy improved the condition.  Chronic alcoholic treatment can lead to 
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decreases in both the number and the function of the lysosome, therefore 
reducing autophagic degradation [147].  Early studies showed the rate of hepatic 
protein degradation in EtOH-fed animals could decline significantly [148], which 
may be due to declines in both proteasome and autophagy function, contributing 
to the development of hepatomegaly and the development of Mallory-Denk body 
(MDB), a characteristic of alcoholic liver disease.  MDB is positive for ubiquitin 
and p62/SQSTM1, a condition found in protein aggregates, which is often seen in 
autophagy deficiency.  Indeed, by augmenting autophagy using rapamycin, an 
mTOR inhibitor, clearance of MDB can be achieved in a mouse model of MDB 
pathology [149].  
 
NAFLD is more prevalent in the content of the metabolic syndrome together with 
obesity and diabetes [150], and accounts for 75% of all chronic liver disease. 
There is no effective therapeutic approach for NAFLD [151, 152]. Multiple 
etiologies and regulatory disturbances can be involved in the pathogenesis of 
NAFLD.  Autophagy can affect, and in turn can be affected by, NAFLD.  Mice 
with a hepatocyte-specific deletion of Atg7 developed markedly hepatic steatosis, 
which was exacerbated by high fat diet-feeding [153].  Conversely, in both 
genetic and dietary models of obesity, autophagy was suppressed in the liver at 
least in part due to a reduction in the expression level of key autophagy 
molecules, such as Atg7 [154]. Autophagy deficiency was accompanied with 
defective insulin signaling and elevated ER stress. Restoration of Atg7 
expression in liver resulted in reduced hepatic steatosis, dampened ER stress, 
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enhanced hepatic insulin action, and systemic glucose tolerance in obese mice. 
The beneficial effects of Atg7 restoration in obese mice could be completely 
prevented by blocking a downstream mediator, Atg5, supporting its dependence 
on autophagy in regulating insulin action. These data indicate that autophagy is 
an important regulator, not only for the hepatic phenotype of the obesity, but also 
for the other metabolic disturbances, such as insulin resistance [154], which are 
often associated together [155]. 
  
In the development of NAFLD, autophagy can be regulated through different 
pathways and regulators, including the classic insulin-mTOR pathway [156]. 
More recent works have identified new regulators, such as p73, a member of the 
p53 tumor suppressor family.  Mice functionally deficient in all the p73 isoforms 
exhibit decreased Atg5 expression and lower levels of autophagy in livers, and 
increased steatosis [157]. P73 can transcriptionally regulate the expression of 
Atg5.  In a different scenario, stimulation of fatty acid β-oxidation by thyroid 
hormone (TH) is coupled with induction of hepatic autophagy, facilitating the 
delivery of fatty acids to mitochondria [158]. Blockade of autophagy markedly 
decreased TH-mediated fatty acid β-oxidation in both cell cultures and in animals. 
Consistent with this model, autophagy was altered in livers of mice expressing a 
mutant TH receptor that causes resistance to the actions of TH as well as in mice 
with mutant nuclear receptor corepressor (NCoR). These results demonstrate 
that THs can regulate lipid homeostasis via autophagy and help to explain how 
THs increase oxidative metabolism in liver.  
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Conversely, the fatty liver condition has significant effects on hepatic autophagy 
function.  Steatosis can impair autophagic degradation. p62/SQSTM1, an 
autophagy adaptor molecule, was accumulated in the liver of Ob/Ob mice, 
suggesting a deficiency in autophagic degradation [159]. Indeed, the hepatic 
levels of cathepsin B and L in Ob/Ob mice and NAFLD patients were reduced, 
accompanied with a reduced lysosome proteolytic activity.  In NAFLD patients, 
p62 aggregation was correlated with serum alanine aminotransferase value and 
inflammatory activity by NAFLD score [160]. In addition, the fusion between the 
autophagosome and the lysosome can be compromised by the excessive 
amount of lipids [161].  Hepatic lysosomal and autophagic compartments isolated 
from mice under different hepatic steatosis conditions had different levels of 
fusion. Increases in lipid concentration suppressed autophagosome/lysosome 
fusion up to 70% of that observed in untreated fractions or from animals under a 
normal regular diet. Furthermore, hepatic transcription levels of certain key 
autophagy genes could be suppressed in high fat diet fed mice, which seemed to 
involve the FoxO1-mediated transcriptional regulation [156, 162].  Finally, 
abnormal activation of protease, such as calpain, in fatty liver can significantly 
reduce the protein level of key autophagy molecules, including Atg5, Atg7 and 
Beclin 1, leading to a compromised autophagy function [154]. 
 
How autophagy may affect the pathogenesis of fatty liver condition is not quite 
clear. However, one of the main features of fatty liver is the excessive 
accumulation of fatty acids.  Free fatty acids can be detrimental to hepatocytes. 
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The esterified form sequestered in lipid droplets (LD) would be considered non-
harmful, although de-esterification can occur, which would increase cellular free 
fatty acids level.  Removal of lipid droplet may favor the equilibrium toward the 
formation of lipid droplets. Autophagosomes can transport the content of lipid 
droplets the lysosome in which lipids are degraded by the lysosomal acid lipase.  
This process is known as lipophagy [153]. Lipophagy is a type of selective 
autophagy processes but it is not clearly how autophagosomes recognize lipid 
droplets.  Colocalization of an autophagosome marker, LC3 and lipid droplet can 
be demonstrated in vivo and in vitro [140, 146, 153, 163].  Hepatic TG level in 
either alcoholic or non-alcoholic fatty liver disease models can be reduced by 
activating autophagy, or is elevated when autophagy is inhibited [140, 146, 153].   
 
Autophagy may also promote clearance of damaged mitochondria, a select 
autophagy process known as mitophagy, to protect against disease progression.  
This may be particularly relevant in alcoholic fatty liver disease in which 
mitochondrial damage is more apparent [164].  It is found that autophagy induced 
by acute ethanol administration did not influence much the turnover of long-lived 
proteins [140].  But mitophagy is clearly present based on the colocalization of an 
autophagosome marker, LC3, and the mitochondria in a lysosome function-
dependent manner.  Damaged mitochondria are prone to free radical generation 
and promote cellular injury.  Mitophagy could thus protect against this type of 
cellular injury.   
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The benefits of autophagy in protecting against ALD and NAFLD suggest that it 
may be possible to pharmacologically elevate or restore autophagy function to 
improve the liver status.  Indeed, applications of clinical available agents, such as 
rapamycin and carbamazepine, in mouse models of ALD and NAFLD have 
demonstrated the anticipated benefits [146]. These findings provide a basis for 
the future exploration of this approach in clinic.    
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1.2. Materials and Methods  
 
1.2.1 Animal Experiment 
 
All animal experimental protocols were approved by the Institutional Animal Care 
and Use Committee of Indiana University (IACUC). Animals were housed under 
approved conditions in a secured animal facility at the Indiana University School 
of Medicine with 12 hour light dark cycle. Bid knockout mice were generated in 
our lab. Wild type mice were purchased from Jackson Animal Laboratory. At 8 
weeks of age, mice were placed on normal chow diet, high fat diet (diet D12492, 
Research diets) for different durations. Animals were provided ad libitum access 
to these diets. 
 
1.2.2 Immunoblotting 
 
Mice liver was dissected and 250 mg of liver tissue was homogenized in NP-40 
lysis buffer containing 1% NP-40, 50mM Tris-Hcl (pH 7.5), 150mM NaCl, 0.05% 
SDS, 1mM aprotinin, 20ug/ml PMSF, 1.7ug/ml Aprotinin, 2.5ug/ml  Leupeptin, 
1ug/ml Pepstatin A and supplemented with 1 tablet per 10 ml Complete Mini 
Protease Inhibitor Cocktail (Roche, Mannheim, Germany). Mice liver tissue was 
dounced for 15 times using tight (B) pestle of a glass homogenizer.  Liver lysate 
was kept in pre-chilled Eppendorf tube on ice for 40 min. After centrifugation at 
15 000 × g for 15 min at 4°C, the supernatant was stored at −80°C until further 
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us. Protein concentration were measured by BCA method. Immunoblots with 
SDS-PAGE electrophoresis system were performed as previously described. Gel 
Running buffer contains 25 mM Tris Base, 192 mM Glycine, 0.1% SDS at PH 
8.2. Transfer buffer contains 25 mM Tris Base, 192 mM Glycine and 20% 
methanol (v/v). Transfer condition: 7 volt overnight/ 20 volt 2.5h. First antibody 
was dissolved in 5% Skimmed milk in TBS buffer or 5% BSA in TBS buffer. 2nd 
antibody from Jackson Laboratory was used at 1:5000 dilution. P-P70S6K 
antibody: Cell Signaling 9234 used in dilution of 1:1000. T-P70S6K antibody: Cell 
Signaling 9202 used in dilution of 1:1000. P62/SQSTM1 antibody: MBL PM045 
used in dilution of 1:1000. LAMP1 antibody: U of Iowa 1D4B used in dilution of 
1:1000. Atg7 antibody: Cell Signaling 2631 used in dilution of 1:1000. Beclin1 
(BECN1) antibody: Santa Cruz S11427 used in dilution of 1:1000. Actin antibody: 
Sigma A5441 used in dilution of 1:5000. TFEB: Abcam 113372 used in dilution of 
1:1000. Blots were developed by Immobilon Chemiluminescent HRP substrate 
(Millipore).  Image was acquired by Kodak 4000 image station system. 
 
1.2.3 Immunostaining and Bodipy Staining 
 
Briefly, slides containing 5µm cryosection prepared from frozen liver tissue was 
soaked in PBS and subjected to antigen retrieval using Citrate buffer pH 6.0. 
Slides were blocked with 5% serum/PBS containing 0.1% Triton X (PBS-Tx) for 1 
h and then incubated with primary antibody diluted in 5% serum/PBS-Tx for 2 h 
at room temperature or overnight at 4oC. Sections were washed in PBS-Tx, 
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following by incubation with fluorescence conjugated secondary antibody and 
nuclear staining by using Hoechst 33342 (1μg/ml). Fluorescent images were 
obtained using a Nikon Eclipse TE 200 immunofluorescence microscope. TFEB 
immunofluorescent antibody: Santacruz SC11009 was used in dilution of: 1:200. 
For Bodipy staining, liver tissue were fixed in 4% PFA for 4h, fixed tissues were 
subjected to gradient sucrose washing (5%-20%). Liver tissues were than fixed in 
OCT and subjected to cutting by Indiana University Health Pathology Laboratory. 
Bodipy (493/503) was dissolved (0.1mM) in 0.4% Triton X-100 and stained for 10 
min.  
 
1.2.4 Histology 
 
Different tissues from mice were harvested, washed with ice-cold PBS, and fixed 
in 10% formalin overnight and transferred to 70% ethanol the next day. Tissue 
blocks were processed by Indiana University Health Pathology Laboratory. 
Histochemical analysis was carried out on 4-um-thick sections using hematoxylin 
and eosin (H&E) and images were taken by Nikon Eclipse E200 microscope. 
 
1.2.5 ALT, Triglyceride and Cholesterol measurement 
 
Serum glutamic-pyruvic transaminase (SGPT) or alanine aminotransferase (ALT) 
were measured by ALT (SPGT) reagent kit (Pointe Scientific, Canton, MI).Briefly, 
serum was diluted for five times and samples were read in 340nm absorbance at 
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37C. Plasma triglyceride and cholesterol level were measured by Triglyceride/ 
Cholesterol kit (Pointe Scientific, Canton, MI).  
 
1.2.6 Hepatic Triglyceride Measurement 
 
80mg of frozen liver tissue were powdered under liquid nitrogen and incubated 
for 1 hour at room temperature with shaking to extract the lipid phase in total of 
1ml of chloroform-methanol mix (2:1). After addition of 200ul of H2O, samples 
were vortexed and centrifuged for 5min at 3000g. The lower lipid phase was 
collected and dried in hood overnight. The lipid pellet was resuspended in 60ul of 
tert-butanol and 40ul of a Triton X-114-methanol (2:1) mix. Triglycerides were 
than measured using the Pointe Scientific Triglycerides kit (Pointe Scientific, MI) 
 
1.2.7 Lysosome Enzyme Activity Assay 
 
Briefly, Liver tissue were homogenized using lysis buffer: Cathepsin B/D/E (0.1 M 
Sodium acetate 0.1 M Sodium chloride, pH 4.0), lysosomal acidic lipase (0.2 M 
Sodium acetate, Tween-80 0.1ul/ml, pH 5.5), and acidic phosphatase using 
assay kit (Sigma CS0740). Protein concentration of each sample were measured 
for standardization. Substrate and reaction buffer for each enzyme were added to 
reaction mix and incubate at 37oC for 45 min or 90 min (lysosomal acidic lipase). 
Plate were read in Tecan 96-well plate reader. Acidic phosphatase: absorbance 
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OD405, Cathepsin D/E: Ex: 365nm, Em: 440nm, Cathepsin B: Ex: 365nm, Em: 
440nm, Lysosomal acidic lipase: Ex: 327nm, Em: 449nm at 90min.  
 
1.2.8 Human Patient Study 
 
Liver biopsy samples from NAFLD clinically diagnosed patients in Indiana 
University Health were collected in Division of Gastroenterology and Hepatology. 
Clinical data acquisition was approved by Office of Research Administration of 
Indiana University. TFEB antibody: Abcam 113372 used in dilution of 1:100 
 
1.2.9 Gene Expression Analysis: Real-time PCR 
 
Liver tissue total RNA was extracted with GeneJET RNA purification kit (Thermo 
Scientific). Briefly, 30mg of frozen tissue were lysed by lysis buffer provided by 
kit, 600 ul of proteinase K were added and subsequently centrifuged for 12000g. 
Next, 450ul of ethanol were used and lysates were subjected for series washing 
by washing buffer provided by kit for RNA purification. RNA quality and 
concentration/amount was /quantified by A260/A280.  
 
Next, 5ug of RNA was reverse transcrived by M-MLV reverse transcriptase 
(Invitrogen), procedures were followed by manual from the supplier. For RT PCR 
amplification of target genes, Applied BioSystem and AmpliTaq Fast DNA 
polymerase were used for 40 cycles, temperature and duration were set 
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according to the manual. ---Analysis was performed by the 2∆∆CT method. 
QPCR results were normalized against gene PPIA 
Primer sequences used for the amplification are as follows: 
 
 ATP6V0D2   Fw - 5'-AAGCCTTTGTTTGACGCTGT-3' 
                      Rv - 5'-TTCGATGCCTCTGTGAGATG-3' 
 
Cathepsin B (CTSB)     Fw-5'-AAAAAGGCCTGGTTTCAGGT-3' 
                                      Rv-5'-GGGAGTAGCCAGCTTCACAG-3' 
 
Cathepsin D (CTSD)     Fw-5'-TCAGGAAGCCTCTCTGGGTA-3' 
                                      Rv-5'-CCCAAGATGCCATCAAACTT-3' 
 
Lysosomal Acidic Lipase (LIPA)     Fw-5'-AAGGTCCCAGACCAGTTGTG-3' 
                                               Rv-5'-TGTGCTTCAGAGACCAGGTG-3' 
  
Acid Phosphatase (ACP2)     Fw-5'-GAGCCTGTCATACCCAAGGA-3' 
                                               Rv-5'-AACATGGTGGTAGCCAGGAG-3' 
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1.2.10 Statistical Analysis  
 
Data were expressed as mean±SE. Differences between two treatment groups 
were compared by t test. When more than two groups were compared, on way 
ANOVA analysis was used. Results were considered statistically significant when 
P<0.05. All analyses were performed with Sigma Stat 3.5. 
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1.3   Results: 
 
1.3.1   The mTOR Activity Oscillates Under the Sustained Hyper-nutrition 
Condition.  
 
Excessive nutrition uptake is perhaps the most common cause of metabolic 
syndrome and non-alcoholic fatty liver disease (NAFLD). mTOR, as one of the 
most important molecules responsive to cellular nutrient status, is known to play 
a role in the development of NAFLD. We reasoned that its activity was likely 
changing in response to the change in nutrient supply. To examine this 
hypothesis, we fed mice with high fat diet for up to 32 weeks and collect samples 
at varies time points to examine the mTOR activity in correlation with hepatic 
steatosis.   
 
When activated, mTOR phosphorylates p70S6 kinase as its main target. The 
mTOR activity could be indicated by level of the phosphorylated p70S6 kinase 
(pp70S6K). A higher mTOR activity was reflected by a higher level of pp70S6K 
normalized by the level of total p70S6K. Conversely, a reduced mTOR activity 
was indicated by a lower level of pp70S6K.  When pp70S6K level, as measured 
by immunoblotting essay (Fig 1A) and densitometry (Fig 1B), was plotted against 
the duration of HFD feeding, a damping oscillation pattern was observed (Fig 
1C).  pp70S6K was steadily increased in the first 3 weeks of HFD feeding, but 
became reduced by 6 weeks and bottomed out at 10 weeks.  However, pp70S6K 
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level was increased again at 16 week of feeding, reduced again at 24 weeks, and 
returned to a higher level by 32 weeks.  This oscillation pattern, however, is 
reduced in magnitude over the time. Therefore it is mathematically known as the 
damping oscillation.  In order to further confirm the oscillation pattern of mTOR 
activity, we also stained the liver sections obtained from mice fed with regular 
diet or HFD for 3wk or 10wk for phospo-S6. As shown in Fig 1D, the 
phosphorylated S6, which is a target of p70S6K downstream of mTOR first 
increased in 3wk but then suppressed on the10wks samples.  
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1.3.2   TFEB is Activated in an Oscillation Pattern Under the Sustained Hyper-
nutrition Condition. 
 
Transcription Factor EB (TFEB) is a master transcription factor for lysosome 
function and biogenesis. More importantly, TFEB itself can be directly 
phosphorylated by mTOR at specific sites and becomes trapped in the cytosol, 
unable to activate its target genes [72]. Using the same groups of mice that were 
studied for mTOR activity (Fig 1), we conducted TFEB immunostaining on the 
cryosections of the liver (Fig 2A). As indicated in the quantification analysis, the 
percentage of cells with nucleus TFEB location, also showed a dynamic 
oscillation pattern (Fig 2B), but in a direction opposite to that of p70S6K 
phosphorylation. TFEB was more likely found in the nucleus of mice fed with 
regular diet but it moved out to the cytosol when mTOR was activated, e.g. at 
3wk and 16wk of high fat diet feeding. TFEB was back to the nucleus when 
mTOR was suppressed, i.e. at HFD 10wk.  Interestingly, the percentage of cells 
with TFEB-positive nuclei after 10wks of high fat diet treatment was even higher 
than that in mice given regular diet (Fig 2B), implicating that other possible 
regulations of TFEB may exist. Nucleus location of TFEB also showed a pattern 
of damping oscillation (Fig 2C). To test whether this dynamic change of TFEB 
location had any physiological impact, we also measured the expression of 
representative lysosomal enzyme genes by RT-PCR (Fig 2D). Correlated with 
TFEB location, the expression of three genes, lysosomal acidic lipase, cathepsin 
D and acidic phosphatase had all dynamic pattern. Another lysosomal membrane 
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protein gene, ATP synthase A6, didn’t show similar pattern. Its expression was 
lowest in 10wks and started to recover in 16wks after HFD feeding, indicating a 
possible delayed regulation by TFEB.  
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1.3.3. Lysosomal Functions Oscillate during Long-term High Fat Diet Feeding. 
 
Consistent with the nucleus location of TFEB and the lysosomal gene 
expression, the activities of cathepsin B, cathepsin D/E, lysosomal acidic lipase 
and acidic phosphatase all oscillated in the same (Fig3A-D). 
 
 Another major function of TFEB is to regulate lysosome biogenesis. Thus, we 
examined the level of a major lysosomal marker LAMP-1 by immunoblotting 
analysis (Fig3 E). Densitometry analysis (Fig 3F) indicated that expression of 
LAMP-1 also showed a dynamic change at different time of high fat diet 
treatment.  
 
Because mTOR negatively regulates TFEB function, the oscillation of the 
lysosome activity was the opposite in direction of that of mTOR activity. However, 
reduced mTOR activity can in turn leads to the suppression of mTOR activity as 
the action of mTOR requires a normal lysosomal function (see introduction). 
Thus we think the change in lysosome enzyme activity not only regulate the 
lysosome degradation capability, but also contribute to the damping oscillation 
pattern of mTOR in Fig 1.  
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1.3.4. Autophagy Degradation is Dynamically Regulated. 
 
Autophagy process is one of the major downstream events regulated by the 
mTOR complex 1. It can be directly suppressed by mTORC1 activation. 
Autophagy function has also been shown to be both altered by and contributed to 
NAFLD development. Autophagy’s contribution to NAFLD is mainly mediated by 
the lipophagy process [153]. But autophagy process can also be affected by 
excessive lipids in the cell. Previous studies have shown that the autophagy 
process either was activated [165] or suppressed [159], leaving some 
controversies in findings. It was not known how autophagy may be affected by 
high fat diet. We thus examined the autophagy activation and degradation at 
different time points. GFP-LC3 mice were fed with regular diet or high fat diet for 
different times. Chloroquine (CQ) was given (i.p) 16 hours before sacrifice to 
suppress the lysosome function and thus autophagic degradation in the liver. As 
shown in Fig 4A and B, autophagosomes were represented by GFP-LC3 dots. 
The number of GFP-LC3 dots per cell was increased after high fat diet treatment. 
However, further treatment with CQ did not give rise to a significantly higher 
increase, as would be expected in an activation status. In contrast, the increment 
of the increase following CQ treatment in the high fat group was smaller than that 
in the regular diet (Fig 4B), which was not due to the aging of the mice since 
mice at the same age but fed with regular diet did shown a significant increase in 
GFP-LC3 dots upon CQ treatment (Fig 4A, C). The incremental changes 
between these groups were the base for us to calculate the level of autophagy 
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activation and autophagy degradation capability (see Figure 4 legend for the 
detailed description of the formula). The result showed that activation of 
autophagy was suppressed through the duration of high fat diet (Fig 4D). 
However, the capability of the degradation of autophagosome was suppressed at 
0.5, 3wk and 16wk, but recovered at 1wk and 10wk of high fat diet feeding. The 
gain in the degradation occurred at 10wk (Fig 4E), in parallel with the lysosomal 
function. Notably, several autophagic molecules did not alter significantly in the 
expression during the same course (Fig 4F), suggesting that the change of 
autophagy degradation is mainly due to the change in lysosome function. 
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1.3.5. Degradation of Lipid Droplets by Lipophagy during NAFLD Development. 
 
Autophagy, more specifically, lipophagy, has been shown to be important in lipid 
degradation by the autophagosome-lysosome pathway [166]. Promotion of 
autophagy in NAFLD could ameliorate the disease [146]. As we have discussed 
in Figure 4, the autophagy degradation capability was reduced but periodically 
rebounded. We wanted to understand whether this oscillation pattern in long term 
high fat diet treatment had same effects on fatty liver development. Therefore, we 
examined the lipid content of the liver at different times after high fat diet with or 
without CQ treatment. Cryosections of the liver were stained and the intrahepatic 
lipid droplets were quantified (Fig 5A, B). Generally, autophagic degradation 
relies on the intact function of lysosome, inhibition of the lysosome function with 
CQ would suppress lipophagy leading to an increase in LD numbers. We found 
that after CQ treatment, the lipid droplet numbers were increased but to different 
degrees in mice with high fat diet treatment for different durations. Thus, the 
degradation of lipid droplet was relatively small in amount on 0.5wk, 1wk high fat 
diet regimen, but fell to nearly zero on 3wk regimen, which was observed again 
by 10wk but decreased again by 16wk of feeding (Fig 5C). Notably, those 
changes shared the same trend with autophagy degradation (Fig 4E), and 
lysosomal function (Fig 3). These findings indicated that autophagy degradation 
capability directly impacted lipid amount within the hepatocytes. 
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As a further confirmation of the finding made with the Bodipy staining method, we 
measured the level of hepatic TG in the same group of mice. Consistent with the 
staining, hepatic TG showed same dynamic changes at different time points of 
high fat diet treatment (Fig 5D).  
 
Severe steatosis, can lead to steatohepatitis and liver injury, the next stage of 
NAFLD, steatohepatitis. In order to check whether autophagy degradation affects 
liver injury, we measured serum ALT level. As shown in Fig 5E, CQ co-treatment 
exacerbated the injury. The trend correlated well with that of autophagy 
degradation and lysosome function in that there was more injury at 10wks, but 
less injury at 3 and 16wk of high fat diet treatment that was affected by 
autophagy or lysosome function. These data suggest that the dynamic of 
autophagy in high fat diet regimen regulates the dynamic development of NAFLD 
at the early stage.  
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1.3.6. The Subcellular Location of TFEB Location Correlates Highly with NAFLD 
and Obesity in Human. 
 
We found that TFEB exhibited dynamic translocations in and out of the nucleus 
under the sustained hypernutrient condition in mice (Fig2), which was inversely 
correlated with the mTOR activity (Fig1) but positive correlated with hepatic lipid 
droplet degradation (Fig 5). We hypothesized that the subcellular location of 
TFEB could be a sensitive marker for hepatic steatosis in human patients as well. 
Thus we collected, and stained with an anti-TFEB antibody on liver biopsy 
samples from patients who had been diagnosed of NAFLD or NASH. Indeed, we 
found that TFEB location in hepatocytes was negatively correlated with the 
severity of steatosis, which was scored using NAFLD scoring system published 
by Non-alcoholic Steatohepatitis Clinical Research Network [167] (Fig 6A-B). 
Those patients with low steatosis scores had a higher percentage of hepatocytes 
that stained positive for nuclear TFEB, whereas patients with high steatosis score 
had a lower percentage of hepatocytes with nuclear TFEB staining.  More 
interestingly, the correlation was stronger when patients younger than 35 years 
old were excluded. Excluding the young patients, the correlation coefficient 
reaches -0.91 (Fig 6C). 
 
We also studied the correlation of TFEB nuclear location with BMI, which 
assesses the severity of obesity. Surprisingly, we found that TFEB nuclear 
location was only mildly correlated with BMI, which become more strongly 
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correlated under the circumstance when younger patients and a patient who had 
discordant obesity and steatosis were excluded (Fig 6D and E). We then 
compared the TFEB staining pattern with other clinical parameters. TFEB nuclear 
location was negatively correlated with serum cholesterol (Fig 6F), but had no 
correlation with serum TG, ALT or AST (Fig 6G, H, I). Consistent with the TFEB 
study in the mouse model of NAFLD, these results suggest that TFEB is 
potentially a sensitive marker for steatosis, especially in high nutrition/obesity 
induced steatosis in middle-aged and elderly patients. But it may not be 
correlated with liver injury or steatohepatitis, a later stage of NAFLD.   
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1.3.7. Suppression of mTOR Activity Promotes TFEB Translocation to the 
Nucleus and Rescues the Lysosome Function in the Fatty Livers. 
 
Previous reports have shown that mTOR can directly suppress TFEB by 
phosphorylation [72]. In order to check whether TFEB nucleus location is due to 
mTOR activation under high fat diet regimen, we pharmacologically suppressed 
mTOR activity using rapamycin. We specially designed an administration 
strategy so that rapamycin was given at the time point when mTOR was highly 
activated, i.e. at 3wk or 16wk after High fat diet treatment. As shown in Fig 7A, 
both dosage of 2mg/kg and 4mg/kg successfully suppressed mTOR’s ability to 
phosphorylate p70S6K and 4EBP1. At the same time TFEB was translocated to 
the nucleus in a dose dependent manner (Fig 7B and C). To further confirm the 
translocation and dephosphorylation of TFEB by mTOR, we performed 
immunoblotting assay. As shown in Fig 7D, more TFEB was found in the nuclear 
fraction of the rapamycin-treated mice. There was a mobility shift of the nuclear 
TFEB in the 4mg/kg group, which was consistent with the molecule being 
dephosphorylated, likely due to mTOR suppression.  
 
We then explored whether the suppression of mTOR had physiological 
consequences. We found that the mRNA expression of several representative 
TFEB target lysosomal enzymes: lysosomal acidic lipase, cathepsin D, acidic 
phosphatase and ATP synthase was increased following rapamycin 
administration, only the ATP synthase didn’t show dose dependent manner, 
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probably meaning saturation at 2mg/kg dosage (Fig7E-H). Consistently, the 
activities of cathepsin B, cathepsin D/E and lysosomal acidic lipase activities had 
recovered in a dose dependent manner (Fig 7I-L). However, the activity of acidic 
phosphatase didn’t further recover at the 16wk time point for which the reason 
was unknown. 
 
We thus confirmed that at 3wk and 16wk of HFD treatment, lysosomal function 
was impaired due to mTOR activation, which could be reserved by the inhibition 
of mTOR.  
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1.3.8. Overexpression of Wild Type or mTOR resistant TFEB Mutant Improves 
Lysosomal Functions, Hepatic Fat content and Liver Injury in 3wk High Fat Diet 
Mice. 
 
The above study indicated that by disrupting mTOR activity with rapamycin, we 
can reactivate TFEB and improve lysosomal functions. To further test whether 
improved lysosmal function can lead to reduced hepatic steatosis, we over-
expressed TFEB in the mouse livers using adenoviral vectors.  
 
As TFEB has been found to be phosphorylated at specific site and be retained in 
the cytosol by mTOR, we used not only wild type TFEB but also a site-specific 
mutant S211A TFEB, which is resistant to mTOR phosphorylation [168]. We 
have made S211A TFEB adenovirus and expected it would have a higher ability 
to regulate lysosome activity. We injected the virus at the first day of high fat diet 
treatment and collected samples three weeks later. By western blotting assay. 
We confirmed that both WT and mutant TFEB had been successfully expressed 
in the mice liver (Fig 8L). We then compared lysosomal enzyme activities in WT-
TFEB, S211A-TFEB and control mice. As we have expected, TFEB S211A - 
injected mice had the highest level of cathepsinB, cathepsin D/E, lysosomal acid 
lipase and acidic phosphatase activities, whereas the enzyme activity levels in 
mice receiving WT- TFEB were also increased (Fig 8A-D). As regards to 
phenotypic changes, administration of either WT or mutant TFEB resulted in 
decreased body weight (Fig 8E). However, only administration of mutant TFEB 
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resulted in decreased liver weight and thus the liver weight/body weight ratio, 
(Fig 9F, G). Similarly, liver steatosis level, as indicated by hepatic triglyceride, 
also decreased in mice receiving wild type TFEB and partially in mice receiving 
mutant TFEB (Fig 9H). Mutant TFEB also had the strongest protection of liver 
injury in NAFLD development, as indicated by in serum ALT level (Fig 8I). We 
didn’t observe any differences in serum triglyceride level (Fig 9K). Mutant TFEB 
had also lowered the serum cholesterol level (Fig 8J).  
 
These findings have implicated that TFEB could improve hepatic lysosomal 
activities and delay NAFLD development induced by high fat diet treatment in 
mice. 
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1.3.9. Overexpression of TFEB Improves Lysosomal Functions, Hepatic Fat 
content and Liver Injury in 16wk High Fat Diet Fed Mice.  
 
To examine the effect of TFEB overexpression in mice given high fat diet for a 
longer term, we gave WT TFEB to mice fed with high fat diet for 16wk.  As shown 
in Fig 9A-D, cathepsinB, cathepsin D/E, lysosomal acid lipase and acidic 
phosphatase all recovered, although not statistically significant in acidic 
phosphatase. In addition, the body weight, liver weight and liver weight/body 
weight ratio were all lower in TFEB-injected mice (Fig 9E-G). Liver steatosis was 
protected by WT TFEB overexpression, as indicated by hepatic triglyceride 
measurement (Fig 9H) and H-E staining (Fig 9I). Serum cholesterol and 
triglyceride (Fig 9J, K) were also decreased, indicating that dyslipidemia was 
protected by WT TFEB expression as well.  Overexpression of TFEB could thus 
improve lysosome function, hepatic steatosis and liver injury (Fig 9L). 
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1.3.10. Consistent Activated RagA Mutant Inhibited TFEB Translocation, TFEB 
Activity, Lysosomal Function and Liver Function. 
 
The above studies showed that enabling TFEB activity by either suppressing 
mTOR or over-expressing TFEB, particularly the mTOR-resistant TFEB, could 
enhance lysosomal function and improve hepatic steatosis. We then examined 
the hypothesis that a sustained mTOR activity would lead to a more severe 
suppression of TFEB and exacerbate hepatic steatosis. To achieve this goal, we 
gave high fat diet - fed mice with an adenovirus carrying a consistently activated 
HA-tagged RagA mutant, RagAGTP/GTP. As mentioned in the Introduction part, 
mTORC1 interacts with, and its activity depends on, Rag proteins. Expression of 
RagAGTP/GTP in cells renders the mTORC1 activation independent of amino acid 
activation and could thus constitutively activate mTOR in nutrient-depleted 
conditions. RagAGTP/GTP adenovirus was injected to mice by tail vein after 6 
weeks of high fat diet treatment and the mice were sacrificed at 10wk after 
another 4 weeks of high fat diet treatment. The total high fat diet feeding time 
was 10 wks, the time points when mTOR activity was low (Fig 1).   
 
As shown in Fig 10A, we first confirmed that exogenous RagAGTP/GTP was 
successfully expressed in the livers, by immunoblotting analysis using anti-RagA 
and anti-HA antibodies.  mTOR activity was consequently elevated, with a high 
level of phosphorylation of p70S6K and 4EBP1, compared to the vector-only 
group. As anticipated, TFEB was retained in the cytosol in virus-injected mice, 
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instead of in the nucleus as in the control group (Fig 10B). To determine whether 
activation of mTOR had the effect on lysosomal function, we measured mRNA 
expressions of lysosomal acidic lipase, cathepsin B, cathepsin D and acidic 
phosphastase and found all were suppressed following virus injection (Fig 10C-
F). Similarly, the activities of cathepsinB, lysosomal acidic lipase and acidic 
phosphatase were also impaired in the RagAGTP/GTP group (Fig 10G-I) 
 
We then studied if constitutive activation of mTOR at 10wks had any effects on 
NAFLD development. As we expected, in virus-injected group, the liver weight 
and the liver/body weight ratio were higher (Fig 8J-L). The levels of hepatic 
triglyceride amount and serum ALT were also increased (Fig 8M-N), compared 
with the control group. These findings indicate that by re-activating mTOR at the 
time point of 10wk of high fat diet feeding, we can promote hepatic injury and 
steatosis. 
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1.4 Discussion: 
 
Activation of mTOR is believed to be related to cell growth and proliferation. 
Whether the activation of mTOR is persistent in the duration of high fat diet 
feeding has not been characterized. This question is meaningful because 
activation of mTOR can cause pathological changes to cells, organs, and the 
body [10].  In this part of study, we have shown that mTOR can be down-
regulated in high nutrition status. mTOR was activated soon after high fat diet 
started and reached the peak activation at 3wks. After 6 to 10wks of feeding, 
mTOR activity has reduced and returned to almost base line. Later during the 
continuous high fat diet stimulation, mTOR activities had gone through several 
oscillations again and finally reached to a quite low level in mice fed with high fat 
diet for 32 wks.  
 
mTOR activation relies on intact lysosomal function. Major genes of lysosome 
biogenesis and enzyme activity are transcriptionally controlled by TFEB. 
Meanwhile, TFEB can be directly phosphorylated and suppressed by mTOR in 
the cytosol. Thus, TFEB plays important role in mTOR activity. We have shown 
in Figure 2 that the subcellular location of TFEB also oscillates during high fat 
diet regimen, in a direction opposite to that of mTOR oscillation (Fig 11B). As we 
expected, expression of downstream genes and activation of lysosomal enzyme 
also changed along with the change of the location of TFEB. This interesting 
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phenomenon demonstrated a link between mTOR activation and lysosome 
activity during long term high fat feeding (Fig 11 A). 
 
Oscillation mTOR activation has been observed in an early study [169]. Under 
the starvation condition, mTOR is suppressed and autophagy is activated. 
However, mTOR can be reactivated by prolonged starvation. Reactivation of 
mTOR is autophagy-dependent and requires the degradation of autophagosome 
contents in lysosomes. This finding implies a mechanism in which mTOR activity 
is dependent on lysosome. Thus lysosome dysfunction can affect mTOR 
activation. A self-feedback regulatory loop of mTOR is composed of mTOR, 
TFEB, lysosome activity. When activated by high fat diet, mTOR suppresses 
TFEB by phosphorylation and subsequently impairs lysosomal activities. When 
the lysosomal function is impaired, mTOR would be in turn de-activated (Fig 
11B). Once the mTOR activity is down-regulated, TFEB is released and 
promotes lysosomal function, which would allow mTOR reactivation once again. 
Interestingly, the magnitude of the reduces over the time, oscillation pattern of 
mTOR indicating that the activity of mTOR finally returns to the baseline. This 
pattern has been reported in physical sciences as a natural response of a system 
to a change from equilibrium. The response of mTOR activation in high fat diet 
regime is not an "on/off" events but rather a process of the body to equilibrate the 
outside stimulation to a more stable status. The damping oscillation pattern has 
been also observed in NF-κB activation followed by the stimulation of TNF-alpha 
[170]. 
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Evolutionarily, human beings have acquired the ability to store excessive 
nutrients in the form of fat for future use when in starvation. Thus, pathways 
related to catabolic metabolism shuts down and anabolic metabolism is 
activated, such as mTOR in high nutritious status. This evolutionary acquirement 
has its advantage in times when food is restricted. However, in times when food 
is in surplus, persistent anabolic activation can be harmful. Excessive fat storage 
can be found in liver, muscle and other non-fat storing tissues. Here, our study 
indicate that anabolic metabolism mediated by mTOR can be down-regulated 
through the TFEB-lysosome mechanism. 
 
Early development of steatosis is critical in the pathogenesis of NAFLD, both in 
terms of diagnosis and treatment. Here in this study, we have also discovered a 
potential sensitive marker for early NAFLD diagnosis. TFEB staining is negatively 
correlated with the traditional steatosis score. As the staining pattern of TFEB 
can be easily quantified, this may become an effective way to access severity of 
steatosis. It is worth to be noticed that the application of TFEB in diagnosis may 
be only effective in diet/obesity induced NAFLD in middle aged to elderly 
patients, as in young patients and patients with non – obesity NAFLD steatosis 
does not seem to correlate with TFEB location. The early and effective treatment 
of NAFLD has not been well developed [171]. We found that overexpression of 
mutant and WT TFEB in mice can significantly improve steatosis and metabolic 
syndrome, which could be a potential target in the treatment.  
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Furture studies should be focused on other consequences of mTOR oscillation 
related to metabolism, such as SREBP1, which is important for lipid synthesis. 
Because mTOR also controls metabolism related to cell growth, whether these 
phenotype show a similar pattern of change remains to be explored. 
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1.5 Figures and Figure Legend 
 
Figure 1:  The mTOR activity oscillates under the sustained hyper-nutrition 
condition. 
(A) GFP-LC3 mice were fed with HFD for the indicated durations and the mTOR 
activity (phospho-p70S6 kinase level) in the liver was analyzed by immunoblot 
assay. Each lane represents one individual mouse. (B) Densitometry analysis 
were performed for phosphor-p70S6 kinase (p-p70S6K) in each group. The value 
(mean + SEM) is normalized with the level of total p70S6 kinase (T-p70S6K). (C) 
The relative levels of p-P70S6K were plotted against the time. A damping 
oscillation pattern can be observed.   
n=4-6 per group, *: p<0.05 
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Figure 1:  The mTOR activity oscillates under the sustained hyper-nutrition 
condition. 
(D) phospho-S6 expression were analyzed by Immunohistochemistry staining in 
the liver tissue of C57BL wild type mice fed with HFD for the indicated time point. 
Magnification X100. Representative images were shown.  
n=4-6 per group, *: p<0.05 
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Figure 2:  TFEB is activated in an oscillation pattern under the sustained 
hyper-nutrition condition.  
(A) GFP-LC3 transgenic mice were fed with HFD for the indicated durations. The 
cryosection of the liver tissues were stained with anti-TFEB and Hoechest 33328 
(for the nucleus). Insets show representative hepatocyts at a higher 
magnification. (B) The percentage of cells with TFEB-positive nuclei was 
quantified. (mean+ [SEM]) 
n=4 per group, scale bar=10um, *: p<0.05 
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Figure 2:  TFEB is activated in an oscillation pattern under the sustained 
hyper-nutrition condition.  
(C) The percentage of cells with TFEB-positive nucleus was plotted against the 
feeding duration. (D) The mRNA levels for the TFEB targets were analyzed by 
RT-PCR in the same group of mice fed with high fat diet for different times. LAL: 
lysosomal acidic lipase; CTSD: cathepsin D; AP: acidic phosphatase; ATP6: ATP 
synthase subunit 6. 
n=3 per group, *: p<0.05 
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Figure 3:  Lysosomal functions oscillate during long-term high fat diet 
feeding. 
GFP-LC3 transgenic mice were fed with HFD for the indicated durations. Livers 
were analyzed for the activity of cathepsin B (A), cathepsin D&E (B), lysosomal 
acidic lipase (C), acidic phosphatase (D). (mean+standard error of mean[SEM])  
n = 4 per group, ∗: p <0.05 
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Figure 3:  Lysosomal functions oscillate during long-term high fat diet 
feeding. 
(E): Expression of LAMP1 in the livers of high fat diet fed mice was analyzed by 
immunoblotting assay. Each lane represents an individual mouse (F): 
Densitometry analysis of LAMP1 expression in the same groups of mice.  
n = 3 per group, ∗: p <0.05  
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Figure 4: Autophagy degradation is dynamically regulated. 
(A) GFP-LC3 transgenic mice were fed with regular diet or high fat diet for the 
indicated duration, with or without a treatment with CQ (60 mg/kg, ip) for 16 h 
before sacrifice. Liver cryosections were prepared and images were obtained by 
fluorescent microscopy. Green GFP-LC3 puncta represent autophagosomes. (B) 
GFP-LC3 puncta per cell (mean+SEM) were quantified from each animal. (A and 
C) GFP-LC3 transgenic mice were fed with a regular chow diet for the indicated 
duration, with or without a treatment with CQ. GFP-LC3 puncta (mean+SEM) 
were quantified from each animal.  
Scale bar: 10 um. n = 4–6 per group, *: p<0.05 
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Figure 4: Autophagy degradation is dynamically regulated. 
(D-E) Autophagy synthesis (D) and degradation (E) were calculated based on 
GFP-LC3 puncta/cell. The values were then plotted against the feeding duration. 
The number of GFP-LC3 dots level in the following groups are subjected to the 
subtractive operations as indicated. Calculation of degradation: HFD/CQ - HFD. 
Synthesis: HFD/CQ – RD/CQ (F) Autophagy related proteins were analyzed by 
immunoblot essay. 
n = 4–6 per group   
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Figure 5: Degradation of lipid droplets by lipophagy during NAFLD 
development. 
(A-B) GFP-LC3 transgenic mice were fed with HFD for the indicated durations. 
The cryosections of the liver were stained with Bodipy (493/503) for lipids 
droplets (A), which were quantified (mean+SEM) (B). (C) Degradation of lipid 
droplets were calculated by subtracting the number of lipid droplets in high fat 
diet group from that of lipid droplets in high fat diet/CQ group. (mean+SEM).  
Scale bar: 10 µm.  n=3-6 per group, *: p<0.05 
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Figure 5: Degradation of lipid droplets by lipophagy during NAFLD 
development. 
(D) Hepatic triglycerides were measured in the same group of mice 
(mean+SEM). (E) Liver injury were assessed by the serum alanine transaminase 
(ALT) measurement in the same group of mice (mean+ SEM).   
n=3-6 per group, *: p<0.05 
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Figure 6: The subcellular location of TFEB correlates highly with NAFLD 
and obesity in human. 
(A) The liver biopsy sample of NAFLD patients were stained with H-E or with 
anti-TFEB antibody. Representative mild and severe cases were shown (200X). 
Insets show enlarged images.  
Patient No. n=15-19 
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Figure 6: The subcellular location of TFEB correlates highly with NAFLD 
and obesity in human. 
(B) Correlation of steatosis score and percentage of cells with TFEB positive 
nucleus. (C) Correlation of steatosis score and percentage of cells with TFEB 
positive nucleus excluding clinically significant outliers. (D): Correlation of BMI 
and percentage of cells with TFEB positive nucleus. (E): Correlation of BMI and 
percentage of cells with TFEB positive nucleus excluding clinically significant 
outliers. Circled symbols in B and D represent patients who were outliers and 
excluded in panel C and E, respectively. 
Patient No. n=15-19 
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Figure 6: The subcellular location of TFEB correlates highly with NAFLD 
and obesity in human. 
(F): Correlation of serum cholesterol and percentage of cells with TFEB positive 
nucleus. (G): Correlation of serum triglyceride and percentage of cells with TFEB 
positive nucleus. (H): Correlation of serum AST and percentage of cells with 
TFEB positive nucleus. (I): Correlation of serum ALT and percentage of cells with 
TFEB positive nucleus.  
Patient No. n=15-19 
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Figure 7: Suppression of mTOR activity promotes TFEB translocation to 
the nucleus and rescues the lysosome function in the fatty livers. 
 
(A) mTOR activity was analyzed in the liver tissues from individual from mice 
following rapamycin (Rap) treatment. (2mg/kg, 4mg/kg) 16 hour before sacrifice. 
(B-C) GFP-LC3 transgenic mice were fed with HFD for the indicated durations, 
rapamycin were given as in A. Cryosections of the liver were stained with anti-
TFEB and Hoechest 33328 for the nucleus. Cells with TFEB positive nucleus 
were quantified (mean+SEM).  
 
Scale bar: 10 um, n=3 per group, *: p<0.05 
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Figure 7: Suppression of mTOR activity promotes TFEB translocation to 
the nucleus and rescues the lysosome function in the fatty livers. 
 
(B-C) GFP-LC3 transgenic mice were fed with HFD for the indicated durations, 
rapamycin were given as in A. Cryosections of the liver were stained with anti-
TFEB and Hoechest 33328 for the nucleus. Cells with TFEB positive nucleus 
were quantified (mean+SEM). (D) Liver tissues from the same group of mice 
were processed to separate the nucleus and the cytosol fractions. The TFEB 
level was analyzed by immunoblot essay in each of the fraction.  
 
n=3 per group, *: p<0.05 
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Figure 7: Suppression of mTOR activity promotes TFEB translocation to 
the nucleus and rescues the lysosome function in the fatty livers. 
 
(E-H) The mRNA level of TFEB targets were quantified in the same group of 
mice by RT-PCR. (E) lysosomal acidic lipase, (F) cathepsin D, (G) acidic 
phosphatase, (H) ATP synthase subunit 6.  
n=3 per group, *: p<0.05 
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Figure 7: Suppression of mTOR activity promotes TFEB translocation to 
the nucleus and rescues the lysosome function in the fatty livers. 
 
(I-L) Lysosomal activity were measured by the enzyme activity assay in the same 
group of mice, (I) cathepsin B, (J) cathepsin D/E, (K) lysosomal acidic lipase, (L) 
acidic phosphatase. 
n=3 per group, *: p<0.05 
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Figure 8: Overexpression of wild type and mTOR resistant TFEB mutant 
improves lysosomal functions, hepatic fat content and liver Injury in 3wk 
High Fat fed diet mice.  
GFP-LC3 transgenic mice were fed with regular chow diet before Ad- TFEB 
(WT), Ad-TFEB (S211A) and Ad-vector were given i.v. Mice were then fed with 
high fat diet for 3wks. (A-D) lysosomal enzyme activity were analyzed in each 
group of the mice. (A) cathepsin B, (B) cathepsin D/E, (C) lysosomal acid lipase 
and, (D) acidic phosphatase. (L): Immunoblotting analysis of liver lysate from 
each mice. The following parameter were determined: (E) body weight, (F) liver 
weight. 
n=3-6 per group, *: p<0.05 
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Figure 8: Overexpression of wild type and mTOR resistant TFEB mutant 
improves lysosomal functions, hepatic fat content and liver Injury in 3wk 
High Fat fed diet mice.  
(G) liver/body weight ratio, (I) serum ALT, (K) serum triglyceride, (J) serum 
cholesterol (H) hepatic triglyceride.  
n=3-6 per group, *: p<0.05 
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Figure 8: Overexpression of wild type and mTOR resistant TFEB mutant 
improves lysosomal functions, hepatic fat content and liver Injury in 3wk 
High Fat fed diet mice.  
(L) Expression of TFEB in treated mice was assessed with immunoblotting 
assay. 
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Figure 9: Overexpression of TFEB improves lysosomal functions, hepatic 
fat content and liver Injury in 16wk high fat diet fed mice. 
GFP-LC3 transgenic mice were fed with high fat diet for 12wks, Adenovirus 
expressing TFEB or the vector were injected through tail vein and mice were fed 
for another 4wks before the experiment. Mice were sacrificed and the following 
parameters were determined: (A) body weight, (B) liver weight, (C) liver 
weight/body weight ratio, (D) serum triglyceride, (E) serum cholesterol, (F) 
hepatic triglyceride. 
n=3-6 per group, *: p<0.05 
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Figure 9: Overexpression of TFEB improves lysosomal functions, hepatic 
fat content and liver Injury in 16wk high fat diet fed mice. 
(G) serum ALT. (A-D) lysosomal enzyme activity were analyzed in each group of 
the mice. (A) cathepsin B, (B) cathepsin D/E, (C) lysosomal acid lipase, and (D) 
acidic phosphatase. (L) H-E staining of liver tissue of TFEB or vector treated 
mice. Representative image are shown (X200). 
n=3-6 per group, *: p<0.05 
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Figure 10: Constitutively activated RagA mutant inhibited TFEB 
translocation, TFEB activity, lysosomal function and liver function. 
GFP-LC3 transgenic mice were fed with high fat diet for 6wks and then given 
adenovirus expressing a HA-tagged constitutively activated RagA mutant 
(RagAGTP/GTP), or the control vector. Mice were then given high fat diet for 
another 4wks before experiment. (A) Livers were analyzed by Immunoblotting for 
RagA expression. (B) Cryosections of the livers were prepared and stained with 
anti-TFEB and Hoechst 33328 for the nucleus (dotted circles). (C-F) RT-PCR 
analysis of the expression of lysosomal enzymes: (C) lysosomal acidic lipase, (D) 
cathepsin B. 
Scale bar: 10um, n=3 per group, *: p<0.05  
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Figure 10: Constitutively activated RagA mutant inhibited TFEB 
translocation, TFEB activity, lysosomal function and liver function. 
(C-F) RT-PCR analysis of the expression of lysosomal enzymes: (E) cathepsin 
D, and (F) acidic phosphastase. (G-I) Lysosomal enzyme activities were 
analyzed in each group of mice (G) cathepsinB, (H) lysosomal acidic lipase, (I) 
acidic phosphatase. (J-N) Phenotypic analysis of each group of mice: (J) body 
weight, (K) liver weight, (L) liver weight/body weight ratio (M) hepatic triglyceride 
and (N) serum ALT. 
n=3 per group, *: p<0.05  
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Figure 10: Constitutively activated RagA mutant inhibited TFEB 
translocation, TFEB activity, lysosomal function and liver function. 
(J-N) Phenotypic analysis of each group of mice: (J) body weight, (K) liver 
weight, (L) liver weight/body weight ratio (M) hepatic triglyceride and (N) serum 
ALT. 
n=3 per group, *: p<0.05  
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Figure 11: Schematic Model of mTOR – TFEB Self-regulatory Loop. 
(A) mTOR and TFEB activity are oscillating in opposite direction. (B) Signaling 
model of mTOR-TFEB-lysosome self-regulatory loop and its downstream effects. 
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Part II. The function of Bid in NAFLD and obesity 
 
1.1 Introduction 
 
1.1.1 Bid and its function 
 
1.1.1.1 Introduction 
 
Bid, or: BH3-interacting domain death agonist, is a member of the Bcl-2 family 
proteins that regulate apoptosis by controlling the permeabilization of the outer 
mitochondrial membrane (OMM). This family of proteins is composed of anti-
death members, such as Bcl-2 and Bcl-xL, and pro-death members, such as Bid, 
Bax and Bak. Structurally, this family of apoptotic regulators can be subdivided 
based on the number of sequence homology domain with the anti-apoptotic 
protein Bcl-2. Most anti-apoptotic proteins, such as Bcl-XL and Bcl-w, share four 
regions of homology with Bcl-2 (BH domain 1–4). The multi-domain pro-apoptotic 
proteins, Bax and Bak, contain the BH domain 1–3. Most other pro-apoptotic Bcl-
2 family proteins, including Bid, Bim and Bad, contain sequence homology only in 
the BH3 domain and hence are referred to as BH3-only proteins [172].  
 
Bid is mainly post-translationally activated in response to apoptotic stimuli. It 
transduces the apoptotic signals to the multi-domain pro-death molecules Bax 
and/or Bak at the site of mitochondria, which induce the release of apoptogenic 
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factors and a number of other events, leading to caspase activation and cell 
death. This constitutes the activation of the mitochondrial death pathway. Bid is 
widely studied in terms of its activation in the cytosol and its subsequent actions 
at the mitochondria. While the pro-death activity is the first function defined for 
Bid, Bid is proven to have alternative functions promoting cell proliferation and 
DNA repairs [173]. These properties of Bid render it to be an unique and 
fascinating molecule to be investigated to understand how an apoptotic protein 
affect cells death and more generously, cell functions.  
 
1.1.1.2 The Structure and Transcriptional Regulation of Bid  
 
Bid was discovered in 1996 [174]. Its function in apoptosis was first determined in 
lymphoma cell lines [175]. Bid was subsequently identified as by two other 
laboratories [176, 177] as a substrate of caspase-8 [178]. Most importantly, these 
studies found that cleaved Bid could translocate from the cytosol to the 
mitochondria and induce the release of cytochrome c from the mitochondria. Its 
ability to interact with the multi-domain pro-death molecules, Bax or Bak, is a 
very distinguished feature of this molecule among the Bcl-2 family proteins [173]. 
 
Both the human and mouse Bid genomic structures have been determined [179, 
180]. In the mouse, the Bid gene is located at chromosome 6. Human Bid is 
located in a syntenic region, chromosome 22q11.2. The molecule is 22 KD and 
contains eight α-helices, with two central hydrophobic helices (helices 6 and 7) 
forming a hairpin structure that is surrounded by the remaining six amphipathic 
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helices. The BH3 domain of Bid (amino acids 90–98), which comprises a region 
of sequence homology to other Bcl-2 proteins and is required for interaction with 
both pro-apoptotic Bax and anti-apoptotic proteins such as Bcl-2 [174], is located 
in Helix 3. Bid also contains a large unstructured loop (amino acids 42–79) that 
separates Helices 2 and 3. This loop contains a variety of sites that are subjected 
to post-translational modifications, which regulate Bid localization and its 
apoptotic function. Finally, structural comparison of Bid with multi-domain anti-
apoptotic proteins, including several viral proteins, suggests that Bid (as well as 
Bax and Bak) contains a redefined BH4 region at the N terminus, a feature 
previously believed to be shared only by anti-apoptotic proteins [181]. 
 
Transcriptionally, Bid can be positively regulated by TP53 [182]. Functional p53-
binding elements have been found in both human and mouse Bid genomic loci 
upstream of the first coding exon. The p53-binding element of human Bid is 85% 
identical to the consensus p53-binding element. Specific protein-DNA complex 
could be formed and the binding element was proved to be functional in a 
transactivation assay only in the presence of wild type p53, but not in the 
presence of a tumor-derived mutant p53. Furthermore, over-expression of p53 
could induce the upregulation of Bid mRNA levels both in cell lines and in mice. 
This upregulation of Bid might be important to p53-mediated apoptosis following 
the administration of DNA damaging agents such as adriamycin and 5-FU so that 
Bid-deficient fibroblasts were more resistant to these agents [182].  
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Transcriptional down-regulation of Bid had also been reported. The 
promyelocytic leukemia zinc finger (PLZF) protein affects myeloid cell growth and 
is involved in some acute promyelocytic leukemia. It could transcriptionally 
suppress the expression of Bid [183]. A high-affinity PLZF-binding site element 
has been identified about 2 Kb upstream of the transcription start site in the 
human Bid gene [183].  
 
1.2.1.3 Post-translational Modification of Bid and Its Pro-apoptotic Function. 
 
Caspase 8 cleavage of Bid is the major mechanism that regulates Bid migration 
to the mitochondrial membrane. Caspase 8 is an initiation caspase, which is 
normally activated following the engagement of death receptors, such as Fas, 
TNF-R1 and TRAIL. The death receptor apoptosis pathway or the extrinsic 
pathway had been thought to involve only the caspase cascade in which caspase 
8 activates the downstream effector caspases, such as Caspase-3. The 
discovery of Bid being activated by caspase indicates the involvement of the 
mitochondria in the death receptor apoptosis pathway. Cleavage by Caspase 8 
releases the inhibition mediated by the N-terminal p7 fragment of Bid, thus 
increasing the number of exposed hydrophobic residues and facilitating the 
binding of p15 truncated Bid (tBid) to the mitochondrial membranes [184]. 
Consistent with hydrophobic interactions holding the p7 N-terminal and the p15 
C-terminal fragments of Bid together, incubation with octyl glucoside is required 
to separate the fragments when purified Bid is cleaved with recombinant 
caspase-8 [185]. However, some recent data reveal that in the presence of 
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membranes, the p7 and p15 tBid fragments spontaneously dissociate following 
cleavage, allowing tBid to insert into the mitochondrial membrane. Therefore, It is 
presumed that in the presence of a membrane target, caspase-8-cleaved Bid 
undergoes a conformational change that displaces the p7 fragment and exposes 
sufficient additional hydrophobicity to drive insertion of the tBid fragment into the 
membrane [172]. The ordered series of steps required for outer membrane 
permeabilization are: (1) tBid rapidly binds to membranes, where (2) tBid 
interacts with Bax, causing (3) Bax insertion into membranes and (4) 
oligomerization, culminating in (5) mitochondrial outer membrane 
permeabilization (MOMP) [186]. Cleavage by caspase-8 also exposes Gly60 at 
the newly formed N-terminus of tBid, which allows N-myristoylation to occur 
subsequently [185]. This secondary post-translational modification significantly 
increases the ability of tBid to interact with membranes and therefore enhances 
its translocation to the mitochondria. As a consequence, myristoylated tBid is 
more potent than the non-modified tBid in inducing a full release of cytochrome c 
from the mitochondria.  
 
It has also been reported that extrinsic caspases such as Caspase-3, activated 
downstream of mitochondrial permeabilization, can also cleave Bid [187], at the 
regulatory loop. Differences in the sensitivity to caspase-8 and caspase-3 are 
present, which might be significant in term of in vivo regulation [188]. However, 
since the cleavage of Bid by caspase-3 apparently occurs downstream of the 
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mitochondria activation, Bid can serve as a key link in the amplification of various 
apoptosis signals other than the death receptor engagement [187]. 
 
Other studies have indicated that Bid can be cleaved in a specific and limited 
way by other proteases such as Granzyme B and calpains. These proteases are 
first activated in response to a plethora of stimuli, including death receptor 
activation, cytotoxic T cell attack, ischemia/reperfusion injury and lysosome 
damage. These observations indicate that Bid is in general a sentinel to protease 
activation resulted from various injury stimuli. As such Bid serves a critical role in 
connecting these stimuli to the mitochondria, thus allowing the death process 
either to be advanced or to be amplified [173]. Finally, Bid can also be activated 
by lysosomal enzymes [173]. Lysosomal enzymes represent a large group of 
catabolic enzymes, which are found to participate in the apoptosis process. In 
particular, cathepsins have been shown to link to the mitochondria pathway [189, 
190]. Bid has been implicated in the process as the mediator connecting 
lysosome to the mitochondria. Bid can be cleaved by the lysosomal enzymes at 
the regulatory loop [166] and the cleaved Bid is able to activate the mitochondria. 
A detailed study now shows that murine Bid can be cleaved by cathepsin B, H, L, 
S, and K, predominantly at Arg65 or Arg71 [190]. However, the aspartic protease 
cathepsin D is not found to be able to cleave Bid [190]. 
 
Another important modification related to Bid function is its phosphorylation. In 
Bid, there are two potentially phosphorylated residues (Thr59 and Ser65) in the 
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vicinity of the caspase-8 cleavage site [172]. Phosphorylation of Thr59 severely 
inhibited cleavage of Bid by caspase-8, whereas phosphorylation of Ser65 had 
no effect [188]. Phosphorylation of Thr59 was achieved by casein kinase II, and 
presumably other cellular kinases. Similarly, phosphorylation of murine Bid (at 
Ser61 and Ser64) by casein kinase I and II also attenuated cleavage by caspase-
8 cleavage [191]. Because cleavage of Bid is an essential prerequisite to its 
binding to membranes, phosphorylation effectively prevents Bid from trans-
locating to the mitochondria.  
 
It is worth to mention that the mitochondrial recruitment of Bid also relies on the 
facilitation of MIMP/MTCH2 (mitochondrial carrier homologue 2/Met-induced 
mitochondrial protein). MTCH2 is a tBid-interacting protein. It is a surface-
exposed outer mitochondrial membrane protein. Knockout of MTCH2/MIMP in 
embryonic stem cells and in mouse embryonic fibroblasts hinders the recruitment 
of tBID to mitochondria, the activation of Bax/Bak, MOMP, cytochrome C release 
and apoptosis. Moreover, conditional knockout of MTCH2/MIMP in the liver 
decreases the sensitivity of mice to Fas-induced hepatocellular apoptosis and 
prevents the recruitment of tBID to liver mitochondria both in vivo and in vitro. 
These findings indicate that MTCH2/MIMP has a critical function in liver 
apoptosis by regulating the recruitment of tBID to mitochondria [192].  
 
Cardiolipin also plays an important role in Bid interaction with the mitochondria. 
Cardiolipin is a unique phospholipid present in the mitochondrial inner 
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membranes and also the outer membranes of the contact site. Initially, Bid–
cardiolipin interaction was defined in vitro using purified proteins and lipids. In 
cardiolipin-deficient cells, induction of cytochrome c by Bid was significantly 
compromised [193]. Direct evidence that Bid could interact with cardiolipin in the 
mitochondria was obtained by mass spectrum analysis of lipids extracted from 
tBid-treated mitochondria [194]. Overall, Bid–cardiolipin interaction is 
independent of the BH3 domain of Bid [194], but dependent on its α4–α6 helices 
[195]. Since tBid is only present in the outer membranes of the mitochondria 
[194] and cardiolipin is most enriched in the inner membranes and the contact 
site, people has studied on where the tBid and cardiolipin interacts with each 
other. Fractionation of the mitochondrial membranes finds that tBid could target 
to different locations of the mitochondrial outer membranes. Most tBid is present 
in the outer membranes of lighter density consistent with the location of Bak and 
the contact site. Further studies using a cardiolipin-specific dye, 10-nonyl-
acridine orange (NAO), shows that it is at the contact site where tBid seems to 
interact with the cardiolipin [194]. This finding is consistent with the study of 
electron microscopy tomography, which supports the presence of tBid in the 
contact site[196]. 
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1.1.2 Bid’s role in the Liver, the Apoptotic and Non-apoptotic Functions  
 
The functional role of Bid has been studied in the liver related to its pro-apoptotic 
function. Thus, several liver injury models in murine are triggered by the death 
receptor agonists. Although engagement of the death receptors could trigger 
apoptosis without the participation of the mitochondria pathway in the so called 
types I cells, the latter is required in the type II cells [197]. Type I cells have been 
defined to be independent of mitochondria for the induction of death receptor-
mediated apoptosis, whereas Type II cells are mitochondria-dependent [198]. 
Hepatocytes were the first type II cells defined in vivo when it was shown that 
bid-deficient mice were resistant to anti-Fas antibody-induced liver injury [199].  
 
Bid is also important for TNFα- and TNF-related apoptosis-inducing ligand 
(TRAIL)-initiated apoptosis. In that case, Bid is cleaved and activated on 
TNFα/cycloheximide stimulation [178]. The mediation of Bid in TRAIL-induced 
mitochondrial is critical to the killing of cancer cells [200] and to the synergistic 
effects of TRAIL and DNA-damaging agents [201]. A notable difference seen in 
TNFα-induced liver injury is that deletion of Bid impedes, but does not prevent 
TNFα-induced killing. This is likely due to the fact that TNFα can activate several 
other death effector mechanisms, among which c-Jun N-terminal kinase and 
Bim, another BH3-only molecule that can be activated by c-Jun N-terminal 
kinase, turn out to be crucial players. Combined deletion of Bid and Bim could 
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protect mice from lipopolysaccharide/D-galactosamine (LPS/GalN)-induced liver 
injury, which is also mediated by TNFα [202].  
 
Varies other studies have shown Bid’s role in different liver diseases, with 
possible hepatocyte apoptosis as a consequences. For example, liver ischemia-
reperfusion injury [203], hepatobiliary cyst and hepatocellular carcinoma [204],  
liver intoxication [205] and alcoholic liver disease [206], etc. Interestingly, under 
physiological conditions without adverse stimulation, a small amount of cleaved 
Bid is found in wild-type mouse livers, which can cause cytochrome c release. 
However, such a condition does not lead to noticeable liver injury unless an anti-
apoptotic molecule, such as Bcl-xL, is deleted, or suppressed by a 
pharmacological inhibitor. Further studies showed that deletion of Mcl-1, another 
anti-death Bcl-2 family molecule constitutively expressed in the liver, can also 
result in spontaneous hepatocyte apoptosis [207]. Co-deletion of Bid suppressed 
the spontaneous apoptosis [208]. Taken together, these studies indicated that 
Bid is important to hepatocyte homeostasis under both physiological and 
pathological conditions [209]. 
 
Previously findings have all focused on Bid’s function and effect in apoptosis. 
However, recently, more studies have shown Bid participates in non-apoptosis 
functions. One study shows that Bid is important in immune response [210]. 
Innate immunity is a fundamental defense response that depends on 
evolutionarily conserved pattern recognition receptors for sensing infections or 
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danger signals [211]. Bid has been found related to nucleotide-binding and 
oligomerization domain (NOD) proteins. NODs are cytosolic pattern-recognition 
receptors of paramount importance in the intestine, and their dysregulation is 
associated with inflammatory bowel disease. The Salehs’ group [212] has used 
genome-wide RNA interference and identified a significant crosstalk between 
innate immunity and Bid. Colonocytes lack of BID or macrophages from Bid KO 
mice are markedly defective in cytokine production in response to NOD 
activation. Furthermore, Bid KO mice are unresponsive to local or systemic 
exposure to NOD agonists or their protective effect in experimental colitis. 
Mechanistically, BID interacts with NOD1, NOD2 and the IκB kinase (IKK) 
complex and ERK signalling. Those findings have shown the connection between 
apoptosis and immunity via linkage of Bid. 
 
Several other studies have focused on Bid’s role in hematopoiesis [209]. 
Generally, hematopoietic cell quiescence maintains hematopoietic stem cell 
function. Quiescent cells are less vulnerable to DNA damage from exogenous 
toxins, the chromatin packed DNA is protected from modification by ROS. Loss 
of Bid in mice results in abnormal myeloid homeostasis and tumorigenesis [210, 
213]. Initially, Bid knockout mice maintain hematopoietic homeostasis with 
normal blood counts in all lineages. After 1 year of age, Bid knockout mice 
display a decrease in blood counts, with anemia and thrombocytopenia. This 
progresses to an increase in cells of the myeloid lineage, culminating in a 
disorder that closely resembles chronic myelomonocytic leukemia with evidence 
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of significant chromosomal instability. Two groups subsequently showed that Bid 
is a phosphorylation substrate of the DNA damage kinases, ATM and ATR, 
namely ataxia telangiectasia mutated (ATM)/ataxia telangiectasia and Rad3-
related (ATR) kinases. The ATM kinase was previously demonstrated to have a 
role in regulating the self-renewal and quiescence of hematopoietic stem cells 
[214]. In addition, Bid has a role in S phase checkpoint regulation following DNA 
damage [215]. This cell cycle checkpoint role requires phosphorylation at serine 
78, but does not require the BH3 or death domain of Bid [216]. Those important 
findings not only have described a role for Bid in preserving genomic integrity but 
also have showed Bid functions at an early point in the path to determine the fate 
of a cell. Bid plays an unexpected role in the intra-S phase checkpoint 
downstream of DNA damage distinct from its proapoptotic function. New findings 
have indicated that Bid associates with the ATR/Atrip/replication protein A (RPA) 
complex and the association between ATR/Atrip and RPA is significantly 
diminished in Bid-deficient cells following replicative stress, another evidence 
suggesting that Bid has a role to maintain the DNA damage sensor complex 
[209]. Interestingly, exposing wild-type mice to irradiation also triggers an 
increase in mitochondrial Bid and an increase in mitochondrial ROS [217] 
suggesting that the ATM–Bid complex may affect metabolism changes in DNA 
damage. Taken together, these results suggest that at low levels of DNA damage 
ATM phosphorylates Bid to keep it away from the mitochondria resulting in low 
levels of ROS generated from mitochondria. Increasing the levels of DNA 
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damage proportionally increases the levels of mitochondrial Bid, which leads to a 
proportional increase in mitochondrial ROS.  
 
In regards to the function of Bid’s phosphorylation, it is well established that ATM 
is a nuclear kinase and it was previously demonstrated that part of the Bid 
protein pool is localized to the nucleus [215]. Thus, it is most likely that ATM 
phosphorylates Bid in the nucleus and that this phosphorylation inhibits Bid exit 
from the nucleus and thereby its accumulation in mitochondria. However, most 
recently, it is demonstrated that ATM is also localized to the mitochondria [218]. 
An alternative possibility is thus that ATM phosphorylates Bid at the 
mitochondria, leading to its retrotranslocation into the cytosol.   
 
These findings, although in the hematopoietic systems, have unveiled some of 
the other non-apoptotic function of Bid. How does the ATM–Bid complex regulate 
the metabolic status and ROS generation from the mitochondria? As mentioned 
in the previous section, MTCH2 has been shown to serve as a mitochondrial 
receptor for Bid and is very important for Fas-induced liver apoptosis. 
Interestingly, MTCH2 was previously identified in a genome-wide association 
study as one of six new gene loci associated with body mass index (BMI) in 
humans [218, 219]. Body mass index is the most commonly used quantitative 
measure of adiposity, and adults with high values of body mass index are 
associated with obese. Thus, MTCH2 may also be involved in fatty acid/glucose 
metabolism in the mitochondria. It is logical to make a hypothesis that the 
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function of MTCH2 is coupled with Bid. Thus, it is possible that Bid could play a 
role in regulating mitochondrial function in a non-apoptotic way.  
  
111 
 
1.2 Materials and Methods  
 
1.2.1 Animal Experiment: 
 
All animal experimental protocols were approved by the Institutional Animal Care 
and Use Committee of Indiana University (IACUC). Animals were housed under 
approved conditions in a secured animal facility at the Indiana University School 
of Medicine with 12 hour light dark cycle. Bid knockout mice were generated in 
our lab. Wild type mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME). At 10 weeks of age, mice were placed on normal chow diet, high fat 
diet (diet D12492, Research diets) or high-fat high-carbohydrate (HFHCD) diet. 
For HFHCD diet, mice were given high fat diet along with the drinking water 
enriched with high-fructose corn syrup equivalent to a total of 42 g/L of 
carbohydrates. Drinking solution was made by mixing in drinking water at a ratio 
of 55% fructose (Acros Organics, Morris Plains, NJ) and 45% sucrose (Sigma-
Aldrich, St. Louis, MO) by weight. Animals were provided ad libitum access to 
these diets for 10-24 weeks. Body weight was recorded weekly. 
 
1.2.2 Immunoblotting 
 
Mouse livers were dissected and 250 mg of liver tissue was homogenized in NP-
40 lysis buffer containing 1% NP-40, 50mM Tris-Hcl (pH 7.5), 150mM NaCl, 
0.05% SDS, 1mM aprotinin, 20µg/ml PMSF, 1.7µg/ml Aprotinin, 2.5µg/ml  
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Leupeptin, 1µg/ml Pepstatin A. The buffer is supplemented with 1 tablet 
Complete Mini Protease Inhibitor Cocktail (Roche, Mannheim, Germany) per 10 
ml. Mice liver tissue was dounced for 15 times using tight (B) pestle of a glass 
homogenizer.  Liver lysate was kept in pre-chilled Eppendorf tube on ice for 40 
min. After centrifugation at 15 000 × g for 15 min at 4°C, the supernatant was 
stored at −80°C until further us. Protein concentrations were measured by the 
BCA method. Immunoblots with SDS-PAGE electrophoresis system were 
performed as previously described. Gel Running buffer contains 25 mM Tris 
Base, 192 mM Glycine, 0.1% SDS at PH 8.2. Transfer buffer contains 25 mM 
Tris Base, 192 mM Glycine and 20% methanol (v/v). Transfer condition is 7 volt 
overnight or 20 volt 2.5h. First antibody was dissolved in 5% Skimmed milk in 
TBS buffer or 5% BSA in TBS buffer. Secondary antibody in conjugation HRP 
(Jackson Immuno-Research Laboratory) was used at 1:5000 dilution. Rabbit anti-
mouse Bid antibody was made by in house and was used at the dilution of 1:500. 
MTCH2 antibody, (Proteintech 16888-1-AP) was used at the dilution of 1:1000, 
CPT1 antibody (Santa Cruz 98834) was used at the dilution of 1:500. Blots were 
developed using Immobilon Chemiluminescent HRP substrate (EMD Millipore, 
Billerica, MA).  Image was acquired by Kodak 4000 image station system.  
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1.2.3 Indirect Calorimetry  
 
The TSE (Chesterfield, MO) Labmaster calorimetry cage is a set of live-in cages 
for automated, non-invasive, and simultaneous monitoring of oxygen 
consumption, and CO2 production. Eight 10wk old mice from Bid KO and WT 
groups were given HFD for 10wks (accumulated age 20 wks) and then placed in 
calorimetry cages. Each cage was maintained at 25o C at the 12 hour dark-light 
cycle. After acclimatization individually for 72h, the O2 consumption (VO2, 
mL/kg/min), CO2 production (VCO2, mL/kg/min), and respiratory quotient (ratio of 
VCO2/VO2) were continuously measured. VO2 and VCO2 were recorded every 
10 min for a total of 48 h. The hourly file displays all measurements for each 
parameter.  
 
1.2.4 Histology 
 
Different tissues from mice were harvested, washed with ice-cold PBS, and fixed 
in 10% formalin overnight and transferred to 70% ethanol the next day. Tissue 
blocks were processed by Indiana University Health Pathology Laboratory. 
Histochemical analysis was carried out on 4-µm-thick sections stained with 
hematoxylin and eosin (H&E), and Trichrome C. 
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1.2.5 Gene Expression Analysis: with Real-time PCR 
 
Total RNA from liver tissue was extracted with GeneJET RNA purification kit 
(Thermo Scientific). Briefly, 30mg of frozen tissue were lysed with the lysis buffer 
provided by the kit. Six hundred µl of proteinase K were then added followed by 
centrifugation at 12000g. Next, 450ul of ethanol were added and the precipitated 
pallets were washed with washing buffer provided by the kit for RNA purification. 
RNA quality and concentration was quantified by spectrometry at A260/A280.  
Next, 5µg of RNA was used in a reverse transcription reaction using M-MLV 
reverse transcriptase (Invitrogen), per manufacture’s introduction. For RT-PCR 
amplification of the target genes, cDNAs were mixed with AmpliTaq Fast DNA 
polymerase and other necessary ingredients. Amplification was conducted for 40 
cycles using an Applied Bioscience PCR system. ---Analysis was performed 
using the 2∆∆CT method. QPCR results were normalized against gene PPIA 
Primer sequences used for the amplification are as follows: 
 
PPIA     Fw: 5’- CACCGTGTTCTTCGACATCA -3’ 
              Rv: 5’- CAGTGCTCAGAGCTCGAAAGT -3’ 
 
IL-1beta     Fw: 5’- GCTGCTTCCAAACCTTTGAC -3’ 
                  Rv: 5’- TGTCCTCATCCTGGAAGGTC -3’ 
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INF-gamma      Fw: 5'-GATGCATTCATGAGTATTGCCAAGT-3' 
                         Rv: 5'-GTGGACCACTCGGATGAGCTC-3' 
TGF-beta     Fw: 5'-CACCGGAGAGCCCTGGATA-3' 
                    Rv: 5'-TGTACAGCTGCCGCACACA-3' 
 
Collagen – 1l    Fw: 5'-ACGGCTGCACGAGTCACAC-3' 
                          Rv: 5'-GGCAGGCGGGAGGTCTT-3' 
 
TIMP1     Fw: 5'- ATTCAAGGCTGTGGGAAATG -3'  
                 Rv: 5'- CTCAGAGTACGCCAGGGAAC -3'   
 
IL-18      Fw: 5’- ACGTGTTCCAGGACACAACA -3’    
              Rv: 5’- ACAAACCCTCCCCACCTAAC -3’   
 
PGC-1 alpha    Fw:  5'-TCCTCTGACCCCAGACTCAC-3'  
                         Rv:  5'-TAGAGTCTTGGAGCTCCT-3' 
PGC1 beta     Fw: 5’ –CCGAGCTCTTCCAGATTGAC– 3’  
                       Rv: 5’ –TTCATCCAGTTCTGGGAAGG– 3’  
 
PRC     Fw:  5’ –GCTACTTCCCAGGAGCCTCT– 3’  
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             Rv:  5’ –GGTGAAGCCTCAGGAGACAG– 3’  
 
 
PPAR delta    Fw:  5’ –TGGAGCTCGATGACAGTGAC– 3’ 
                 Rv:  5’ –GGTTGACCTGCAGATGGAAT– 3’  
 
arnitine/acylcarnitine translocase (CAC) 
                Fw: 5’ –TGCCAGTGGGATGTATTTCA– 3’  
               Rv: 5’ –GTTGAAGATCCCTGCAAAGC– 3’ 
 
MTCH2:    Fw:    5’ –TTTGGGCGACAAGTATGTCA– 3’  
                 Rv:     5’ –CTTTCCCATGGACCACAGTT– 3’  
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1.2.6 Ketone Body Measurement 
 
Whole blood from mice was collected through axillary artery. Serum were 
collected after centrifugation at 4000 rpm for 15 mins. Serum ketone body was 
measured with beta –hydroxybutyrate colorimetric assay kit (Cayman Chemical, 
Ann Arbor, MI). Absorbance was taken at 445-455 nm. To measure the ketone 
body in liver tissue, 400 µg of liver were dounced in1.5 ml of tissue lysis buffer 
provided by the kit and subjected to procedure as described above. Final 
concentrations were normalized to protein concentrations.  
 
1.2.7 Ex-Vivo Fatty Acid Oxidation Rate Measurement 
 
Live mitochondria was extracted for ex-vivo fatty acid oxidation measurement. 
Briefly, 250-350 mg of liver tissue from different lobes were dounced with the 
loose (A) pestle of a glass homogenizer for 3 times by HIM buffer containing 
200mM mannitol, 70mM Sucrose, 5mM Hepes, 0.5mM EGTA. Liver lysates were 
centrifuged for 10min at 2000 rpm. Supernatant was collected as the 
mitochondria fraction and kept on ice.  
 
Radiolabelled substrate was prepared by aliquoting radiolabled substrate 
(0.7uCi/recaction) into an Eppendorf tube. The organic phase dried off under air. 
Nonradiaolabeled palmatic acid and BSA carrier were then added. The reaction 
mixture contains 100 mM Sucrose, 10 mM Tris-Hcl, 5mM KH2PO4, 0.2 mM 
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EDTA, 5 mM Nicotinamide, 1 µM TricostatinA, 0.3% fatty acid free BSA, 80 mM 
KCl, 1mM MgCl2, 2mM L-carnitine, 0.1mM Malate, 0.05 mM Co-enzymeA, 2mM 
ATP, 1mM DTT, adjust to pH 8.0 were made to 380ul per reaction.  
 
A filter paper was cut to fit in the cap of Eppendorf tube and was soaked with 
10ul of NaOH. This was subsquently to trap the C14 labeled CO2 released from 
the oxidation reaction. Generally, 20 ul of mitochondria fraction, 12 ul of substrate 
(radiolabled and nonradiolabled) were added to the reaction mix which was 
incubated at 37C water bath. The time from tissue dissection to reaction initiation 
should be less than 30min to ensure mitochondria vitality for the reaction. After 
incubation, 200µl of percholic acid were added to each reaction tube followed by 
incubation of 1 hour at room temperature and centrifuge at 14000rpm to separate 
the radiolabeled acetyl CoA from the unoxidized fatty acid. The 200 µl of 
supernatant after centrifugation and the filter papers trapped with CO2 were put 
into separate scintillation vial containing 4ml of scintillation fluid for reading in a 
Packman Scintillation Counter. CPM readings were finally adjusted for protein 
concentration. 
 
1.2.8 Hepatic Triglyceride Measurement 
 
80 mg of frozen liver tissue were powdered under liquid nitrogen and incubated 
in total of 1ml of chloroform-methanol mix (2:1) for 1 hour at room temperature 
with shaking to extract lipids phase. After addition of 200 µl of H2O, samples 
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were vortexed and centrifuged for 5min at 3000g. The lower lipid phase was 
collected and dried in a chemical hood overnight. The lipid pellet was 
resuspended in 60 µl of tert-butanol and 40 µl of a Triton X-114-methanol (2:1) 
mix. Triglycerides were than measured using the Pointe Scientific Triglycerides 
Assay Kit (Pointe Scientific, MI) 
 
1.2.9 Blood Biochemistry Assay and Insulin Resistance Measurement  
 
Serum glutamic-pyruvic transaminase (SGPT) or alanine aminotransferase (ALT) 
was measured with an ALT (SPGT) reagent kit (Pointe Scientific, Canton, 
MI).Briefly, serum was diluted five times. After reaction, samples were read at 
340nm absorbance at 37oC. Plasma triglyceride and cholesterol level were 
measured by Triglyceride/ Cholesterol kit (Pointe Scientific, Canton, MI). Serum 
insulin level was measured with an insulin ELISA kit (Millipore, Billierica, MA). 
Blood glucose level was measured using the Contour blood glucose monitoring 
system (Bayer, Mishawaka, IN). Insulin resistance (HOMA) was calculated by the 
following formula, (fasting glucose/18 mg/dl * fasting insulin * 25ng/ml)/22.5. 
 
1.2.10 Free Fatty Acid Measurement 
 
Serums collected from the mice were used for the free fatty acid measurement 
with the free fatty acid assay kit from Cayman Chemical (Ann Arbor, MI). 
Generally, 10µl of serum sample were used and the assay was performed at 
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37oC. Fluorescence with an excitation wavelength between 530-540 nm and an 
emission wavelength between 585-595 nm were measured by a fluorescent 
spectrometer Infinite200 plate reader (Tecan) 
 
1.3.11 Statistical analysis  
 
Data were expressed as mean±SE. Differences between two treatment groups 
were compared by t test. When more than two groups were compared, on way 
ANOVA analysis was used. Results were considered statistically significant when 
P<0.05. All analyses were performed with Sigma Stat 3.5. 
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1.3 Results 
 
1.3.1 Bid Knockout Mice Are Protected from High Fat Diet Induced Obesity 
 
As we have discussed in the introduction, Bid protein plays an important role in 
apoptosis initiation via the mitochondria pathway. Recently, various findings have 
shown Bid also functions in DNA homeostasis, hematopoietic stem cell 
metabolism ROS generation and cell proliferation [209, 217]. There was other 
findings that have shown that MTCH2, Bid carrier protein, is one of the gene loci 
whose polymorphism associated with obesity in human [219]. We hypothesized 
that Bid may have a new function in regulating metabolism via its interaction with 
the mitochondria in a non-apoptotic condition. 
 
To test our hypothesis, we gave wild type (WT) and Bid-deficient (KO) mice 
regular chow diet, high fat diet or high fat high carbohydrate diet and measured 
their body weight gains. We confirmed that the Bid protein was successfully 
deleted in Bid-deficient mice (Fig S1). To our surprise, we found that Bid KO 
mice have significantly smaller body weight gain following either high fat diet or 
high fat high carbohydrate diet (Fig 1A, B). The high fat diet regimen seemed to 
yield a larger difference between the WT and KO mice. However, the body 
weight was not significant changed in regular chow diet group (Fig 1A, B), 
indicating that obesity protection by Bid deletion is diet specific. We also 
calculated the percentage of body weight gain to rule out any possible baseline 
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variations.  Under the regular diet, 6wk to 10wk old mice gained body weight 
naturally as a normal growth process. WT mice started to gain more weight, but 
less so, than the Bid KO mice in the subsequent 0-8wk and 8-16wk, respectively 
(Fig 1C). This suggested the different growth rates between the two groups, 
although the body weight gain did not differ noticeably in the full grown-ups. 
However, under the high fat diet and high fat high carbohydrate diet, the WT 
mice consistently showed a higher body weight gain through the whole course.  
The lack of rapid increase in body weight following high fat diet and high fat high 
carbohydrate diet in Bid KO mice overall lead to a lower body mass index (BMI), 
a clinical marker of obesity (Fig 1D). We conducted the F2 segregation assay to 
study whether the effect of Bid deletion is dominant or recessive. As showed in 
Fig S2A, the body weight in the Bid heterozygous mice following high fat diet was 
no different than that in WT mice, indicating that the effect of Bid deletion is a 
recessive feature. Yet the effect could be clearly observed in all Bid KO mice, 
suggesting that it is a single gene event. It is worth to note that the smaller body 
weight gain by Bid KO mice was only seen in male mice, but not in female mice 
(Fig S3). We think the sex discrepancy may be due to the fact that a high level of 
estrogen in female counteracts the effect of Bid knockout, many findings have 
shown that estrogen affects fat metabolism and mitochondrial function [220, 221]. 
We also found that Bid deletion did not affect obesity caused by leptin deficiency 
(Fig S4). Bid-deficient mice were crossed to OB/OB mice, and the body weight of 
OB/OB mice and OB/OB/Bid KO mice were monitored for 20 weeks. There were 
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no significant body weight differences. This finding indicates that deletion of Bid 
is only impact on obesity caused by hyper-nutrients (high fat diet).  
 
Most body weight gain under hyper-nutrients is due to significant adipose tissue 
accumulation. Thus, we studied if the smaller body weight gain in Bid KO is due 
to a less fat accumulation. Indeed, both epigonadal adipose tissue weight and its 
ratio with the whole body weight were lower in Bid KO mice following high fat diet 
or high fat high carbohydrate treatment (Fig E, F, S2B). Histological analysis 
indicated a smaller size of adipocytes in Bid KO adipose tissue, suggesting a 
smaller fat-content. Thus, there were fewer WT adipocytes than Bid-deficient 
adipocytes in a given microscopic field (Fig 1G-H). 
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1.3.2. Bid Knockout Mice Are Protected from Hyper-nutrients-Induced Metabolic 
Syndrome 
 
Clinically, obesity causes multiple metabolic disturbances. As we have showed in 
Fig 1, Bid KO can protect high fat diet and high fat high carbohydrate diet -
induced body weight gain.  We thus studied whether Bid KO also protected 
against the development of metabolic syndrome in high fat diet and high fat high 
carbohydrate diet regimes.  
 
As shown in Fig 2A, fasting glucose level was lower in Bid KO following 16wk of 
high fat diet or high fat high carbohydrate diet treatment, although statistical 
significance was only achieved in high fat diet regimen. It is possible that, high 
carbohydrate diet caused severe diabetes, which masked the protective effect of 
Bid KO [222]. The insulin level was significantly lower in Bid KO mice after either 
diet treatment (Fig 2B). The assessment of insulin resistance is based on the 
level of fasting glucose and fasting insulin, which leads to the calculation of the 
HOMA value. The HOMA value was lower in Bid KO mice (Fig 2C), indicating a 
lower insulin resistance level. Serum cholesterol levels (Fig 2C), but not serum 
triglyceride levels (Fig 2B), were lower in Bid KO group in high fat diet and high 
fat high carbohydrate diet, Hypercholesterolemia is one of the most common 
indications of atherosclerosis and risk factors of coronary artery disease. It is 
worth to note that Bid KO could potentially protect the development of coronary 
artery disease by lowering serum cholesterol.  
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In a long-term study (24wk) with only high fat diet treatment (Fig S5), we found 
that the fasting glucose level was not as high as in the 16wk group (compare Fig 
S5A and Fig 2A), although Bid –deletion still led to a lower glucose level than that 
in the wild type and Bid heterozygous mice. Serum cholesterol level remained 
significantly lower in Bid KO mice (Fig S5B). The levels of triglycerides were 
increased in all groups of mice at 24wk (Fig S5C) compared to those at 16wk 
(Fig 2E). At this time point, the protective effect of Bid deletion was revealed. 
Serum triglyceride level was significantly lower in Bid KO mice than the WT mice 
or the Bid heterozygous mice (Fig S5C).  
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1.3.3. Bid Knockout Mice Are Protected from Steatosis, Steatohepatitis and Liver 
Fibrosis. 
 
Liver is the largest organ in the body and carries most of the metabolism 
functions.  High fat diet can cause liver steatosis [223] whereas high fat high 
carbohydrate diet can also trigger steatohepatitis and early stage of fibrosis 
[167]. All these lead to the development of NAFLD, which is an important 
contributor to the metabolic syndrome. Since deficiency of Bid protects against 
diet induced obesity and metabolic syndrome. We would like to study how Bid 
deficiency may affect NAFLD development in mice under high fat diet and high 
fat high carbohydrate diet regimes. 
 
We found that Bid deletion had a strong protection against steatosis development 
in both diet regimes as assessed by histology (Fig 3A) or by the level of hepatic 
triglyceride (Fig 3B). Severe liver steatosis could lead to steatohepatitis where 
there is severe liver injury. We found Bid KO could protect liver injury induced by 
high fat diet and high fat high carbohydrate diet treatment measured by serum 
ALT level (Fig 3C, Fig S5D).  
 
High fat high carbohydrate diet gives rise to a more severe liver phenotype, 
which is not only characterized by a more severe steatosis (Fig 3B), a more 
severe liver injury (Fig 3C) but also the development of hepatic fibrosis (Fig 3D). 
The expression of inflammatory cytokines (Fig 3E-G) and fibrogenic molecules: 
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Collagen 1l, TGF-beta, TIMP (metallopeptidase inhibitor 1) (Fig 3H-J) were all 
significantly increased. However, deletion of Bid led to a significant reduction of 
hepatic fibrosis and the expression of these genes in high fat high carbohydrate 
diet treatment (Fig 3D-J).  
 
Steatosis, steatohepatitis and liver fibrosis/cirrhosis and hepatocellular carcinoma 
are sequential pathologies in NAFLD, in which fibrosis is a step before the 
pathogenesis become irreversible. Bid may thus prompt the pathogenesis of 
NAFLD and deletion of it may have a significant beneficial effect. 
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1.3.4. Bid Knockout Mice Have Higher Whole Body Metabolic Rate in vivo 
 
Our data indicate Bid knock out can protect against obesity, metabolic syndrome 
and NAFLD (Fig 1-3). The mechanism leading to this interesting phenotype was 
unknown and could potentially imply a new molecular function of the Bid protein. 
As the size of adipocyte in Bid KO mice were much smaller in high fat diet and 
high fat high carbohydrate diet treatment groups (Fig 1G, H), we hypothesized 
that the phenotype of Bid KO mice could be related to an altered fat metabolism 
and/or energy expenditure. 
 
We conducted calorimetry analysis on WT and Bid KO mice fed with high fat diet 
for 10wk (Fig 4C and D). We found that both O2 consumption and CO2 
generation were higher in Bid KO mice than in WT mice (Fig 4A-C). Bid KO mice 
consistently consumed more O2 without the differences between the day time 
and the night time (Fig 4A). The respiratory exchange ratio, a ratio of the amount 
of CO2 produced above that of O2 consumed, was lower in high fat diet fed Bid 
KO mice (Fig 4D). Respiratory exchange ratio, also known as respiratory 
quotient, is an indicator of the type of energy source (carbohydrate or fat) being 
metabolized to supply the body with the energy. A lower respiratory exchange 
ratio means that the Bid KO mice tended to use more fat as their energy source, 
which may explain the lower fat content in the adipose tissue of the Bid KO mice. 
Consistent with a higher metabolic rate, the heat generated from Bid KO mice in 
high fat diet treatment was also increased. Notably, the food consumption 
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between the WT and Bid KO mice was equivalent in the 16wk high fat diet 
feeding period (Fig 4F).  
 
Calorimetry data thus indicated that Bid KO mice had a higher whole body 
metabolic rate and tended to burn more fat.   
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1.3.5. Deficiency of Bid Leads to a Higher Expression of Genes That Promote 
Energy Expenditure. 
 
The above studies showed that Bid deletion could promote fatty acid metabolism. 
We thus examined the expression of genes important for this process in Bid KO 
mice. PGC-1 alpha (Fig 5E,J) PGC-1 beta (Fig 5A,F) , PGC1-related coactivator 
(PRC) (Fig 5B,G) gene expressions were all had a higher hepatic expression in 
Bid KO mice liver, suggesting a higher mitochondrial biogenesis and metabolism 
[224] with higher mitochondrial biogenesis and function [225]. Gene expression 
of PPAR delta was also increased in Bid KO mice, implying an elevation of the 
expression of its downstream fatty acid oxidation rate related genes. Notably, we 
found that carnitine-acylcarnitine translocase (CAC) expressed at a higher level 
in Bid KO mice. CAC is the enzyme facilitates fatty acid translocation through 
mitochondrial membrane. In the metabolic pathway of fatty acid oxidation, 
Carnitine palmitoyltransferase I (CPT1) is the rate limit enzyme which facilitates 
transportation of free fatty acid across mitochondrial membrane. Previous 
findings using in vivo model have showed tBid could inhibit CPT1 [226]. We 
observed an increased in the liver isoform of the CPT1 gene (LCPT1), although 
not statistically significant. Most significantly, the highest level of the expression 
of the genes in Bid KO livers was further enhanced following high fat diet 
treatment. Taken together, Bid deficient mice could have a higher fatty acid 
oxidation capability, which is further enhanced under the high fat diet condition.  
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1.3.6. High Fat Diet Induces Full Length Bid Translocation, Insertion to 
Mitochondrial Membrane and Destabilize MTCH2. 
 
Bid, when cleaved into a truncated form (tBid) in the presence of apoptotic signal, 
can translocate to the membrane of mitochondria to trigger cytochrome c release 
[173]. We found in this study that high fat diet treatment of WT mice promoted 
the translocation of full length Bid to mitochondria (Fig 6A-B). Increased 
mitochondrial presence of the full length Bid under high fat diet condition was 
accompanied with its binding protein MTCH2 being reduced in the mitochondrial 
membrane (Fig 6A). Interestingly, mitochondrial MTCH2 was decreased in Bid 
KO livers in both regular diet and high fat diet conditions, suggesting that MTCH2 
might be destabilized by the loss of Bid and/or the high fat stimulation.  
Reduction of mitochondrial MTCH2 was also observed in Bid -/- MEFs (Fig S6A), 
suggesting that Bid deletion is sufficient to affect MTCH2 level. On the other 
hand, RT-PCR analysis of MTCH2 suggested its RNA level was only slightly 
increased under either regular diet or high fat diet (Fig S6B, C). As certain 
polymorphism of MTCH2 have been reported to have a close genetic association 
with the obesity [219], and MTCH2 KO mice have shown lean phenotype under 
high fat diet treatment (personal communication with Dr. A.Gross, Weizmann 
Institute of Israel), our finding is potentially interesting in that the lean phenotype 
of Bid KO could possibly due to the reduction of MTCH2. In contrast, CPT-1 
expression level was higher in high fat diet condition and was even higher when 
Bid is not present (Fig 6A, Fig S6A). This finding was consistent with the RT-PCR 
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analysis (Fig 5F) and implied an elevated fatty acid oxidation in the presence of 
high fat diet and/or Bid deletion.  
 
We next tested whether the full length of Bid detected in mitochondrial fraction 
was inserted into the membrane or just loosely attached to it. As shown in Fig 
6C, a strong alkaline condition could not remove all full length Bid from the 
mitochondrial membrane. This finding showed that a portion of full length Bid had 
a strong binding with, or had inserted into mitochondrial membrane, which may 
provide Bid functionally stable environment for its metabolic function.   
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1.3.7. Mitochondria in Bid KO Livers Have Higher Fatty Acid Oxidation Rate  
 
Our data from calorimetry study and the gene expression study suggested that 
Bid deletion caused an increased metabolic rate, with a potential increased use 
of fatty acid as the energy source. Furthermore, there was an increased 
presence of Bid in the mitochondria following high fat diet treatment, suggesting 
that Bid may have regulatory effects on mitochondrial function, such as beta-
oxidation. It had been reported that apoptotic condition, tBid can suppress 
mitochondrial fatty acid oxidation flux by malonyl-CoA-independent inhibition of 
CPT1 [226]. We thus decided to directly measure and compare fatty acid 
oxidation rate in hepatic mitochondria prepared from WT and Bid KO mice fed 
with high fat diet.  
 
During fatty acid beta-oxidation, long chain fatty acids need to first transport 
through the mitochondrial membrane with the facilitation of CPT1 in the outer-
membrane and Carnitine palmitoyltransferase II (CPT II) in the inner-membrane. 
Fatty acids are then oxidized to multiple acetyl-CoAs, which enter into the Kreb 
cycle to generate ATP as the final product, with CO2 as the byproduct [227].  
Alternatively, acetyl-CoAs are converted to the ketone body and exported mainly 
occurring in the liver. 
 
We first prepared liver homogenates from mice fed with high fat diet for 10wks 
and added C14 labeled palmitic acid as the beta-oxidation substrate. After the 
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incubation for 60min or 120min, we quantified the production of C14 – Actyl-CoA 
and CO2 as the measurement of beta-oxidation. Mitochondria from WT livers 
showed an increased Actly-CoA production from 60min to 120min, while CO2 
production remained steady. An increased C14-acetylCoA level was observed in 
Bid KO mice mitochondria (Fig7A), although it was somewhat unexpected that a 
much higher C14-CO2 level was also generated in Bid KO mitochondria (Fig7B).  
These results suggested that fatty acid oxidation in Bid KO mitochondria moved 
through the Kreb cycle to generate the final product, CO2. Consistently, we did 
not observe any differences in ketone body generation between WT and Bid KO 
mitochondria (Fig S7).  
 
The elevated beta-oxidation in Bid KO mitochondria was inhibited by exogenous 
Bid when purified recombinant Bid protein was added to Bid KO liver 
homogenate. Both C14 – Actyl-CoA and C14 -CO2 were dose-dependently 
decreased to the level produced by the WT homogenate (Fig 7C-D). The 
inhibitory effect was reversed by a pharmacological inhibitor of Bid, BI6C9. 
Adding BI6C9 at difference doses led to the recovery of fatty acid oxidation rate 
that was suppressed by exogenous recombinant Bid protein (Fig 7C-D). These 
findings thus confirmed that the fatty acid oxidation rate could be modulated by 
Bid.   
 
Enhanced fatty acid oxidation in the liver would need a higher supply of free fatty 
acid, mainly from adipose tissue, although also from the liver. Fatty acids 
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released from adipose tissue need to be transported to the liver through the 
circulation.  Therefore, we measured the free fatty acid level in the serum of Bid 
KO and WT mice. As shown in Fig S8, there were higher concentrations of free 
fatty acid in Bid KO mice under regular diet and under short term high fat diet 
(5wk). However, there was more free fatty acids in WT mice in longer term of 
high fat diet treatment (15wk). These findings may be explained that fatty acid 
level in the blood is affected not only by the beta-oxidation but also the metabolic 
disturbances which is more severe in the WT mice. 
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1.4 Discussion 
 
In this part of the study, we have demonstrated a new function of Bid, which is 
not related to its traditional function in apoptosis. Bid seems to be a susceptible 
factor for diet - induced obesity, metabolic syndrome, and hepatic steatosis and 
fibrosis. There are some unique features in this Bid function. First, this effect is 
more prominent in high fat diet regime and in high fat high carbohydrate diet 
regime, and shows least effect under regular diet. High fructose uptake may 
mask the effect of Bid, or render the contribution of Bid irrelevant to obesity 
development. Second, the effect of Bid is not seen in leptin deficiency induced 
obesity, suggesting that the contribution of Bid is relatively smaller when obesity 
is caused by an overwhelming uptake of food. Third, Bid’s contribution in high fat 
diet - induced obesity is minimal in female mice, which suggests that estrogen 
may counteract the effect of Bid, perhaps at the mitochondrial level. Fourth, the 
contribution of Bid is genetically dominant and only homozygous deletion could 
remove this effect.  
 
Evolutionally, animals and human being, tend to store excessive nutrients. High 
fat diet intake may overwhelm catabolic metabolism such as by downregulating 
the rate limiting enzyme CPT-1 in fatty acid oxidation pathway. Our findings give 
a potential mechanism of how fatty acid oxidation rate might be reduced in high 
fat diet regime. Full length Bid probably participates in this process. The majority 
of the previous studies of Bid have focused on its role in apoptosis. It is known 
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that when death receptors are engaged, Bid is cleaved by caspase-8 and the 
truncated Bid, known as tBid, is translocated to the mitochondrial membranes. 
However, in this study, we have shown that full length Bid is found in the 
mitochondrial membrane under the high fat diet condition, which could be related 
to its new function in suppressing fatty acid oxidation. Translocation of full length 
Bid seems to be trigged by high fat diet. It has been reported that tBid can 
interact with a lipid component, caridolipin, in mitochondrial membrane during 
apoptosis [194, 228]. Considering that mitochondrial membrane is composed of 
lipids, we speculate that high fat diet may alter lipid composition in the 
mitochondrial membrane that may stabilize inserted full length Bid on it. The 
actual mechanism of full length Bid translocation has yet to be determined.  
 
Bid may inhibit beta-oxidation once it is on the mitochondrial membrane. CPT-1 
is the rate limiting step of beta-oxidation and Bid could thus inhibit beta-oxidation 
via this mechanism. It may inhibit CPT-1 either functionally or via reduction of the 
protein level. CPT-1 level is increased in Bid -/- cells. Previous findings using an 
in vitro model have also shown that tBid could inhibit CPT1 [226]. Further, under 
apoptotic signal, tBid can suppress mitochondrial fatty acid oxidation flux by 
malonyl-CoA-independent inhibition of carnitine palmitoyltransferase-1[226].  
 
How may full length Bid affect CPT-1? We suggest that Bid may do so by 
interacting with MTCH2, which belongs to the family of mitochondrial carrier 
proteins. Other members of this family include ANT (adenosine nucleotide 
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translocator), which is important for transporting ADP and ATP in and out of the 
mitochondrial membrane. 
 
It has been reported that translocation of tBid to mitochondrial membrane needs 
the help of its carrier protein MTCH2 [192]. We have shown that there is a 
dramatic decrease of MTCH2 in the mitochondria of Bid KO mice, suggesting 
that Bid can promote the stability of MTCH2 in the mitochondria. There are 
additional reasons for us to raise the hypothesis that Bid could possibly have its 
function mediated by MTCH2. First, certain single nucleotide polymorphism of 
MTCH2 has been associated to human obesity development [219]. Second, 
MTCH2 knockout mice have a lean phenotype and metabolic change similar to 
that found in Bid KO mice reported in this study (personal communication with 
Dr. A Gross, Weizmann Institute, Israel). We thus can hypothesize that full length 
Bid, when present in the mitochondrial membrane under certain condition, e.g. in 
high fat diet treatment, could affect MTCH2 stability on mitochondrial 
membranes, which leads to a negative effect on CPT-1 and transportation of free 
fatty acids into the mitochondria. Future studies will be focused on seeking direct 
evidence to prove or disprove this hypothesis. 
 
In this study, we have also found that there were significant differences in the 
expression of a set of genes that are involved in the mitochondrial biogenesis 
and mitochondrial function which is elevated in the absence of Bid. The 
difference is found in the regular diet treatment, but is enhanced in the high fat 
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diet regime. It is not clear how absence of Bid could cause or re-program the 
expression profile of these genes.  It is possible that the enhanced beta-oxidation 
in Bid-deficient hepatocytes may trigger this positive re-enforcement for 
mitochondria function, which in turn would also contribute to the lean phenotype 
of Bid deletion in high fat diet regime. 
 
In conclusion, we have shown a new function of Bid protein in this study, a 
function that relates to metabolism. Previous studies have found that Bid can 
promote cell death and proliferation, and can participate in DNA repair and in 
innate immunity. Thus, Bid has a very broad effect on cellular functions under a 
diverse set of conditions, which may dictate the specific role of Bid in specific 
cellular locations. 
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1.5 Figures and Figure Legend 
 
 
Figure 1: Bid knockout mice are protected from high fat diet induced 
obesity. 
(A-B): Male 10wk old WT and Bid KO mice were fed with regular chow diet (RD), 
high fat diet (HFD) or high fat high carbohydrate diet (HFHCD) for 16wks (A-B). 
Body weight were measured every 2 weeks. (C): Body weight gain was 
expressed as the percentage of starting body weight. (D): Body mass index 
(BMI) were calculated as weight divided by the square of the nose-to-anus 
length.  
n=5-8 per group, *: p<0.05 
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Figure 1: Bid knockout mice are protected from high fat diet induced 
obesity. 
(E): Epigonadol tissue were obtained from one testis of each mouse and the 
weight was measured. (F): The ratio of epigonadol tissue and body weight ratio 
was determined. (G): H-E staining of the epigonadol tissue in each group of mice 
100X. (H): The number of adipocytes per 100X field was determined. 
 n=5-8 per group, *: p<0.05 
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Figure S1: Expression of Bid in WT and Bid KO mice.  
Male 10wk WT and Bid KO mice were fed with regular chow diet (RD), high fat 
diet (HFD) or high fat high carbohydrate diet (HFHCD) for 16wks. Liver tissue 
were homogenized and analyzed by immunoblotting assay. 
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Figure S2: Bid-heterozygous male mice were not protected from high fat 
diet induced obesity.  
(A): Male WT, Bid heterozygous (Het) and Bid knockout (KO) mice were fed with 
high fat diet for 24wks. Body weight were measured every 2 weeks. (B): 
Unilateral epigonadol adipose tissue were obtained and weight were measured.  
n= 5-8 per group, *: p<0.05 
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Figure S3: Female Bid KO mice were not protected from high fat induced 
obesity.  
Female WT, Het and Bid KO mice were fed with high fat diet for 24wks. Body 
weight was measured every two weeks.  
n= 5-8 per group 
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Figure S4: Bid deletion does not protect against obesity induced by leptin 
deficiency. 
(A) Male Bid KO and Ob/Ob/Bid KO mice were fed with regular chow diet for 
20wks and body weight were measured every two weeks.  
n= 5-8 per group. 
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Figure 2:  Bid Knockout Mice Are Protected from High Fat Diet Induced 
Metabolic Syndrome.  
(A-E): Male Bid KO and WT mice were fed with high fat diet for 16wks. Different 
parameters of metabolic syndrome were measured. (A): 12 hour fasting blood 
glucose level, (B): Serum insulin, (C): Insulin resistance (HOMA): (fasting 
glucose/18 mg/dl * fasting insulin * 25ng/ml)/22.5. (D): Serum Cholesterol, (E): 
Serum Triglyceride (TG)  
n=5-8 per group, *: p<0.05 
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Figure S5: Heterozygous Bid mice were not protected from high fat diet 
induced metabolic disturbances. 
(A-D): Male wild type (WT), Bid heterozygous (Het) and Bid knockout (KO) mice 
were fed with high fat diet for 24 wks. The following parameters were measured 
(A) blood glucose level, (B) serum triglyceride (TG), (C) serum cholesterol, (D) 
serum ALT (alanine transaminase).   
n= 5-8 per group, *: p<0.05 
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Figure 3. Bid knockout mice are protected from steatosis, non-alcoholic 
steatohepatitis and hepatic Fibrosis.  
(A-C): Male WT and Bid KO mice were fed with regular diet (RD), high fat diet 
(HFD) and high fat high carbohydrate diet (HFHCD) for 16 weeks. Hepatic 
steatosis was examined by H-E staining (A) and measurement of Hepatic 
triglyceride (TG) (B) and serum alanine transaminase (ALT) (C). (D-J): Male WT 
and Bid KO mice were fed with high fat high carbohydrate diet for 16 weeks, and 
hepatic fibrosis was examined by Trichrome C staining (D). 
n=5-8 per group, *: p<0.05 
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Figure 3. Bid knockout mice are protected from steatosis, non-alcoholic 
steatohepatitis and hepatic Fibrosis.  
Male WT and Bid KO mice were fed with high fat high carbohydrate diet for 16 
weeks and RT-PCR analysis of the following genes. (E): IL-1 beta, (F): IL-18, 
(G): IFN gamma, (H): Collagen 1l, (I): TGF-beta, (J): TIMP metallopeptidase 
inhibitor 1 (TIMP1).  
n=5-8 per group, *: p<0.05 
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Figure 4: Bid Knockout mice have a higher whole body metabolic rate in 
vivo. 
(A-E): Male WT and Bid KO mice were fed with high fat diet for 10wks and 
subjected to in vivo calorimetry analysis. (A): Hourly O2 consumption in 48 hours, 
data shown hourly. (B): Average O2 consumption in 48 hours.  
n=4 per group, *: p<0.05 
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Figure 4: Bid Knockout mice have a higher whole body metabolic rate in 
vivo. 
Male WT and Bid KO mice were fed with high fat diet for 10wks and subjected to 
in vivo calorimetry analysis. (C): Average CO2 generation in 48 hours. (D): 
Average respiratory exchange ratio in 48 hours. (E): Average heat generation in 
48 hours. (F): Male WT and Bid KO mice were fed with high fat diet for 16 weeks, 
food consumption were measured every 4 days. Average daily food intake was 
determined.    
n=4 per group, *: p<0.05 
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Figure 5: Deficiency of Bid leads to a higher expression of genes that 
promote energy expenditure. 
Male 10wk old WT and Bid KO mice were fed with regular chow diet (RD) or high 
fat diet (HFD) for 16wks. (A-J): mRNA expression analysis by RT-PCR in liver 
from regular diet and high fat diet groups (A, F): Peroxisome proliferator-
activated receptor gamma coactivator 1-beta (PGC1-beta). (B, G): PGC-1-related 
coactivator (PRC).  (C, H): Carnitine-acylcarnitine translocase (CAC). (D, I): 
peroxisome proliferator-activated receptor (PPAR-delta). (E, J): Peroxisome 
proliferator-activated receptor gamma coactivator 1-beta (PGC-1 alpha) 
n=4 per group 
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Figure 5: Deficiency of Bid leads to a higher expression of genes that 
promote energy expenditure. 
Male 10wk old WT and Bid KO mice were fed with regular chow diet (RD) or high 
fat diet (HFD) for 16wks. (K, L):  carnitine palmitoyltransferse I (LCPT1).  
n=4 per group 
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Figure 6: High fat diet induces full length Bid translocation, insertion to 
mitochondrial membrane and destabilize MTCH2. 
(A): WT and Bid KO mice were fed with high fat diet or regular diet for 10 weeks. 
Homogenates of the liver were separated to the cytosol (S10) and mitochondria 
enriched (P10) fractions, which were subjected to immunoblotting assays. (B): 
Densitometry analysis of immunoblotting assays. (C) WT and Bid KO mice were 
fed with high fat diet for 10wks. The subcellular fractions S10 and P10 were 
prepared as in (A). A portion of the P10 fraction was further treated with 0.1M 
Na2CO3 PH11.5 for 30min on ice. The pallet (P10) and the Supernatant (S10) 
were recovered after alkaline treatment. All fractions were then analyzed by 
immunoblotting assay. 
*:p<0.05 
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Figure S6: Expression of LCPT-1 and MTCH2 in MEF and in mice. 
(A): WT and Bid KO MEFs were subjected to subcellular fractionation into the 
mitochondria - enriched P10 fraction and the cytosol (S10). Both fractions were 
analyzed by immunoblotting assay.  Note MTCH2 only presents in the 
mitochondria – enriched P10 fraction. The signals in the S10 cytosol fraction is 
non-specific. (B, C): MTCH2 gene expression was analysis by RT-PCR in 10 wks 
of regular and high fat diet mice.   
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Figure 7:  Mitochondrion in Bid KO mice have higher fatty acid oxidation 
rate and higher free fatty acid in circulation. 
10wk old WT and Bid KO mice were fed with high fat diet for 10wks. Liver 
homogenates were prepared and subjected to ex-vivo fatty acid oxidation assay. 
(A, C): Measurement of C14-Acyl-CoA after a 60min and a 120min reaction, GST: 
Glutathione S-transferases. (B, D): Measurement of C14-CO2 fatty acid oxidation 
after a 60 min and a 120 min reaction (C-D). A Bid inhibitor, BI6C9 was added at 
a 4X or 10X molar ratio against Bid.  n=4 per group (A-D) *p<0.05. (E): Free fatty 
acid concentration in the blood was measured.  
n=3 per group, *: p<0.05 
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Figure S7: Measurement of ketone body in Bid KO and WT mice Liver. 
(A): 10wk old WT and Bid KO mice were fed with high fat diet for 10wks. Liver 
homogenize were subjected to ex-vivo beta-oxidation assay. Ketone body (beta-
Hydroxybutyric acid) was measured after exogenous palmitic acid added to the 
reaction. (B): Liver homogenates were directly subjected to the measurement of 
ketone body (beta-Hydroxybutyric acid).  
n=3 per group. 
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Figure S8: Serum free fatty acid concentration measurement. 
10wk old WT and Bid KO mice were fed with regular diet or high fat diet for 5 or 
15wks. Serum free fatty acid concentration was then measured. n=3 per group, *: 
p<0.05 
  
159 
 
Part III References 
 
1. Laplante, M. and D.M. Sabatini, mTOR signaling at a glance. J Cell Sci, 
2009. 122(Pt 20): p. 3589-94. 
2. Albert, V. and M.N. Hall, mTOR signaling in cellular and organismal 
energetics. Curr Opin Cell Biol, 2014. 33C: p. 55-66. 
3. Polak, P. and M.N. Hall, mTOR and the control of whole body metabolism. 
Curr Opin Cell Biol, 2009. 21(2): p. 209-18. 
4. Hara, K., et al., Raptor, a binding partner of target of rapamycin (TOR), 
mediates TOR action. Cell, 2002. 110(2): p. 177-89. 
5. Kim, D.H., et al., mTOR interacts with raptor to form a nutrient-sensitive 
complex that signals to the cell growth machinery. Cell, 2002. 110(2): p. 
163-75. 
6. Pearce, L.R., et al., Identification of Protor as a novel Rictor-binding 
component of mTOR complex-2. Biochem J, 2007. 405(3): p. 513-22. 
7. Loewith, R., et al., Two TOR complexes, only one of which is rapamycin 
sensitive, have distinct roles in cell growth control. Mol Cell, 2002. 10(3): 
p. 457-68. 
8. Sancak, Y., et al., PRAS40 is an insulin-regulated inhibitor of the 
mTORC1 protein kinase. Mol Cell, 2007. 25(6): p. 903-15. 
9. Wullschleger, S., et al., Molecular organization of target of rapamycin 
complex 2. J Biol Chem, 2005. 280(35): p. 30697-704. 
160 
 
10. Laplante, M. and D.M. Sabatini, mTOR signaling in growth control and 
disease. Cell, 2012. 149(2): p. 274-93. 
11. Inoki, K., et al., TSC2 is phosphorylated and inhibited by Akt and 
suppresses mTOR signalling. Nat Cell Biol, 2002. 4(9): p. 648-57. 
12. Inoki, K., et al., Rheb GTPase is a direct target of TSC2 GAP activity and 
regulates mTOR signaling. Genes Dev, 2003. 17(15): p. 1829-34. 
13. Ma, L., et al., Phosphorylation and functional inactivation of TSC2 by Erk 
implications for tuberous sclerosis and cancer pathogenesis. Cell, 2005. 
121(2): p. 179-93. 
14. Manning, B.D., et al., Identification of the tuberous sclerosis complex-2 
tumor suppressor gene product tuberin as a target of the phosphoinositide 
3-kinase/akt pathway. Mol Cell, 2002. 10(1): p. 151-62. 
15. Thedieck, K., et al., PRAS40 and PRR5-like protein are new mTOR 
interactors that regulate apoptosis. PLoS One, 2007. 2(11): p. e1217. 
16. Vander Haar, E., et al., Insulin signalling to mTOR mediated by the 
Akt/PKB substrate PRAS40. Nat Cell Biol, 2007. 9(3): p. 316-23. 
17. Lee, D.F., et al., IKK beta suppression of TSC1 links inflammation and 
tumor angiogenesis via the mTOR pathway. Cell, 2007. 130(3): p. 440-55. 
18. Inoki, K., et al., TSC2 integrates Wnt and energy signals via a coordinated 
phosphorylation by AMPK and GSK3 to regulate cell growth. Cell, 2006. 
126(5): p. 955-68. 
19. Gwinn, D.M., et al., AMPK phosphorylation of raptor mediates a metabolic 
checkpoint. Mol Cell, 2008. 30(2): p. 214-26. 
161 
 
20. Feng, Z., et al., The coordinate regulation of the p53 and mTOR pathways 
in cells. Proc Natl Acad Sci U S A, 2005. 102(23): p. 8204-9. 
21. Budanov, A.V. and M. Karin, p53 target genes sestrin1 and sestrin2 
connect genotoxic stress and mTOR signaling. Cell, 2008. 134(3): p. 451-
60. 
22. Blommaart, E.F., et al., Phosphorylation of ribosomal protein S6 is 
inhibitory for autophagy in isolated rat hepatocytes. J Biol Chem, 1995. 
270(5): p. 2320-6. 
23. Sancak, Y., et al., The Rag GTPases bind raptor and mediate amino acid 
signaling to mTORC1. Science, 2008. 320(5882): p. 1496-501. 
24. Sancak, Y., et al., Ragulator-Rag complex targets mTORC1 to the 
lysosomal surface and is necessary for its activation by amino acids. Cell, 
2010. 141(2): p. 290-303. 
25. Jewell, J.L., et al., Metabolism. Differential regulation of mTORC1 by 
leucine and glutamine. Science, 2015. 347(6218): p. 194-8. 
26. Zoncu, R., et al., mTORC1 senses lysosomal amino acids through an 
inside-out mechanism that requires the vacuolar H(+)-ATPase. Science, 
2011. 334(6056): p. 678-83. 
27. Pena-Llopis, S., et al., Regulation of TFEB and V-ATPases by mTORC1. 
EMBO J, 2011. 30(16): p. 3242-58. 
28. Fang, Y., et al., Phosphatidic acid-mediated mitogenic activation of mTOR 
signaling. Science, 2001. 294(5548): p. 1942-5. 
162 
 
29. Zoncu, R., A. Efeyan, and D.M. Sabatini, mTOR: from growth signal 
integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol, 2011. 
12(1): p. 21-35. 
30. Hara, K., et al., Regulation of eIF-4E BP1 phosphorylation by mTOR. J 
Biol Chem, 1997. 272(42): p. 26457-63. 
31. Ma, X.M., et al., SKAR links pre-mRNA splicing to mTOR/S6K1-mediated 
enhanced translation efficiency of spliced mRNAs. Cell, 2008. 133(2): p. 
303-13. 
32. Thoreen, C.C., et al., A unifying model for mTORC1-mediated regulation 
of mRNA translation. Nature, 2012. 485(7396): p. 109-13. 
33. Hay, N. and N. Sonenberg, Upstream and downstream of mTOR. Genes 
Dev, 2004. 18(16): p. 1926-45. 
34. Gingras, A.C., B. Raught, and N. Sonenberg, Regulation of translation 
initiation by FRAP/mTOR. Genes Dev, 2001. 15(7): p. 807-26. 
35. Ma, X.M. and J. Blenis, Molecular mechanisms of mTOR-mediated 
translational control. Nat Rev Mol Cell Biol, 2009. 10(5): p. 307-18. 
36. Martin, K.A. and J. Blenis, Coordinate regulation of translation by the PI 3-
kinase and mTOR pathways. Adv Cancer Res, 2002. 86: p. 1-39. 
37. Jastrzebski, K., et al., Coordinate regulation of ribosome biogenesis and 
function by the ribosomal protein S6 kinase, a key mediator of mTOR 
function. Growth Factors, 2007. 25(4): p. 209-26. 
163 
 
38. Mayer, C., et al., mTOR-dependent activation of the transcription factor 
TIF-IA links rRNA synthesis to nutrient availability. Genes Dev, 2004. 
18(4): p. 423-34. 
39. Brugarolas, J.B., et al., TSC2 regulates VEGF through mTOR-dependent 
and -independent pathways. Cancer Cell, 2003. 4(2): p. 147-58. 
40. Hudson, C.C., et al., Regulation of hypoxia-inducible factor 1alpha 
expression and function by the mammalian target of rapamycin. Mol Cell 
Biol, 2002. 22(20): p. 7004-14. 
41. Ricoult, S.J. and B.D. Manning, The multifaceted role of mTORC1 in the 
control of lipid metabolism. EMBO Rep, 2013. 14(3): p. 242-51. 
42. Horton, J.D., J.L. Goldstein, and M.S. Brown, SREBPs: activators of the 
complete program of cholesterol and fatty acid synthesis in the liver. J Clin 
Invest, 2002. 109(9): p. 1125-31. 
43. Horton, J.D., et al., Combined analysis of oligonucleotide microarray data 
from transgenic and knockout mice identifies direct SREBP target genes. 
Proc Natl Acad Sci U S A, 2003. 100(21): p. 12027-32. 
44. Brown, N.F., et al., The mammalian target of rapamycin regulates lipid 
metabolism in primary cultures of rat hepatocytes. Metabolism, 2007. 
56(11): p. 1500-7. 
45. Peterson, T.R., et al., mTOR complex 1 regulates lipin 1 localization to 
control the SREBP pathway. Cell, 2011. 146(3): p. 408-20. 
46. Laplante, M. and D.M. Sabatini, An emerging role of mTOR in lipid 
biosynthesis. Curr Biol, 2009. 19(22): p. R1046-52. 
164 
 
47. Kim, J.E. and J. Chen, regulation of peroxisome proliferator-activated 
receptor-gamma activity by mammalian target of rapamycin and amino 
acids in adipogenesis. Diabetes, 2004. 53(11): p. 2748-56. 
48. Zhang, H.H., et al., Insulin stimulates adipogenesis through the Akt-TSC2-
mTORC1 pathway. PLoS One, 2009. 4(7): p. e6189. 
49. El-Chaar, D., A. Gagnon, and A. Sorisky, Inhibition of insulin signaling and 
adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs 
eIF4E-BP1. Int J Obes Relat Metab Disord, 2004. 28(2): p. 191-8. 
50. Lamming, D.W. and D.M. Sabatini, A Central role for mTOR in lipid 
homeostasis. Cell Metab, 2013. 18(4): p. 465-9. 
51. Um, S.H., et al., Absence of S6K1 protects against age- and diet-induced 
obesity while enhancing insulin sensitivity. Nature, 2004. 431(7005): p. 
200-5. 
52. Sengupta, S., et al., mTORC1 controls fasting-induced ketogenesis and its 
modulation by ageing. Nature, 2010. 468(7327): p. 1100-4. 
53. Yecies, J.L., et al., Akt stimulates hepatic SREBP1c and lipogenesis 
through parallel mTORC1-dependent and independent pathways. Cell 
Metab, 2011. 14(1): p. 21-32. 
54. Umemura, A., et al., Liver damage, inflammation, and enhanced 
tumorigenesis after persistent mTORC1 inhibition. Cell Metab, 2014. 
20(1): p. 133-44. 
165 
 
55. Kenerson, H.L., M.M. Yeh, and R.S. Yeung, Tuberous sclerosis complex-1 
deficiency attenuates diet-induced hepatic lipid accumulation. PLoS One, 
2011. 6(3): p. e18075. 
56. Cornu, M., et al., Hepatic mTORC1 controls locomotor activity, body 
temperature, and lipid metabolism through FGF21. Proc Natl Acad Sci U S 
A, 2014. 111(32): p. 11592-9. 
57. Csibi, A., et al., The mTORC1 pathway stimulates glutamine metabolism 
and cell proliferation by repressing SIRT4. Cell, 2013. 153(4): p. 840-54. 
58. Newsholme, P., et al., Glutamine and glutamate--their central role in cell 
metabolism and function. Cell Biochem Funct, 2003. 21(1): p. 1-9. 
59. Li, Z., et al., Ghrelin promotes hepatic lipogenesis by activation of mTOR-
PPARgamma signaling pathway. Proc Natl Acad Sci U S A, 2014. 
111(36): p. 13163-8. 
60. Hagiwara, A., et al., Hepatic mTORC2 activates glycolysis and lipogenesis 
through Akt, glucokinase, and SREBP1c. Cell Metab, 2012. 15(5): p. 725-
38. 
61. Yuan, M., et al., Identification of Akt-independent regulation of hepatic 
lipogenesis by mammalian target of rapamycin (mTOR) complex 2. J Biol 
Chem, 2012. 287(35): p. 29579-88. 
62. Lamming, D.W., et al., Rapamycin-induced insulin resistance is mediated 
by mTORC2 loss and uncoupled from longevity. Science, 2012. 
335(6076): p. 1638-43. 
166 
 
63. Carr, C.S. and P.A. Sharp, A helix-loop-helix protein related to the 
immunoglobulin E box-binding proteins. Mol Cell Biol, 1990. 10(8): p. 
4384-8. 
64. Hodgkinson, C.A., et al., Mutations at the mouse microphthalmia locus are 
associated with defects in a gene encoding a novel basic-helix-loop-helix-
zipper protein. Cell, 1993. 74(2): p. 395-404. 
65. Hughes, M.J., et al., A helix-loop-helix transcription factor-like gene is 
located at the mi locus. J Biol Chem, 1993. 268(28): p. 20687-90. 
66. Martina, J.A., et al., Novel roles for the MiTF/TFE family of transcription 
factors in organelle biogenesis, nutrient sensing, and energy homeostasis. 
Cell Mol Life Sci, 2014. 71(13): p. 2483-97. 
67. Aksan, I. and C.R. Goding, Targeting the microphthalmia basic helix-loop-
helix-leucine zipper transcription factor to a subset of E-box elements in 
vitro and in vivo. Mol Cell Biol, 1998. 18(12): p. 6930-8. 
68. Beckmann, H., L.K. Su, and T. Kadesch, TFE3: a helix-loop-helix protein 
that activates transcription through the immunoglobulin enhancer muE3 
motif. Genes Dev, 1990. 4(2): p. 167-79. 
69. Kuiper, R.P., et al., Regulation of the MiTF/TFE bHLH-LZ transcription 
factors through restricted spatial expression and alternative splicing of 
functional domains. Nucleic Acids Res, 2004. 32(8): p. 2315-22. 
70. Settembre, C., et al., TFEB links autophagy to lysosomal biogenesis. 
Science, 2011. 332(6036): p. 1429-33. 
167 
 
71. Martina, J.A., et al., MTORC1 functions as a transcriptional regulator of 
autophagy by preventing nuclear transport of TFEB. Autophagy, 2012. 
8(6): p. 903-14. 
72. Settembre, C., et al., A lysosome-to-nucleus signalling mechanism senses 
and regulates the lysosome via mTOR and TFEB. EMBO J, 2012. 31(5): 
p. 1095-108. 
73. Roczniak-Ferguson, A., et al., The transcription factor TFEB links 
mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci 
Signal, 2012. 5(228): p. ra42. 
74. Ferron, M., et al., A RANKL-PKCbeta-TFEB signaling cascade is 
necessary for lysosomal biogenesis in osteoclasts. Genes Dev, 2013. 
27(8): p. 955-69. 
75. Settembre, C., et al., TFEB controls cellular lipid metabolism through a 
starvation-induced autoregulatory loop. Nat Cell Biol, 2013. 15(6): p. 647-
58. 
76. Sardiello, M., et al., A gene network regulating lysosomal biogenesis and 
function. Science, 2009. 325(5939): p. 473-7. 
77. Bellot, G., et al., Hypoxia-induced autophagy is mediated through hypoxia-
inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. 
Mol Cell Biol, 2009. 29(10): p. 2570-81. 
78. Crighton, D., et al., DRAM, a p53-induced modulator of autophagy, is 
critical for apoptosis. Cell, 2006. 126(1): p. 121-34. 
168 
 
79. Palmieri, M., et al., Characterization of the CLEAR network reveals an 
integrated control of cellular clearance pathways. Hum Mol Genet, 2011. 
20(19): p. 3852-66. 
80. Deter, R.L. and C. De Duve, Influence of glucagon, an inducer of cellular 
autophagy, on some physical properties of rat liver lysosomes. J Cell Biol, 
1967. 33(2): p. 437-49. 
81. Shintani, T. and D.J. Klionsky, Autophagy in health and disease: a double-
edged sword. Science, 2004. 306(5698): p. 990-5. 
82. Meijer, A.J. and P. Codogno, Regulation and role of autophagy in 
mammalian cells. Int J Biochem Cell Biol, 2004. 36(12): p. 2445-62. 
83. Mijaljica, D., M. Prescott, and R.J. Devenish, Microautophagy in 
mammalian cells: revisiting a 40-year-old conundrum. Autophagy, 2011. 
7(7): p. 673-82. 
84. Farre, J.C., et al., Turnover of organelles by autophagy in yeast. Curr Opin 
Cell Biol, 2009. 21(4): p. 522-30. 
85. Li, W.W., J. Li, and J.K. Bao, Microautophagy: lesser-known self-eating. 
Cell Mol Life Sci, 2012. 69(7): p. 1125-36. 
86. Suzuki, K., Selective autophagy in budding yeast. Cell Death Differ, 2013. 
20(1): p. 43-8. 
87. Mijaljica, D., M. Prescott, and R.J. Devenish, The intricacy of nuclear 
membrane dynamics during nucleophagy. Nucleus, 2010. 1(3): p. 213-23. 
88. Tolkovsky, A.M., Mitophagy. Biochim Biophys Acta, 2009. 1793(9): p. 
1508-15. 
169 
 
89. Kaushik, S. and A.M. Cuervo, Chaperone-mediated autophagy: a unique 
way to enter the lysosome world. Trends Cell Biol, 2012. 22(8): p. 407-17. 
90. De Duve, C. and R. Wattiaux, Functions of lysosomes. Annu Rev Physiol, 
1966. 28: p. 435-92. 
91. Hamasaki, M., S.T. Shibutani, and T. Yoshimori, Up-to-date membrane 
biogenesis in the autophagosome formation. Curr Opin Cell Biol, 2013. 
25(4): p. 455-60. 
92. Dunn, W.A., Jr., Studies on the mechanisms of autophagy: formation of 
the autophagic vacuole. J Cell Biol, 1990. 110(6): p. 1923-33. 
93. Matsunaga, K., et al., Autophagy requires endoplasmic reticulum targeting 
of the PI3-kinase complex via Atg14L. J Cell Biol, 2010. 190(4): p. 511-21. 
94. Ge, L. and R. Schekman, The ER-Golgi intermediate compartment feeds 
the phagophore membrane. Autophagy, 2014. 10(1): p. 170-2. 
95. Hailey, D.W., et al., Mitochondria supply membranes for autophagosome 
biogenesis during starvation. Cell, 2010. 141(4): p. 656-67. 
96. Moreau, K. and D.C. Rubinsztein, The plasma membrane as a control 
center for autophagy. Autophagy, 2012. 8(5): p. 861-3. 
97. Karanasios, E., et al., Dynamic association of the ULK1 complex with 
omegasomes during autophagy induction. J Cell Sci, 2013. 126(Pt 22): p. 
5224-38. 
98. Hayashi-Nishino, M., et al., Electron tomography reveals the endoplasmic 
reticulum as a membrane source for autophagosome formation. 
Autophagy, 2010. 6(2): p. 301-3. 
170 
 
99. Eskelinen, E.L., Fine structure of the autophagosome. Methods Mol Biol, 
2008. 445: p. 11-28. 
100. Itakura, E. and N. Mizushima, Characterization of autophagosome 
formation site by a hierarchical analysis of mammalian Atg proteins. 
Autophagy, 2010. 6(6): p. 764-76. 
101. Tan, D., et al., The EM structure of the TRAPPIII complex leads to the 
identification of a requirement for COPII vesicles on the macroautophagy 
pathway. Proc Natl Acad Sci U S A, 2013. 110(48): p. 19432-7. 
102. Mizushima, N., T. Yoshimori, and Y. Ohsumi, The role of Atg proteins in 
autophagosome formation. Annu Rev Cell Dev Biol, 2011. 27: p. 107-32. 
103. Hosokawa, N., et al., Nutrient-dependent mTORC1 association with the 
ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell, 2009. 
20(7): p. 1981-91. 
104. Lamb, C.A., T. Yoshimori, and S.A. Tooze, The autophagosome: origins 
unknown, biogenesis complex. Nat Rev Mol Cell Biol, 2013. 14(12): p. 
759-74. 
105. Kim, J., et al., AMPK and mTOR regulate autophagy through direct 
phosphorylation of Ulk1. Nat Cell Biol, 2011. 13(2): p. 132-41. 
106. Russell, R.C., et al., ULK1 induces autophagy by phosphorylating Beclin-1 
and activating VPS34 lipid kinase. Nat Cell Biol, 2013. 15(7): p. 741-50. 
107. Dove, S.K., et al., Svp1p defines a family of phosphatidylinositol 3,5-
bisphosphate effectors. EMBO J, 2004. 23(9): p. 1922-33. 
171 
 
108. Stromhaug, P.E., et al., Atg21 is a phosphoinositide binding protein 
required for efficient lipidation and localization of Atg8 during uptake of 
aminopeptidase I by selective autophagy. Mol Biol Cell, 2004. 15(8): p. 
3553-66. 
109. Efe, J.A., R.J. Botelho, and S.D. Emr, Atg18 regulates organelle 
morphology and Fab1 kinase activity independent of its membrane 
recruitment by phosphatidylinositol 3,5-bisphosphate. Mol Biol Cell, 2007. 
18(11): p. 4232-44. 
110. Obara, K., et al., The Atg18-Atg2 complex is recruited to autophagic 
membranes via phosphatidylinositol 3-phosphate and exerts an essential 
function. J Biol Chem, 2008. 283(35): p. 23972-80. 
111. Polson, H.E., et al., Mammalian Atg18 (WIPI2) localizes to omegasome-
anchored phagophores and positively regulates LC3 lipidation. Autophagy, 
2010. 6(4): p. 506-22. 
112. Mauthe, M., et al., Resveratrol-mediated autophagy requires WIPI-1-
regulated LC3 lipidation in the absence of induced phagophore formation. 
Autophagy, 2011. 7(12): p. 1448-61. 
113. Ohsumi, Y. and N. Mizushima, Two ubiquitin-like conjugation systems 
essential for autophagy. Semin Cell Dev Biol, 2004. 15(2): p. 231-6. 
114. Hanada, T., et al., The Atg12-Atg5 conjugate has a novel E3-like activity 
for protein lipidation in autophagy. J Biol Chem, 2007. 282(52): p. 37298-
302. 
172 
 
115. Nair, U., et al., Roles of the lipid-binding motifs of Atg18 and Atg21 in the 
cytoplasm to vacuole targeting pathway and autophagy. J Biol Chem, 
2010. 285(15): p. 11476-88. 
116. Ichimura, Y., et al., In vivo and in vitro reconstitution of Atg8 conjugation 
essential for autophagy. J Biol Chem, 2004. 279(39): p. 40584-92. 
117. Fujita, N., et al., The Atg16L complex specifies the site of LC3 lipidation 
for membrane biogenesis in autophagy. Mol Biol Cell, 2008. 19(5): p. 
2092-100. 
118. Mao, Y., et al., Hepatitis B virus X protein reduces starvation-induced cell 
death through activation of autophagy and inhibition of mitochondrial 
apoptotic pathway. Biochem Biophys Res Commun, 2011. 415(1): p. 68-
74. 
119. Reggiori, F., et al., Atg9 cycles between mitochondria and the pre-
autophagosomal structure in yeasts. Autophagy, 2005. 1(2): p. 101-9. 
120. Mari, M., et al., An Atg9-containing compartment that functions in the early 
steps of autophagosome biogenesis. J Cell Biol, 2010. 190(6): p. 1005-22. 
121. Young, A.R., et al., Starvation and ULK1-dependent cycling of mammalian 
Atg9 between the TGN and endosomes. J Cell Sci, 2006. 119(Pt 18): p. 
3888-900. 
122. Webber, J.L. and S.A. Tooze, Coordinated regulation of autophagy by 
p38alpha MAPK through mAtg9 and p38IP. EMBO J, 2010. 29(1): p. 27-
40. 
173 
 
123. Itakura, E., C. Kishi-Itakura, and N. Mizushima, The hairpin-type tail-
anchored SNARE syntaxin 17 targets to autophagosomes for fusion with 
endosomes/lysosomes. Cell, 2012. 151(6): p. 1256-69. 
124. He, C. and D.J. Klionsky, Regulation mechanisms and signaling pathways 
of autophagy. Annu Rev Genet, 2009. 43: p. 67-93. 
125. Alers, S., et al., Role of AMPK-mTOR-Ulk1/2 in the regulation of 
autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol, 2012. 
32(1): p. 2-11. 
126. Kim, J., et al., Differential regulation of distinct Vps34 complexes by AMPK 
in nutrient stress and autophagy. Cell, 2013. 152(1-2): p. 290-303. 
127. Kimata, Y. and K. Kohno, Endoplasmic reticulum stress-sensing 
mechanisms in yeast and mammalian cells. Curr Opin Cell Biol, 2011. 
23(2): p. 135-42. 
128. Ogata, M., et al., Autophagy is activated for cell survival after endoplasmic 
reticulum stress. Mol Cell Biol, 2006. 26(24): p. 9220-31. 
129. Ding, W.X., et al., Linking of autophagy to ubiquitin-proteasome system is 
important for the regulation of endoplasmic reticulum stress and cell 
viability. Am J Pathol, 2007. 171(2): p. 513-24. 
130. Ding, W.X. and X.M. Yin, Sorting, recognition and activation of the 
misfolded protein degradation pathways through macroautophagy and the 
proteasome. Autophagy, 2008. 4(2): p. 141-50. 
174 
 
131. Hoyer-Hansen, M. and M. Jaattela, Connecting endoplasmic reticulum 
stress to autophagy by unfolded protein response and calcium. Cell Death 
Differ, 2007. 14(9): p. 1576-82. 
132. Schworer, C.M., K.A. Shiffer, and G.E. Mortimore, Quantitative 
relationship between autophagy and proteolysis during graded amino acid 
deprivation in perfused rat liver. J Biol Chem, 1981. 256(14): p. 7652-8. 
133. Mortimore, G.E., N.J. Hutson, and C.A. Surmacz, Quantitative correlation 
between proteolysis and macro- and microautophagy in mouse 
hepatocytes during starvation and refeeding. Proc Natl Acad Sci U S A, 
1983. 80(8): p. 2179-83. 
134. Takamura, A., et al., Autophagy-deficient mice develop multiple liver 
tumors. Genes Dev, 2011. 25(8): p. 795-800. 
135. Rusten, T.E. and H. Stenmark, p62, an autophagy hero or culprit? Nat Cell 
Biol, 2010. 12(3): p. 207-9. 
136. Xie, Z. and D.J. Klionsky, Autophagosome formation: core machinery and 
adaptations. Nat Cell Biol, 2007. 9(10): p. 1102-9. 
137. Komatsu, M., et al., Homeostatic levels of p62 control cytoplasmic 
inclusion body formation in autophagy-deficient mice. Cell, 2007. 131(6): 
p. 1149-63. 
138. Komatsu, M., et al., The selective autophagy substrate p62 activates the 
stress responsive transcription factor Nrf2 through inactivation of Keap1. 
Nat Cell Biol, 2010. 12(3): p. 213-23. 
175 
 
139. Green, D.R. and B. Levine, To Be or Not to Be? How Selective Autophagy 
and Cell Death Govern Cell Fate. Cell, 2014. 157(1): p. 65-75. 
140. Ding, W.X., et al., Autophagy reduces acute ethanol-induced 
hepatotoxicity and steatosis in mice. Gastroenterology, 2010. 139(5): p. 
1740-52. 
141. Kim, S.J., et al., Hepatitis B virus disrupts mitochondrial dynamics: 
induces fission and mitophagy to attenuate apoptosis. PLoS Pathog, 
2013. 9(12): p. e1003722. 
142. Pi, H., et al., Dynamin 1-like-dependent mitochondrial fission initiates 
overactive mitophagy in the hepatotoxicity of cadmium. Autophagy, 2013. 
9(11): p. 1780-800. 
143. Masaki, R., A. Yamamoto, and Y. Tashiro, Cytochrome P-450 and 
NADPH-cytochrome P-450 reductase are degraded in the autolysosomes 
in rat liver. J Cell Biol, 1987. 104(5): p. 1207-15. 
144. Bernales, S., K.L. McDonald, and P. Walter, Autophagy counterbalances 
endoplasmic reticulum expansion during the unfolded protein response. 
PLoS Biol, 2006. 4(12): p. e423. 
145. Thomes, P.G., et al., Proteasome activity and autophagosome content in 
liver are reciprocally regulated by ethanol treatment. Biochem Biophys 
Res Commun, 2012. 417(1): p. 262-7. 
146. Lin, C.W., et al., Pharmacological promotion of autophagy alleviates 
steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in 
mice. J Hepatol, 2013. 58(5): p. 993-9. 
176 
 
147. Dolganiuc, A., et al., Autophagy in alcohol-induced liver diseases. Alcohol 
Clin Exp Res, 2012. 36(8): p. 1301-8. 
148. Donohue, T.M., Jr., R.K. Zetterman, and D.J. Tuma, Effect of chronic 
ethanol administration on protein catabolism in rat liver. Alcohol Clin Exp 
Res, 1989. 13(1): p. 49-57. 
149. Harada, M., et al., Autophagy activation by rapamycin eliminates mouse 
Mallory-Denk bodies and blocks their proteasome inhibitor-mediated 
formation. Hepatology, 2008. 47(6): p. 2026-35. 
150. Tiniakos, D.G., M.B. Vos, and E.M. Brunt, Nonalcoholic fatty liver disease: 
pathology and pathogenesis. Annu Rev Pathol, 2010. 5: p. 145-71. 
151. Clark, J.M., F.L. Brancati, and A.M. Diehl, The prevalence and etiology of 
elevated aminotransferase levels in the United States. Am J 
Gastroenterol, 2003. 98(5): p. 960-7. 
152. Ruhl, C.E. and J.E. Everhart, The association of low serum alanine 
aminotransferase activity with mortality in the US population. Am J 
Epidemiol, 2013. 178(12): p. 1702-11. 
153. Singh, R., et al., Autophagy regulates lipid metabolism. Nature, 2009. 
458(7242): p. 1131-5. 
154. Yang, L., et al., Defective hepatic autophagy in obesity promotes ER 
stress and causes insulin resistance. Cell Metab, 2010. 11(6): p. 467-78. 
155. Sanyal, A.J., et al., Nonalcoholic steatohepatitis: association of insulin 
resistance and mitochondrial abnormalities. Gastroenterology, 2001. 
120(5): p. 1183-92. 
177 
 
156. Liu, H.Y., et al., Hepatic autophagy is suppressed in the presence of 
insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent 
expression of key autophagy genes by insulin. J Biol Chem, 2009. 
284(45): p. 31484-92. 
157. He, Z., et al., p73 regulates autophagy and hepatocellular lipid metabolism 
through a transcriptional activation of the ATG5 gene. Cell Death Differ, 
2013. 20(10): p. 1415-24. 
158. Sinha, R.A., et al., Thyroid hormone stimulates hepatic lipid catabolism via 
activation of autophagy. J Clin Invest, 2012. 122(7): p. 2428-38. 
159. Inami, Y., et al., Hepatic steatosis inhibits autophagic proteolysis via 
impairment of autophagosomal acidification and cathepsin expression. 
Biochem Biophys Res Commun, 2011. 412(4): p. 618-25. 
160. Fukuo, Y., et al., Abnormality of autophagic function and cathepsin 
expression in the liver from patients with non-alcoholic fatty liver disease. 
Hepatol Res, 2013. 
161. Koga, H., S. Kaushik, and A.M. Cuervo, Altered lipid content inhibits 
autophagic vesicular fusion. FASEB J, 2010. 24(8): p. 3052-65. 
162. Xiong, X., et al., The autophagy-related gene 14 (Atg14) is regulated by 
forkhead box O transcription factors and circadian rhythms and plays a 
critical role in hepatic autophagy and lipid metabolism. J Biol Chem, 2012. 
287(46): p. 39107-14. 
178 
 
163. Kashima, J., et al., Immunohistochemical study of the autophagy marker 
microtubule-associated protein 1 light chain 3 in normal and steatotic 
human livers. Hepatol Res, 2013. 
164. Serviddio, G., et al., Targeting mitochondria: a new promising approach 
for the treatment of liver diseases. Curr Med Chem, 2010. 17(22): p. 2325-
37. 
165. Singh, R. and A.M. Cuervo, Lipophagy: connecting autophagy and lipid 
metabolism. Int J Cell Biol, 2012. 2012: p. 282041. 
166. Stoka, V., et al., Lysosomal protease pathways to apoptosis. Cleavage of 
bid, not pro-caspases, is the most likely route. J Biol Chem, 2001. 276(5): 
p. 3149-57. 
167. Kleiner, D.E., et al., Design and validation of a histological scoring system 
for nonalcoholic fatty liver disease. Hepatology, 2005. 41(6): p. 1313-21. 
168. Martina, J.A. and R. Puertollano, Rag GTPases mediate amino acid-
dependent recruitment of TFEB and MITF to lysosomes. J Cell Biol, 2013. 
200(4): p. 475-91. 
169. Yu, L., et al., Termination of autophagy and reformation of lysosomes 
regulated by mTOR. Nature, 2010. 465(7300): p. 942-6. 
170. Hoffmann, A., et al., The IkappaB-NF-kappaB signaling module: temporal 
control and selective gene activation. Science, 2002. 298(5596): p. 1241-
5. 
179 
 
171. Pallayova, M. and S. Taheri, Non-alcoholic fatty liver disease in obese 
adults: clinical aspects and current management strategies. Clin Obes, 
2014. 4(5): p. 243-53. 
172. Billen, L.P., A. Shamas-Din, and D.W. Andrews, Bid: a Bax-like BH3 
protein. Oncogene, 2008. 27 Suppl 1: p. S93-104. 
173. Yin, X.M., Bid, a BH3-only multi-functional molecule, is at the cross road of 
life and death. Gene, 2006. 369: p. 7-19. 
174. Wang, K., et al., BID: a novel BH3 domain-only death agonist. Genes Dev, 
1996. 10(22): p. 2859-69. 
175. Nunez, G., et al., Deregulated Bcl-2 gene expression selectively prolongs 
survival of growth factor-deprived hemopoietic cell lines. J Immunol, 1990. 
144(9): p. 3602-10. 
176. Li, H., et al., Cleavage of BID by caspase 8 mediates the mitochondrial 
damage in the Fas pathway of apoptosis. Cell, 1998. 94(4): p. 491-501. 
177. Luo, X., et al., Bid, a Bcl2 interacting protein, mediates cytochrome c 
release from mitochondria in response to activation of cell surface death 
receptors. Cell, 1998. 94(4): p. 481-90. 
178. Gross, A., et al., Caspase cleaved BID targets mitochondria and is 
required for cytochrome c release, while BCL-XL prevents this release but 
not tumor necrosis factor-R1/Fas death. J Biol Chem, 1999. 274(2): p. 
1156-63. 
180 
 
179. Footz, T.K., et al., The gene for death agonist BID maps to the region of 
human 22q11.2 duplicated in cat eye syndrome chromosomes and to 
mouse chromosome 6. Genomics, 1998. 51(3): p. 472-5. 
180. Wang, K., et al., BID, a proapoptotic BCL-2 family member, is localized to 
mouse chromosome 6 and human chromosome 22q11. Genomics, 1998. 
53(2): p. 235-8. 
181. Kvansakul, M., et al., Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like 
domain-swapped dimer that binds a highly selective subset of BH3-
containing death ligands. Cell Death Differ, 2008. 15(10): p. 1564-71. 
182. Sax, J.K., et al., BID regulation by p53 contributes to chemosensitivity. Nat 
Cell Biol, 2002. 4(11): p. 842-9. 
183. Parrado, A., et al., The promyelocytic leukemia zinc finger protein down-
regulates apoptosis and expression of the proapoptotic BID protein in 
lymphocytes. Proc Natl Acad Sci U S A, 2004. 101(7): p. 1898-903. 
184. McDonnell, J.M., et al., Solution structure of the proapoptotic molecule 
BID: a structural basis for apoptotic agonists and antagonists. Cell, 1999. 
96(5): p. 625-34. 
185. Zha, J., et al., Posttranslational N-myristoylation of BID as a molecular 
switch for targeting mitochondria and apoptosis. Science, 2000. 
290(5497): p. 1761-5. 
186. Lovell, J.F., et al., Membrane binding by tBid initiates an ordered series of 
events culminating in membrane permeabilization by Bax. Cell, 2008. 
135(6): p. 1074-84. 
181 
 
187. Slee, E.A., S.A. Keogh, and S.J. Martin, Cleavage of BID during cytotoxic 
drug and UV radiation-induced apoptosis occurs downstream of the point 
of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop 
for amplification of apoptosis-associated mitochondrial cytochrome c 
release. Cell Death Differ, 2000. 7(6): p. 556-65. 
188. Degli Esposti, M., et al., Post-translational modification of Bid has 
differential effects on its susceptibility to cleavage by caspase 8 or 
caspase 3. J Biol Chem, 2003. 278(18): p. 15749-57. 
189. Guicciardi, M.E., et al., Cathepsin B contributes to TNF-alpha-mediated 
hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. 
J Clin Invest, 2000. 106(9): p. 1127-37. 
190. Cirman, T., et al., Selective disruption of lysosomes in HeLa cells triggers 
apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal 
cathepsins. J Biol Chem, 2004. 279(5): p. 3578-87. 
191. Desagher, S., et al., Phosphorylation of bid by casein kinases I and II 
regulates its cleavage by caspase 8. Mol Cell, 2001. 8(3): p. 601-11. 
192. Zaltsman, Y., et al., MTCH2/MIMP is a major facilitator of tBID recruitment 
to mitochondria. Nat Cell Biol, 2010. 12(6): p. 553-62. 
193. Lutter, M., et al., Cardiolipin provides specificity for targeting of tBid to 
mitochondria. Nat Cell Biol, 2000. 2(10): p. 754-61. 
194. Kim, T.H., et al., Bid-cardiolipin interaction at mitochondrial contact site 
contributes to mitochondrial cristae reorganization and cytochrome C 
release. Mol Biol Cell, 2004. 15(7): p. 3061-72. 
182 
 
195. Liu, J., et al., The cardiolipin-binding domain of Bid affects mitochondrial 
respiration and enhances cytochrome c release. Apoptosis, 2004. 9(5): p. 
533-41. 
196. Lutter, M., G.A. Perkins, and X. Wang, The pro-apoptotic Bcl-2 family 
member tBid localizes to mitochondrial contact sites. BMC Cell Biol, 2001. 
2: p. 22. 
197. Scaffidi, C., et al., Two CD95 (APO-1/Fas) signaling pathways. Embo j, 
1998. 17(6): p. 1675-87. 
198. Ozoren, N. and W.S. El-Deiry, Defining characteristics of Types I and II 
apoptotic cells in response to TRAIL. Neoplasia, 2002. 4(6): p. 551-7. 
199. Yin, X.M., et al., Bid-deficient mice are resistant to Fas-induced 
hepatocellular apoptosis. Nature, 1999. 400(6747): p. 886-91. 
200. Deng, Y., Y. Lin, and X. Wu, TRAIL-induced apoptosis requires Bax-
dependent mitochondrial release of Smac/DIABLO. Genes Dev, 2002. 
16(1): p. 33-45. 
201. Broaddus, V.C., et al., Bid mediates apoptotic synergy between tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA 
damage. J Biol Chem, 2005. 280(13): p. 12486-93. 
202. Kaufmann, T., et al., Fatal hepatitis mediated by tumor necrosis factor 
TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and 
Bim. Immunity, 2009. 30(1): p. 56-66. 
203. DuBray, B.J., Jr., et al., BH3-only proteins contribute to steatotic liver 
ischemia-reperfusion injury. J Surg Res, 2015. 194(2): p. 653-8. 
183 
 
204. Hsu, S.H., et al., Hepatic loss of miR-122 predisposes mice to 
hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine 
exposure. Am J Pathol, 2013. 183(6): p. 1719-30. 
205. Badmann, A., et al., TRAIL enhances paracetamol-induced liver sinusoidal 
endothelial cell death in a Bim- and Bid-dependent manner. Cell Death 
Dis, 2012. 3: p. e447. 
206. Roychowdhury, S., et al., Inhibition of apoptosis protects mice from 
ethanol-mediated acceleration of early markers of CCl4 -induced fibrosis 
but not steatosis or inflammation. Alcohol Clin Exp Res, 2012. 36(7): p. 
1139-47. 
207. Hikita, H., et al., Mcl-1 and Bcl-xL cooperatively maintain integrity of 
hepatocytes in developing and adult murine liver. Hepatology, 2009. 50(4): 
p. 1217-26. 
208. Hikita, H., et al., BH3-only protein bid participates in the Bcl-2 network in 
healthy liver cells. Hepatology, 2009. 50(6): p. 1972-80. 
209. Zinkel, S.S., X.M. Yin, and A. Gross, Rejuvenating Bi(d)ology. Oncogene, 
2013. 32(27): p. 3213-9. 
210. Liu, Y., et al., Proapoptotic Bid mediates the Atr-directed DNA damage 
response to replicative stress. Cell Death Differ, 2011. 18(5): p. 841-52. 
211. Garrett, W.S., J.I. Gordon, and L.H. Glimcher, Homeostasis and 
inflammation in the intestine. Cell, 2010. 140(6): p. 859-70. 
212. Yeretssian, G., et al., Non-apoptotic role of BID in inflammation and innate 
immunity. Nature, 2011. 474(7349): p. 96-9. 
184 
 
213. Zinkel, S.S., et al., Proapoptotic BID is required for myeloid homeostasis 
and tumor suppression. Genes Dev, 2003. 17(2): p. 229-39. 
214. Ito, K., et al., Regulation of oxidative stress by ATM is required for self-
renewal of haematopoietic stem cells. Nature, 2004. 431(7011): p. 997-
1002. 
215. Kamer, I., et al., Proapoptotic BID is an ATM effector in the DNA-damage 
response. Cell, 2005. 122(4): p. 593-603. 
216. Zinkel, S.S., et al., A role for proapoptotic BID in the DNA-damage 
response. Cell, 2005. 122(4): p. 579-91. 
217. Maryanovich, M., et al., The ATM-BID pathway regulates quiescence and 
survival of haematopoietic stem cells. Nat Cell Biol, 2012. 14(5): p. 535-
41. 
218. Ito, K., et al., Regulation of reactive oxygen species by Atm is essential for 
proper response to DNA double-strand breaks in lymphocytes. J Immunol, 
2007. 178(1): p. 103-10. 
219. Willer, C.J., et al., Six new loci associated with body mass index highlight 
a neuronal influence on body weight regulation. Nat Genet, 2009. 41(1): p. 
25-34. 
220. Gupte, A.A., H.J. Pownall, and D.J. Hamilton, Estrogen: An Emerging 
Regulator of Insulin Action and Mitochondrial Function. J Diabetes Res, 
2015. 2015: p. 916585. 
185 
 
221. Varlamov, O., C.L. Bethea, and C.T. Roberts, Jr., Sex-specific differences 
in lipid and glucose metabolism. Front Endocrinol (Lausanne), 2014. 5: p. 
241. 
222. Shah, M. and A. Garg, High-fat and high-carbohydrate diets and energy 
balance. Diabetes Care, 1996. 19(10): p. 1142-52. 
223. Anstee, Q.M. and R.D. Goldin, Mouse models in non-alcoholic fatty liver 
disease and steatohepatitis research. Int J Exp Pathol, 2006. 87(1): p. 1-
16. 
224. Sonoda, J., et al., PGC-1beta controls mitochondrial metabolism to 
modulate circadian activity, adaptive thermogenesis, and hepatic 
steatosis. Proc Natl Acad Sci U S A, 2007. 104(12): p. 5223-8. 
225. Liang, H. and W.F. Ward, PGC-1alpha: a key regulator of energy 
metabolism. Adv Physiol Educ, 2006. 30(4): p. 145-51. 
226. Giordano, A., et al., tBid induces alterations of mitochondrial fatty acid 
oxidation flux by malonyl-CoA-independent inhibition of carnitine 
palmitoyltransferase-1. Cell Death Differ, 2005. 12(6): p. 603-13. 
227. Bonnefont, J.P., et al., Carnitine palmitoyltransferases 1 and 2: 
biochemical, molecular and medical aspects. Mol Aspects Med, 2004. 
25(5-6): p. 495-520. 
228. Kuwana, T., et al., Bid, Bax, and lipids cooperate to form supramolecular 
openings in the outer mitochondrial membrane. Cell, 2002. 111(3): p. 331-
42. 
 
 Curriculum Vitae 
Hao Zhang 
 
Education: 
Ph.D - Indiana University                                                                                 2015 
M.D. - School of Medicine, Tongji University, China                                        2009 
 
Publications (journal articles and abstracts): 
1. Zhang H* (co-first author), Lin CW*, , Li M, Xiong X, Chen X, Chen X, Charlie 
Dong X, Yin XM. Pharmacological Promotion of Autophagy Alleviates Steatosis 
and Injury in Alcoholic and Non-alcoholic Fatty Liver Conditions in Mice.  Journal 
of Hepatology. 2013 Jan 19. pii: S0168-8278(13)00054-8. doi: 
10.1016/j.jhep.2013.01.011. Epub 2013 Jan 12. 
2. Li M, Khambu B, Zhang H, Kang JH, Chen X, Chen D, Vollmer L, Liu PQ, Vogt 
A, Yin XM. Suppression of lysosome function induces autophagy via a feedback 
down-regulation of MTOR complex 1 (MTORC1) activity.  Journal of Biological 
Chemistry. 2013 Dec 13;288(50):35769-80. doi: 10.1074/jbc.M113.511212. Epub 
2013 Oct 30. 
3.  Chen X, Khambu B, Zhang H, Gao WT, Li M, Chen X, Yorshimori T, Yin XM 
Autophagy induced by calcium phosphate precipitates targets damaged 
endosomes. Journal of Biological Chemistry. published March 11, 2014 as 
doi:10.1074/jbc.M113.531855 
4. Chen D, Chen X, Li M, Zhang H, Ding WX, Yin XM. CCCP-Induced LC3 
Lipidation Depends on Atg9 Whereas FIP200/Atg13 and Beclin 1/Atg14 are 
Dispensable. Biochemical and Biophysical Research Communications. 2013 Mar 
8;432(2):226-30.  
5.  Hai J, Lin Q, Lu Y, Zhang H, Yi J.  Induction of apoptosis in rat C6 glioma cells 
by panaxydol.  Cell Biology International. 2007 Jul;31(7):711-5. Epub 2007 Jan 
14.     
6.  Hai J, Lin Q, Zhang H, Lu Y, Yi J. Cyclic AMP-dependent regulation of 
differentiation of rat C6 glioma cells by panaxydol.  Neurological Research. 2009 
Apr;31(3):274-9. 
7.  Hai J, Lin Q, Lu Y, Yi J, Zhang H.  Growth inhibition and induction of 
differentiation by panaxydol in rat C6 glioma cells.  Neurological Research. 2008 
Feb;30(1):99-105.     
 8.  Zhang H, Yang CQ.  Glycomics as a non-invasive diagnostic method for liver 
fibrosis. Chinese Journal of Hepatology. 2008 Mar;16(3):239-40   
9.  Yang CQ, Yang L, Yang WZ, Zhang Z, Zhang H, et al. Mechanism of hepatic 
satellite cell migration during liver fibrosis. National Medical Journal of China. 
2008 Jan 8;88(2):119-22   
10.  Zhang H, Hai J. The Molecular Mechanisms of Ubiquitin-proteasome system 
in Cognition.  International Journal of Cerebrovascular Disease   2008 (16) 11; 
862-5 
12. Zhang H, Khambu B, Chen X, Chalasani NP, Liangpungsakul S, Li Y, Yin XM. 
mTOR-TFEB feedback loop regulates NAFLD development and metabolic 
syndrome in mice. In preparation. 
13. Zhang H, Khambu B, Chen X, Yin XM. Deletion of Bid Protects Against Diet 
Induced Obesity and Metabolic Syndrome by Upregulation of Fatty Acid 
Oxidation.  In preparation. 
14.  Zhang H, Chen X, Yin XM.  The Dynamics of Liver Autophagy Status during 
Steatosis Development.  Hepatology  54:1440, 2013 AASLD Liver Meeting 
abstract 
15. Yin XM, Zhang H, Lin CW, Chen X, Chen XY.  Autophagy regulates steatosis 
in non-alcoholic fatty liver disease in mouse.  Hepatology 54:1157A, 2011 2012 
AASLD Liver Meeting abstract  
16.  Yang Z, Guo N, B Khambu, Zhang H, P Liu, X Yin, M Li  Impaired lysosome 
function can induce autophagy via suppression of mTOR activity. FASEB Journal. 
28:738, 2014 Experimental Biology Meeting abstract 
17.  Zhang H, Khambu B, Chalasani NP, Yin XM. Modulation of Autophagy 
Affects the Hepatic Pathology in Alcoholic and Non-alcoholic Liver Diseases. 
FASEB Journal. 27:1221, 2013 Experimental Biology Meeting abstract 
 
Book chapters: 
1. Zhang H, Khambu B, Yin XM. Chapter: Autophagy “Signaling pathways in liver 
disease.” 3rd Edition, Springer, edited by J.F. Dufour and P.-A. Clavien 
2. Khambu B, Zhang H, Yin XM. Chapter: Mitophagy in liver “Mitochondria in 
Liver Disease” Taylor & Francis, edited by Neil Kaplowitz and Derick Han 
 
Fellowships and Awards: 
Graduate Student Education Enhancement Award, Indiana University School of 
Medicine                                                                                                        2012 
